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Abstract 
Hepatitis C virus causes a chronic infection that affects 2-3 % of the world population and is a 
significant causative agent of liver cirrhosis and hepatocellular carcinoma. It has a positive-
sense, single-stranded genome that encodes for a single polyprotein that is cleaved by both 
host and viral proteases into 10 mature viral proteins. The non-structural 5A (NS5A) protein 
is a pleiotropic protein with essential functions in the replication and production of virus, as 
well as in perturbing host pathways in favour of virus persistence. NS5A is extensively 
phosphorylated, forming two distinct species termed the basally and hyperphosphorylated; 
however the location and function of phosphorylation remains poorly defined.  
 
To address this, a significant quantity of NS5A was purified from an actively replicating 
context and subjected to extensive phospho-mapping by mass spectrometry. Through this 
approach 12 phosphorylation sites were identified. Subsequent phenotyping of 
phosphorylation sites by reverse genetics generated evidence for a sequential 
phosphorylation cascade within the low complexity region I, and that this was responsible 
for the formation of the hyperphosphorylated species. Further analysis identified the 
phosphorylation of the distant serine 146 as negatively regulating formation of the 
hyperphosphorylated species. To investigate phosphorylation events in greater detail the 
SNAP-tag technology (NEB) was applied to NS5A. The insertion of the SNAP-tag into domain 
III of NS5A was shown to be well tolerated with respect to virus replication and function of 
the SNAP-tag. 
 
In parallel this study also set out to establish whether domain II of NS5A had a hitherto 
unknown function in the production of infectious virus, however no such effects were 
observed. In combination with existing data it is clear that no residue within NS5A domain II 
is essential for the production of infectious virus. Furthermore, this work highlights 
significant differences in the requirement for domain II in virus replication between different 
HCV genotypes, despite high conservation within this region.  
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1.1 The Hepatitis C Virus 
1.1.1 Background to the HCV virus 
The Hepatitis C virus (HCV) was first identified in 1989 as the causative agent of non-A non-B 
hepatitis (NANBH) (van der Poel et al., 1989, Kuo et al., 1989). It is a blood-borne pathogen 
and is typically transmitted from exposure to blood products of an infected individual (Chen 
and Morgan, 2006). Prior to the identification of HCV the major route of infection was 
through medical transfusion of unscreened infected blood products. After the 
implementation of screening the incidence of transfusion acquired HCV dramatically reduced 
to around 1:2,000,000 (Schreiber et al., 1996). As a result in the US there was a decline in 
new cases of HCV from an estimated 180,000 in 1988 to around 30,000 by 1995 (Alter et al., 
1999). However increased awareness of disease transmission on the back the HIV epidemic is 
likely also a factor in this reduction. Despite these dramatic reductions in transmission, due 
to the asymptomatic nature and long duration until clinical presentation of symptoms, it is 
likely that the peak of patients with transfusion acquired HCV is only just being identified.  
Major routes of transmission are now mostly confined to intravenous drug use (IDU), sexual 
contact and parenteral transmission. 
 
Current estimates are a global prevalence of around 170 million infected individuals (Chen 
and Morgan, 2006). Whilst HCV is endemic in all countries for which there are data, the 
prevalence varies greatly between countries. The highest prevalence is found in African and 
Eastern Mediterranean regions (2.5 to 10 %) while the vast majority of other countries have 
a lower prevalence of 1-2.5 % (Shepard et al., 2005). However in some countries this has 
been reported as significantly higher, principally in Egypt where reports are of a prevalence 
of up to 28% of the population (Frank et al., 2000). 
 
HCV is classified into 6 major genotypes (1-6), with the recent proposal of a seventh 
genotype (Murphy et al., 2007). Each genotype is divided into multiple subtypes (a, b, c etc.), 
illustrated in Figure 1.1 (Simmonds, 2004). The genetic variability between genotypes is 
around 31-35 %, and between subtypes 20-25 %, and within an infected individual there are 
multiple quasispecies of virus present. The presence of quasispecies is likely the product of a 
long duration of infection and the error prone nature of the polymerase. The presence 
within these quasispecies of naturally occurring resistance mutations to the new direct 
acting antivirals (DAA) is currently under surveillance (Pawlotsky, 2006, Newman et al., 2013, 
Thomas et al., 2012). Genetic recombination of HCV is considered a rare event, with less 
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than 1 % of genomes in a cohort of over 1000 viruses being identified as recombinants (Shi 
et al., 2012). 
 
The distribution of genotypes throughout the world is not uniform, Figure 1.1. In Western 
Europe, the Americas, Russia and Australia there is a dominance of genotype 1 infections, 
with either genotype 2 or 3 being the second most prevalent. However in Africa, the Far East 
and the Middle East there are much higher rates of genotype 4, 5 and 3 infections, with 
genotype 1 infections contributing only a small number of cases (WHO, 2009). Interestingly, 
the sequence homology between the most common 1b genotype and the predominantly 
research 2a genotype is as low as 52-55 %. As these two genotypes respond very differently 
to current treatments, it does raise the question as to how discoveries in genotype 2a will 
translate to the more clinically relevant, and harder to treat, genotype 1b. 
 
HCV is a member of the Hepacivirus genus in the Flaviviridae family, Figure 1.1. While this 
genus is host to other animal viruses, HCV is currently the sole human pathogen found in this 
genus. Other non-human viruses within the Hepacivirus genus are GB virus-B (GBV-B) and 
non-primate Hepacivirus (NPHV) that have been identified in dogs, horses and rodents 
(Kapoor et al., 2011, Kapoor et al., 2013). The recent identification that bats are a natural 
reservoir for both Hepacivirus and Pegivirus could support a model where by an ancient 
zoonotic leap of Hepacivirus from bats to humans was the origins of HCV (Quan et al., 2013). 
The Flaviviridae family contains many well-known pathogens, the Flavivirus genus is host to 
Dengue virus (DENV), West Nile virus (WNV) and Yellow fever virus (YFV); the Pestivirus 
genus, host to bovine viral diarrhoea virus (BVDV); the Pegivirus genus, host to the George 
Barker virus-D (GBV-D). Similarities between the function of proteins from this family of 
viruses is reviewed in (Murray et al., 2008).  
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Figure 1.1. Phylogenetic analysis of the Flaviviridae family and HCV genotypes and their 
worldwide distribution.  
A. Homology of Flaviviridae based on sequence comparison of the viral polymerases, 
reproduced from (Kapoor et al., 2011). B. Sequence homology of HCV genotypes based on 
the NS5B sequence, adapted from (Simmonds, 2004). C. Distribution of HCV by genotype 
across all major continents and sub-continents, reproduced from (WHO, 2009). 
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1.1.2 Disease pathology 
The natural progression of HCV, in the absence of treatment, has been well documented and 
is summarised in Figure 1.2, reviewed in (Chen and Morgan, 2006, Mauss et al., 2011b). After 
exposure to the Hepatitis C virus the initial acute phase of infection is often asymptomatic, 
however clinical markers such as aminotransferases become elevated around 6-12 weeks 
post-exposure and seroconversion often occurs between 8 weeks to several months post-
exposure (Mauss et al., 2011a). Where symptoms are present they are often general malaise 
and nausea. The self-clearance of HCV RNA within this acute infection phase occurs in about 
20 % of infected individuals (Chen and Morgan, 2006). A very rare progression of disease is 
the onset of fulminant hepatitis soon after the acute infection stage, typically progressing to 
complete hepatic failure (Farci et al., 1996). 
 
Individuals who have detectable HCV RNA in the blood and/or liver beyond 6 months are 
considered to be chronically infected, with approximately 80% of infected individuals 
progressing to this stage (Chen and Morgan, 2006). The risk factors for progression into 
chronic infection includes age, gender, ethnic origin and co-infections, and once a chronic 
infection has been established the spontaneous resolution of HCV is very rare. During this 
chronic phase, prior to the onset of cirrhosis, patients often remain asymptomatic but 
symptoms can include fatigue, nausea and weakness (Lauer and Walker, 2001). 
 
It has been estimated that between 10-50 % of patients will progress to cirrhosis within 20 
years of infection, with approximately 30 % of patients not progressing for at least 50 years, 
if at all (Poynard et al., 1997, Seeff, 2002, Mauss et al., 2011a). The risk factors associated 
with the rate at which a patient will progress from chronic HCV to the onset of cirrhosis is 
not fully understood, but known to include excessive consumption of alcohol, gender, age at 
time of infection as well as co-infections (Chen and Morgan, 2006, Seeff, 2002). 
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Figure 1.2. Natural disease progression of hepatitis C virus infection.  
Summary of disease progression in the absence, or failure from, therapeutic treatment. 
Boxes denote permanent self-resolution of infection (green) or end stage liver disease 
followed by death (red). a(Farci et al., 1996); b(Mauss et al., 2011a); c(Poynard et al., 1997); 
d(Tang and Grise, 2009); e(Planas et al., 2004); f(Fattovich et al., 1997a) 
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Cirrhosis is a result of the progressive fibrosis of hepatic tissue, a product of the continual 
deposition of collagen by activated stellate cells in a complex, immune mediated response to 
HCV infection (Guidotti and Chisari, 2006). Initially fibrosis is limited to the portal region but 
eventually progresses to irreversible bridging fibrosis between portal regions. The standard 
in assessing the extent of fibrosis is histological staining of liver biopsies and observational 
grading the extent of fibrosis, the presence of mononuclease inflammatory cells and extent 
of hepatocyte death (Theise, 2007). While the use of liver biopsy is currently considered the 
standard for grading liver fibrosis, new and emerging techniques allow for the non-invasive 
grading of liver disease by measuring liver elasticity and viscosity through a variety of 
methods including ultrasound and magnetic resonance (Faria et al., 2009, Huwart and van 
Beers, 2008). These techniques are more suited to regular screening, monitoring and follow-
up than traditional liver biopsy sampling. 
 
After the diagnosis of HCV induced hepatic cirrhosis the risk for progression to 
decompensated cirrhosis is estimated to increase at 5 % per annum (Poynard et al., 1997). 
After which the 5 year survival rate is around 50 % following decompensation of hepatic 
function (Planas et al., 2004). 
 
Alongside the eventual decompensation of hepatic function there is an increase prevalence 
of hepatocellular carcinoma (HCC) amongst patients with HCV induced cirrhosis. Note that 
this increased prevalence is primarily only in cirrhotic HCV patients, contrary to HBV 
infections where the increased prevalence of HCC is observed in both chronic HBV and 
cirrhotic patients (Tang and Grise, 2009). The primary link between HCV and HCC was 
established through epidemiological observations, with about 70% of HCC cases occurring in 
either HCV or HBV infected patients, however insight into the possible mechanistic links is 
starting to be investigated (Levrero, 2006, Tang and Grise, 2009). The risk of HCC developing 
was shown to be between 1 to 4 % per annum post diagnosis of cirrhosis, although in certain 
populations this has been reported in the range of 5 to 7 % per annum (Fattovich et al., 
1997b, Chen and Morgan, 2006). 
 
The exact role of the innate and adaptive immune response in viral clearance is not fully 
understood, but self-clearance of virus infection does require a rapid response from both of 
these elements of the immune response. Concomitant with an elevation of CD4+, CD8+ T-
cells and well as intrahepatic interferon-γ levels there is rapid decline in viral titre (Feinstone 
et al., 2012). Interestingly seroconversion is not a requirement for the self-clearance of virus, 
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and does not confer a protective immunity upon future re-exposure. However, viral kinetics 
and duration are generally shorter in reinfected individuals, with a reduced risk of a chronic 
infection establishing (Bowen and Walker, 2005, Feinstone et al., 2012, Post et al., 2004).  
   
1.1.3 Current and future therapeutics 
With the exception of the emerging direct acting antivirals (DAAs) discussed shortly, the 
established and most successful treatment for HCV infection is a combination of pegylated 
Interferon-α2 (peg-IFNα2) and ribavirin (RBV) for varying durations. The treatment cascade is 
summarised in Figure 1.3. A sustained virological response (SVR), where HCV RNA is 
undetectable 6 months after completing treatment, is used to define the efficiency of anti—
HCV treatments. Dual therapy of peg-IFNα2/ RBV has reported efficacy of between 46 - 82 % 
depending on the genotype treated, with genotype 2/3 giving the more favourable response 
and genotype 1 being harder to treat. 
 
This is a great improvement from original  SVR rates of 22 % seen following monotherapy of 
IFNα2 for 78 weeks in the past, but still leaves a huge number of patients with untreatable 
HCV infections. Note that the pegylation of IFNα2 was to improve the bioavailability, and so 
improve the dosing regimen, of IFNα2 treatment.  
  
Chapter 1: Introduction 
9 
 
 
 
 
Drug name   Drug ID Company Target, activity 
Stage of 
development 
Expected 
licensed 
Telaprevir VX-950 Janssen NS3/4A, protease Licensed , 2012 - 
Boceprevir SCH503034 Merck NS3/4A, protease Licensed , 2012 - 
Sofosbuvir GS-7977 Gilead NS5B, polymerase Phase III 2014 
Daclatasvir 
BMS-
7900052 
Bristol-Myers 
Squibb 
NS5A, n/a Phase III 2014/5 
Alisporivir DEB025 Novartis Cyclophilin A, PPIase On hold (phase III) n/a 
 
 
Figure 1.3. Current and emerging treatments for HCV infection.  
A. Clinical treatment cascade for HCV infection with peg-IFNα2/RBV. B. Direct acting 
antivirals (DAAs) currently under investigation. Alisporivir was put on a partial clinical hold by 
the FDA due to a small number of cases of pancreatitis, phase II studies have recently 
recommenced.  
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The correlation between an early virological response (EVR) and obtaining an SVR at the end 
of treatment is well established. Indeed it serves as a key guide for the early discontinuation 
of treatment should EVR not be achieved (Figure 1.3). Currently following combination 
therapy of peg-IFNα2 and RBV for 12 weeks, if there is less than a 2-log drop in blood HCV 
RNA levels then there is grounds for the discontinuation of treatment. As is the case at 24 
weeks, were any detectable HCV RNA gives grounds to discontinue treatment. Following a 
genotype and virological response guided duration of peg-IFNα2 and RBV treatment (12, 24, 
28 or 72 weeks), the absence of detectable HCV RNA is termed an end of treatment response 
(ETR). From this point patients will either stay HCV RNA negative, and so achieve a SVR at 6 
months and be considered ‘cured’, or will relapse back into viremia. The treatment cascade 
for relapse is similar to that of treatment naïve patients, with genotype and virological 
response guiding duration of treatment.  
 
It is worth noting that the side effects from the current dual therapy are sufficient to cause 
10 - 20 % of patients to prematurely withdraw from treatment prior to achieving an ETR 
(Manns et al., 2006). The most commonly report symptoms are “flu-like”, including 
headaches, pyrexia, nausea and fatigue, and occur in approximately 50 % of patients (Mauss 
et al., 2011a). Other side effects include severe depression, neutropenia and negative effects 
on bone marrow function (Manns et al., 2006). These side effects are predominantly 
associated with the peg-IFNα2, but adverse reactions to RBV are also reported to included 
haemolytic anaemia (Reddy et al., 2007). 
 
Recently the identification of a variety of single nucleotide polymorphisms (SNPs) in the 
IL28B locus have been shown to be a strong indicator of both response to treatment and 
spontaneous clearance of HCV. Specifically the CC genotype at SNP rs12979860 has been 
shown to be most favourable for treatment response (Ge et al., 2009). The current 
understanding and clinical applications of SNP analysis in the treatment of HCV is reviewed 
extensively in (Rau et al., 2012). 
 
The pipelines of pharmaceutical companies are brimming with new chemical entireties (NCE) 
currently under investigation for their activity towards different elements of the HCV virus. 
There are currently in excess of 1,600 clinical trials listed on clinicaltrial.gov evaluating the 
efficacy of new anti-HCV therapies. This equates to approximately 38 NCE in the late stage of 
clinical development which target a broad spectrum of virus and host protein (phase II-III) 
(Manns and von Hahn, 2013). 
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The first two direct acting antiviral drugs to be licensed in 2012 were the orally available 
Telaprevir (Janssen) and Boceprevir (Merck), reviewed in (Klibanov et al., 2011, Klibanov et 
al., 2012, Chen and Njoroge, 2010). These peptidomimetics target the NS3/4A protease 
complex in a covalent, but reversible manner (Manns and von Hahn, 2013). The addition of 
protease inhibitors to the current triple therapy regime has brought SVR rates for the 
typically harder to treat genotype 1a/b from around 46 % to 70 %, in line with the SVR rates 
observed previously with a peg-IFNα2/RBV regime against genotype 2/3 (Manns and von 
Hahn, 2013). Clinical trials are currently underway for the licensing of interferon free 
combinations of DAAs. 
 
Several other key drugs rapidly approaching expected licensing dates are highlighted in 
Figure 1.3B. Sofosbuvir (Gilead), a nucleotide analogue targeting NS5B was reported at ESAL 
2013 to have made excellent phase II progress, with certain trials reporting a SVR of 90% 
(pan-genotype) after 12 or 24 weeks treatment in combination with peg-IFNα/Rib. While 
other trials did report a lower SVR rate for an interferon free dual therapy of Sofosbuvir/RBV, 
those patients did all reach undetectability, with relapse being the primary cause of non-SVR. 
Interestingly in a manner that correlated with IL28B alleles (Barreiro et al., 2013). 
 
The front running NS5A inhibitor Daclatasvir, (Bristol Myers-Squibb, BMS) has also made 
excellent clinical progress (Lemm et al., 2010). The most exciting clinical trial to date showed 
that a combination of Daclatasvir and Sofosbuvir - dosed once daily, with or without RBV and 
over a 12 or 24 week course - achieved virtually 100 % SVR in patients with genotype 1 
infections, including difficult-to-treat patients (Sulkowski et al., 2012). The current state of 
new and emerging therapeutics is reviewed further in (Manns and von Hahn, 2013). The 
reduced viral kinetics and broader T-cell response observed in reinfected individuals is 
evidence of an adaptive immune response. This, along with the high cost of emerging DAAs 
and occurrence of drug resistance mutation, has encouraged the development of 
prophylactic and therapeutic vaccines (Feinstone et al., 2012). Currently approaches have 
focused on stimulating the adaptive immune response, as a weak HCV-specific T-cell 
response is typical in chronically infected patients. However, to data, vaccines have only 
achieved a transient reduction in viral load (Feinstone et al., 2012). 
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1.2 Molecular biology of HCV 
1.2.1 Genomic organisation 
HCV has a single stranded, 9,600 nucleotide positive-sense RNA genome containing 5’ and 3’ 
untranslated regions (UTRs) and two open reading frames (ORF). The primary ORF codes for 
a ~3000 aa polyprotein which is cleaved co- and post-translationally by both host and viral 
proteases to produce 10 mature viral proteins, Figure 1.4. The second ORF overlaps with the 
start of the primary ORF and codes for a single protein, the ‘F’ or alternative reading frame 
protein, ARFP protein. The reference genome for HCV is the genotype 1a H77 isolate 
(accession number AF009606) and the amino acid number in the polyprotein is typically used 
to describe the position of residues (Kuiken et al., 2006). However as this thesis focuses 
solely on the genotype 2a JFH-1 isolate, numbering herein refers to the NS5A amino acid 
position and not the H77 polyprotein numbering. 
 
The first three proteins to be cleaved from the polyprotein by host proteases are the Core, 
Envelope 1 and 2 (E1 and E2) proteins and these are the principal components of the virus 
particle. Core forms the nucleocapsid while E1 and E2 decorate the phospho-lipid membrane 
envelope. The following 7 proteins are denoted as non-structural (NS) protein due to their 
absence from the virion; p7, NS2, NS3, NS4A, NS4B, NS5A and NS5B. However, the minimal 
genetic requirement for autonomous replication of the RNA genome is the 5’ and 3’ UTRs 
and NS3-5B proteins. In fact inclusions of the p7 and NS2 coding region have been shown to 
impair replication in cell culture systems. 
 
The 5’ UTR is highly structured and composed of five domains (I, II, III, IV and V) of which 
domains II, III and IV and along with the first 12-30 nt of the core coding region form an 
internal ribosome entry site (IRES) (Honda et al., 1996). The translation of both ORFs is 
driven from this IRES in a cap-independent manner to produce both the polyprotein and the 
F protein. The 5’ UTR also contains two binding sites at the very N-terminus for the micro 
RNA miR-122, the function of which is discussed shortly. 
 
The 3’ UTR is a ~230 nt stretch following from the end of the polyprotein coding sequence. It 
is composed of a variable region, a polyuridine and polypyrimidine tract (polyU/UC) and a 
highly conserved 3’ X-tail composed of three stem loops (Blight and Rice, 1997, Ito and Lai, 
1997, Kolykhalov et al., 1996). Whilst deletion of the variable region only impaired 
replication, the deletion of either the polyU/UC or the 3’ X-tail completely abrogated 
replication (Friebe and Bartenschlager, 2002, Yanagi et al., 1999). 
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1.2.2 Structural proteins 
Core is a dimeric protein composed of two domains (Boulant et al., 2005). The first domain is 
hydrophilic and proposed to bind viral RNA during the nucleocapsid formation, although 
precise packaging signals have yet to be identified. The second domain is a hydrophobic 
domain that is responsible for anchoring core to lipid membranes such as the ER and lipid 
droplets (Boulant et al., 2006). The core protein requires an N-terminal cleavage by signal 
peptide peptidase protease in order to traffic from the ER to lipid droplets (LDs) (McLauchlan 
et al., 2002). A disruption of the interaction between core and lipid droplets is sufficient to 
block virus release (Boulant et al., 2007). 
 
The envelope proteins 1 and 2 (E1, E2) are the key components of the virus envelope and are 
essential for viral entry and fusion. They are highly glycosylated type I transmembrane 
proteins that, when in matured virions, have been shown to form large complexes stabilised 
by disulphide bridges (Vieyres et al., 2010). Conversely, intracellular E1/E2 is observed as 
non-covalent heterodimer and this shift to large complexes could be indicative of virion 
maturation post-assembly (Lavie et al., 2007).  
 
1.2.3 Non-structural proteins 
The structural proteins are followed by p7, a viroporin that is an essential factor for the 
release of infectious virions (Griffin, 2010, Jones et al., 2007a). The p7 protein in concert with 
NS2 recruits core from lipid droplets to the proposed site of virus assembly on ER-derived 
membranes in a manner essential for virus production (Boson et al., 2011). Moreover it was 
recently shown that the ion channel activity of p7, and not the formation of protein-protein 
interactions, is required for the release of infectious virus at a late stage (Bentham et al., 
2013). Structurally, p7 is composed of two transmembrane domains that are believed to 
oligomerise into either a hexamer or heptamer forming an ion channel (Bentham et al., 
2013, Griffin, 2010, Foster et al., 2013). The ion channel activity is cation-selective and is 
thought to be gated by the lumen residue His17 (Chew et al., 2009). 
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Figure 1.4. Genome organisation and polyprotein processing of the HCV virus.  
A. HCV 9.6 kb genome, 5’ and 3’ UTRs are indicated with start (AUG) and stop codons 
indicated. B. The HCV polyprotein is cleaved by host proteases (green), the NS2 protease 
(yellow) and the NS3/4A protease complex (red). Following cleavage from the polyprotein 
the core protein is cleaved further by the signal peptide peptidase (black, small) to produce 
the mature core. C. Following proteolytic processing of polyprotein HCV proteins are 
anchored to ER-derived membranes with the indicated orientation. Part C reproduced from 
(Bartenschlager et al., 2013).  
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The NS2 protein is a membrane anchored, 24 kDa protein composed of up to three 
transmembrane domains and a catalytic C-terminal protease domain. The protease is 
responsible for cleaving on the NS2-NS3 protein junction in the polyprotein, however as 
commented earlier, the replication of sub-genomic replicons is increased in the absence of 
the NS2 protein. In recent years a key role for NS2 in the assembly of infectious virus has 
been shown, while transmembrane and catalytic domain are both required for this function, 
the catalytic activity of the protease is not (Jirasko et al., 2008, Jones et al., 2007a). 
Mutations which disrupt NS2 interactions with p7, E2, NS3, and to a reduced degree NS5A, 
were shown to block virus production (Jirasko et al., 2010). As such it has been proposed that 
NS2, in concert with p7, is involved in orchestrating virus assembly at an early stage (Boson 
et al., 2011, Jirasko et al., 2010). 
 
The NS3 protein is a large (69 kDa) multifunctional protein composed of two domains, an N-
terminal serine protease (residues 1 to ~180) linked by a flexible domain to a C-terminal 
helicase domain with NTPase activity, reviewed in (Lin, 2006). The protein is anchored to ER-
derived membranes by both an N-terminal amphipathic helix and the NS4A protein. The 
NS4A protein is a small (6 kDa) co-factor essential for the serine protease activity of NS3, 
contributing an essential β-sheet to the protease domain. NS3 is a type I membrane protein 
that has a short N-terminal transmembrane domain that inserts into membranes post-NS3 
driven cleavage from the polyprotein. The NS3 protease is responsible for cleavage of both 
itself and the remaining non-structural proteins from the polyprotein. The helicase activity of 
NS3 has been shown to unwind dsRNA and RNA-DNA hetero-duplexes in a 3’-5’ direction, in 
an ATP-dependent manner (Serebrov and Pyle, 2004, Tai et al., 1996). Like many of the HCV 
viral proteins, NS3 and NS4A proteins have been shown to interact with host and viral 
proteins in other stages of the virus lifecycle including virus assembly (de Chassey et al., 
2008, Ma et al., 2008). 
 
The NS4B is a 27 kDa integral membrane protein consisting of a two N-terminal amphipathic 
helices, four central transmembrane domains and a cytosolic C-terminal domain (CTD) 
(Lundin et al., 2003). It is proposed that the second of N-terminal amphipathic helices acts as 
a transmembrane helix upon oligomerisation, and so giving the first helices a dual membrane 
topology, luminal and cytosolic (Lundin et al., 2006). Primarily, the NS4B protein is critical in 
driving the rearrangement of cellular membranes to form the membranous web upon which 
replication machinery forms, discussed in detail later (Section 1.3.2), but it is also involved 
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with binding other viral proteins (Aligo et al., 2009, Dimitrova et al., 2003), binding the RNA 
genome (Einav et al., 2008) and recently in the production of infectious virus (Han et al., 
2013). Reviewed further in (Gu and Rice, 2013). 
 
The NS5A protein is a highly phosphorylated, multi-functional protein that has essential roles 
throughout many stages of the virus life cycle. It is introduced in more detail in (Section 1.6) 
 
The NS5B protein is the RNA-dependent RNA-polymerase (RdRp) responsible for the 
synthesis of both intermediary negative-sense and positive-sense RNA genomes. It has a C-
terminal transmembrane domain anchoring it to the cytosolic face of the ER-derived 
membranes and the three classic ‘fingers, palm and thumb’ subdomains homologous to 
other viruses (Choi and Rossmann, 2009). The catalytic ‘palm’ domain contains a GDD motif 
responsible for coordinating two magnesium ions. Mutation of this motif, typically GDD-
>GND, disrupt this coordination and render the polymerase inactive, and this mutation is 
regularly used as a ‘non-replicating’ negative controls in experiments. 
 
1.3 The HCV life cycle 
1.3.1 Binding and Entry of virus 
The current understanding is that the circulating “infectious particle” of HCV is composed of 
an enveloped viral particle in tight association with VLDL/LDL particles, Figure 1.5A (Nielsen 
et al., 2006, Vieyres and Pietschmann, 2013). A recent model suggest that in fact the virus 
envelope and the VLDL particle might actually be a single unit, with lipidation occurring in 
between the phospho-lipid membrane of the virus envelope (Bartenschlager et al., 2011). 
This infectious particle is known to enter hepatocytes from the sinusoidal blood in a complex 
receptor-mediated, clathrin-dependent endocytosis process involving at a minimum the 
following receptors; heparin sulphate glycosaminoglycans (GAGs) (Barth et al., 2003); the 
low density lipoprotein receptor (LDL-R) (Agnello et al., 1999, Molina et al., 2007, Owen et 
al., 2009); the scavenger receptor class B type I (SR-BI) (Evans et al., 2007, Scarselli et al., 
2002); the tetraspanin CD81 (Pileri et al., 1998); and the two tight junction (TJ) proteins, 
claudin-I (Evans et al., 2007) and occludin (Ploss et al., 2009). 
 
It is not clear whether claudin-I and occludin interact directly with incoming virus particles, 
as hepatocyte tight junctions are directly inaccessible to the circulating viral particles. It is 
thought that binding of viral particles to the aforementioned receptors could result in 
translocation of receptor : virus complexes to these tight junctions where endocytosis could 
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subsequently occur, a mechanism paralleled in the Coxsackievirus (Coyne and Bergelson, 
2006). Indeed CD81-complex translocation to cell junctions after receptor engagement (by 
E2 or αCD81) has been previously observed (Brazzoli et al., 2008). 
 
The binding of the virus to the LDL-R is mediated through virus associated apolipoprotein E 
(ApoE), an essential component of the infectious particle discussed shortly (Owen et al., 
2009). This is consistent with observations that antibodies against both envelope proteins 
and ApoE proteins can neutralise the infectivity of viral particles (Owen et al., 2009, Jiang 
and Luo, 2009). The current understanding is that the envelope proteins are shielded from 
immune surveillance through a combination of extensive glycosylation and being intimately 
associated in the VLDL particles (Helle et al., 2007, Bartenschlager et al., 2011). This would be 
compatible with a model whereby the initial attachment to hepatocytes would occur via the 
glycosylated envelope proteins interacting with GAGs, and ApoE binding the LDL-R and SR-BI 
receptors. These initial binding events in turn could promote the interaction of envelope 
proteins with the CD81 receptor, and subsequent translocation to tight junctions for claudin-
I and occluding mediated endocytosis (Bartenschlager et al., 2011, Popescu et al., 2011b). 
Such a model would allow for minimal exposure of envelope proteins to the circulating 
immune system. It is worth noting that the majority of our understanding of the HCV entry 
process has been derived from the non-polarised, hepatocellular carcinoma cell lines, Huh7 
and HepG2. Extrapolation of these mechanisms to polarised hepatocytes like those observed 
in hepatic tissue needs to be carefully measured. 
 
After the highly orchestrated attachment of the infectious particle, internalisation is known 
to occur through clathrin-mediated endocytosis (Blanchard et al., 2006, Coller et al., 2009). 
Following endocytosis the infectious particle is trafficked to early endosomes, thought to be 
in a Rab5a dependent manner (Coller et al., 2009). In support of this iet al.  the co-
endocytosis of CD81 and claudin-1 followed by fusion with Rab5 positive endosomes was 
recently visualised (Farquhar et al., 2012). The subsequent acidification of the endosome 
results in envelop directed membrane fusion and release of RNA into the cytoplasm. 
 
The targeting of HCV entry is an attractive therapeutic option, and several monoclonal 
antibodies targeting viral and host entry factors are currently being developed. However only 
two antibodies, targeting the E1 and E2, have so far progress into phased clinical trials (Zeisel 
et al., 2011).   
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Figure 1.5. Structure and entry process of the HCV virus. 
A. Cartoon structure of the HCV virion with E1 and E2 proteins (dark and light blue 
respectively), double membrane envelop (orange), capsid (black) and virus associated 
lipoprotein particle, (V)LDL (light orange). B. Illustration of the known elements of HCV entry 
process. Figures adapted from (Vieyres and Pietschmann, 2013). 
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1.3.2 Replication of viral RNA 
Once in the cytoplasm the 9.6kb genome is rapidly translated into a ~3000 aa polyprotein 
that is cleaved co and post-translationally by host and viral proteases. This translation occurs 
rapidly, and within 8 hours of HCV RNA entering the cytoplasm the virus replication and 
translation of RNA exceeds that of degradation. From this point the intracellular levels of 
both viral proteins and genomes, positive and negative, exponentially increase until a steady 
state is reached at around 24 hours (Binder et al., 2013). 
 
A key feature of many positive-sense RNA virus is the rapid remodelling of cellular 
membranes into what is termed, a membranous web, Figure 1.6A. These structures are 
often derived from ER-membranes, are rich in phosphatidylinositol-4-phosphate lipids (PI4P) 
and are the proposed sites of viral replication and virus assembly, as is the case in HCV 
(Delang et al., 2012). There are many benefits that this membrane remodelling is thought to 
confer, there is an aggregation of protein synthesis machinery and the environment is tightly 
excluded from the surveillance of the host cell innate immunity, Figure 1.6B. 
 
In the case of HCV, the NS4B protein is the major viral protein required for the remodelling 
of ER-derived membranes. The host factor phosphatidylinositol-4 kinase-III alpha/beta 
(PI4KIIIα/β) is responsible for the phosphorylation of inositol rings to generate PI4P lipids and 
has also been shown to be essential in remodelling the ER-derived membranes; with 
knockdown or inhibition abrogating HCV replication, and in certain HCV genotypes entry and 
release (Berger et al., 2009, Borawski et al., 2009, Reiss et al., 2011, Tai et al., 2009). More 
recently it was shown that NS5A interacts with and stimulates the kinase activity of PI4KIIIα 
in a manner critical for the correct formation of the membranous web (Reiss et al., 2011, 
Reiss et al., 2013). The interaction of NS5A and PI4PKIIIα is discussed in further detail later 
(Section 1.6.2.1). Other host factors involved in the membranous web formation and virus 
replication are reviewed in (Berger and Randall, 2009).  
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Figure 1.6. The membranous web and the structure of the replication complex. 
A. Comparison of the perinuclear region of mock infected (i) and HCV infected (ii) Huh7.5 
cells showing the formation of multi-membrane vesicles (MMVs). Reproduced from 
(Romero-Brey et al., 2012) B. Cartoon schematic of the replication complex showing NS3 
(green) tethered to the ER-derived membrane by NS4A (yellow), in close association with 
NS4B (grey), NS5A (purple) and NS5B (blue). Other host factors are denoted by pentagon 
(violet). Adapted from (Gu and Rice, 2013).  
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The sub-structure of the membranous web has been shown to be composed of single and 
double membrane vesicles tightly packed together (SMV and DMV) and it is accepted that 
these are the structures upon which replication machinery is tightly associated (Romero-Brey 
et al., 2012). These structures were also recently shown to be significantly enriched in 
proteins like NS3, NS5A and NS5B as well has host factors like VAP-A, VAP-B and cholesterol 
(Paul et al., 2013). The VAP-A/B proteins are essential host factors discussed in detail later 
(Section 1.6.2). An illustration of these ER-membranes forming deep pockets containing the 
replication machinery is shown in Figure 1.6B.  
 
Whether these DMVs are completely encircled or have small - possibly gated - pores has yet 
to be conclusively demonstrated, but recent EM-tomography is highly suggestive of such a 
model. As is the consistent finding that HCV RNA, HCV proteins and even in vivo replicase 
activity in isolated DMVs is both protease and nuclease resistant until the addition of 
detergent (Paul et al., 2013, Quinkert et al., 2005). Recent work has highlighted the 
involvement of elements from the nuclear pore complex (NPC), showing they were 
relocalised to the membranous web in HCV infected cells, and that knockdown was 
inhibitory to replication and release (Neufeldt et al., 2012). This is thought to be a potential 
mechanism for regulating the influx and efflux from either DMVs or the membranous web in 
general, perhaps now hinting at the function of putative nuclear localisation sequences 
found within NS5A. 
 
Studies by Wolk et al. showed that the membranous web was composed of structures of 
different mobility. The fluorescent labelling of NS5A highlighted large, static structures that 
were stable and showed minimal NS5A exchange post bleaching. They also observed smaller, 
highly mobile structures that trafficked in a dynein dependent manner over long distances 
(Wolk et al., 2008). It is feasible that the larger static structures represent the 
aforementioned RC DMVs, while the small mobile structures represent either the 
recruitment of factors into replication complexes or NS5A fulfilling the numerous other 
functions it is involved with outside of replication. 
 
It was recently shown that micro-RNA 122 (miR-122) is an essential host factor for HCV 
replication as well as virus production (Jangra et al., 2010). Exactly how miR-122 functions in 
the virus lifecycle is not fully understood but it is known to bind the 5’ UTR at two binding 
sites in a non-canonical manner. Recent studies show that at a minimum miR-122 recruits 
Argonaute-2 (Ago-2) to the HCV genome and prevents degradation by the cellular 
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exonuclease Xrn1 (Li et al., 2013). But Li et al. concede that this is likely not the sole function 
of miR-122 that is critical for virus replication. 
 
A paradox for positive-sense RNA viruses like HCV is their genome must fulfil multiple, 
mutually exclusive roles. The genome must serve as template for negative-strand synthesis 
by the RdRp, as well as a template for protein synthesis by the ribosomal complex and also 
being available for packaging into assembling virions. What regulates the fate of RNA 
genomes is complex and not fully understood. The quantification of genomes in RCs has 
shown a 10-1000 fold excess of positive-sense genomes (Komurian-Pradel et al., 2004, 
Quinkert et al., 2005). This hints that perhaps once RCs are established, negative-sense 
genomes are used for the repeated synthesis of an excess of positive-sense genomes. These 
can then be trafficked out of tightly excluded replication complex into the cytoplasm, from 
where they are directed to either protein synthesis or encapsidation.  
 
1.3.3 Assembly and release of virions  
The exact mechanics of how RNA is packaged into the virion and subsequently associates 
with VLDL to form the circulating infectious particle is still poorly defined, reviewed in 
(Bartenschlager et al., 2011, Popescu et al., 2011b). The association of core with lipid 
droplets has been well validated as critical for the production of infectious particle (Boulant 
et al., 2007, Miyanari et al., 2007, Targett-Adams et al., 2008). As the core protein is 
recruited (by domain II) to the lipid droplet (LD) there is a concomitant displacement of 
adipocyte differential related protein (ADRP) from the surface of LDs, and a redistribution of 
LD to the membranous web region (Boulant et al., 2008). The exact function of this 
association and redistributing is not fully understood, but it appears more complex than a 
simple “increase core on LD = increase in virus assembly” model. Indeed a comparison of the 
sub-cellular distribution of core from the high titre JcI chimera with that of the low titre JFH-
1 virus, showed virus titre inversely correlated with the extent of core accumulation on lipid 
droplets. Furthermore, it was shown that this was a result of the difference in mobility of 
core domain II (Boson et al., 2011, Shavinskaya et al., 2007). 
 
The association of core on LDs is likely to fulfil multiple roles. The LD could be utilised as a 
cellular trafficking mechanism, transporting core from sites of protein synthesis to sites of 
virus assembly (Welte, 2009); the accumulation of core on LD could also act as a reservoir for 
core, as significantly more core per RNA molecule is required for nucleocapsid formation; 
finally the LD itself could be the de novo site of RNA encapsidation. Although the 
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aforementioned inverse relationship between core accumulation on LD and virus titre 
suggests this is less likely (Shavinskaya et al., 2007). Interestingly in naïve Huh7 cells the LDs 
are only rarely closely associated with other organelles, however in HCV infected cells a 
significant percentage of the LD are in close association with the re-arranged ER-derived 
membranes (Miyanari et al., 2007). 
 
It has been well established that the maturation of the virion into an infectious particle is 
highly dependent on the VLDL pathway (Chang et al., 2007, Gastaminza et al., 2008, Huang 
et al., 2007, Jiang and Luo, 2009). Typically, VLDL particles are synthesised at the ER and 
secreted from the cell via the Golgi (Bamberger and Lane, 1990). However, at what stage the 
core-encapsidated RNA acquires the E1/2 containing lipid envelope and subsequently 
associates with VLDL to form the infectious particle is poorly understood. The identification 
of oxysterol binding protein (OSBP) as a host factor that interacts with NS5A in a manner 
essential for virus maturation could shed some light on this (Amako et al., 2009). It is known 
that the HCV envelope proteins traffic through the cisternae of the Golgi compartment for 
glycosylation (Op De Beeck et al., 2004).  
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Figure 1.7. A proposed model for the assembly of infectious virus. 
Illustration showing the replication of RNA in membrane invaginations, then subsequent 
encapsidation of viral RNA in the close proximity to both ER-derived membranes and lipid 
droplets (LD). At what point the lipoviralparticle associates with VLDL components is unsure.   
Reproduced from (Popescu et al., 2011b).  
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Recently several other virus proteins have been shown to be essential for the assembly of 
infectious virus. As mentioned earlier the p7 and NS2 are both critical factors for the 
assembly and maturation of infectious virus (Section 1.2.3). The interaction of domain I of 
core (residues 64-66) with the helicase domain of NS3 (Jones et al., 2011) and elements 
within the C-terminal domain of NS4B are all required for virus assembly and egress (Han et 
al., 2013). Exactly how these proteins function in these processes is not fully understood. 
NS2 was shown to be able to interact with both structural (E2) and non-structural elements 
(p7, NS3 and NS5A) in a manner required for assembly of virus, suggesting a role in 
coordinating viral proteins in virus assembly (Jirasko et al., 2010, Ma et al., 2011). It has also 
been shown that specifically the ion channel activity of p7 is critical for release (Bentham et 
al., 2013) and evidence suggests that this might be important in protecting the immature E2 
glycoprotein from degradation during the process of either assembly or egress (Atoom et al., 
2013).  
 
The importance of apolipoproteins (Apo) and the VLDL pathway in the production of virus 
have been well studies. However, it is disputed as to which Apo proteins are required for 
virus production, and which are incorporated into the infectious particle, reviewed in 
(Bartenschlager et al., 2011). The ApoE protein is known to be essential for the production of 
infectious virus but was only recently shown biochemically as a component of the infectious 
particle when produced from Huh7.5 cells (Chang et al., 2007, Merz et al., 2011). The siRNA 
knockdown ApoE dramatically reduced virus titres but the same was not observed for ApoB 
knockdown (Benga et al., 2010, Jiang and Luo, 2009). Interestingly, both Merz et al. and Icard 
et al. did not identify ApoB as a component of Huh7 cell derived infectious particles, but 
ApoB containing infectious particles have been identified in patients (Andre et al., 2002, 
Icard et al., 2009). 
 
It was noted by Bartenschlager et al. that while there is no clear mechanism behind these 
discrepancies in ApoE and ApoB, this difference could in part be a result of the different cell 
lines utilised (Bartenschlager et al., 2011). As mentioned VLDL is the key pathway in virus 
production, and the ApoB100 protein is an essential component in this production of VLDL. 
While the two common hepatocellular carcinoma cell lines utilised, Huh7 and HepG2, are 
both able to secrete ApoB100 lipoparticles, it is relatively dense and lipid poor when 
compared to VLDL secretion in vivo (Meex et al., 2011). Suggesting that in the context of 
Huh7/HepG2 cells, HCV production might not utilise ApoB to the same extent as in vivo. 
Chapter 1: Introduction 
26 
 
Consistent with observations that antibodies targeting ApoE, but not ApoB, neutralised viral 
particles produced from Huh7.5 cells (Owen et al., 2009). 
 
This could correlate with differences observed by EM between HCV particles derived from 
cell culture systems and from patients. Infectious particles isolated from HCV-positive 
patients (treatment naïve) were shown to be VLDL like, being rich in triglycerides, containing 
ApoB and were large spherical particles of > 100 nm. Following delipidation smaller, core-
positive and capsid like particles were observed (Andre et al., 2002). Characterisation of virus 
produced from cell culture observed enveloped particles that were significantly smaller, ~60 
nm, but with a small sub-population of particles >100 nm smaller (Gastaminza et al., 2010). A 
comparison between infectious particles generated in a cell culture system verses those 
isolated from patient blood showed key differences. Patient derived particles were less 
dense (~1.05 g/ml), had a higher ApoB content and had a higher specific infectivity 
(Bartenschlager et al., 2011). 
 
Other host proteins such as diacylglycerol acyltransferase-1 (DAGT1), microsomal triglyceride 
transfer protein (MTP) and Annexin A2 have all been shown to be essential for virus 
assembly (Backes et al., 2010, Herker et al., 2010, Jiang and Luo, 2009). DAGT1 is involved in 
triglyceride synthesis, lipid droplet formation and is thought to be involved in the 
recruitment of core to LD while MTP is important for the formation of lipoprotein particles. 
How Annexin A2 functions in assembly is not well understood, but the interaction it makes 
with NS5A is discussed later (Section 1.6.2). Production of infectious virus was also recently 
shown to be dependent on core trafficking via the adapter protein-2-M (AP2M1) (Neveu et 
al., 2012). 
 
1.4 Systems for the study of HCV 
1.4.1 Cell culture systems 
At this point it is worth briefly discussing the different types of systems available for 
investigating HCV. The development of the first sub-genomic replicon (SGR) systems in 1999 
dramatically increased our ability to study the HCV lifecycle (Lohmann et al., 1999). This was 
a bicistronic system that composed the 5’ UTR IRES of HCV driving expression of a reporter 
gene, followed by the EMCV IRES driving the expression of the non-structural genes either 
NS2-5B or NS3-5B, Figure 1.8. Initially a neomycin phosphotransferase (npt) reporter gene 
was utilised as it allowed for positive selection of replication. The minimal polyprotein 
requirement for the replication of HCV RNA is NS3-5B and from an early stage it was 
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established that the incorporation of the NS2 protein into subgenomic replicons elicited a 
negative effect on replication and so was frequently omitted (Bartenschlager and Sparacio, 
2007, Lohmann et al., 1999). The majority of genotypes required culture adaptive mutations 
in order replicate to detectable levels. 
 
This was the case until 2003 when Kato et al. identified a genotype 2a isolate, termed JFH-1 
whose NS3-5B replicon was capable of high level of replication in the absence of culture 
adaptations (Kato et al., 2003). The insertion of a firefly luciferase (luc) gene in place of the 
npt gene allowed for easy measurement of replication kinetics (Lohmann et al., 2001, 
Targett-Adams and McLauchlan, 2005) which itself facilitated for the first time the high 
throughput screening of anti-HCV compounds. 
 
 
 
 
 
Figure 1.8. Structure of virus and replicon constructs. 
The genotype 2a JFH-1 isolate (Wakita et al., 2005), the chimeric JcI virus (Pietschmann et al., 
2006) and the two common subgenomic replicon (SGR) system (Kato et al., 2003, Targett-
Adams and McLauchlan, 2005) with reporter genes firefly luciferase (luc) or neomycin 
phosphotransferase (npt) 
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The next leap forward in the ability to investigate the HCV lifecycle came in 2005 when 
Wakita et al. and Lindenbach et al. showed that the JFH-1 isolate was capable of undergoing 
the entire virus life cycle in the hepatocellular carcinoma cell line Huh7 (Lindenbach et al., 
2005, Wakita et al., 2005). A chimeric virus, JcI composed of structural genes from the 
genotype 2a J6CF isolate (5’ UTR to p7) and non-structural genes from the genotype 2a JFH-1 
isolate (NS2 to 3’ UTR) gave a 100 - 1000 fold increase in virus release over the WT JFH-1 
isolate, Figure 1.8 (Pietschmann et al., 2006). 
 
Based on the same approach as for JcI there are now chimeric viruses with respectable levels 
of virus release for all major genotypes, and these are all based around JFH-1 non-structural 
elements (Gottwein et al., 2009).. For a complete review on the current state of molecular 
clones, culture adaptive derivatives and their amenity to either sub-genomic (i.e. RNA 
replication) or full length virus (whole virus life cycle) see review (Bartenschlager and 
Sparacio, 2007, Vieyres and Pietschmann, 2013).  
 
Along with advances in virus chimera, two groups recently demonstrated the ability of HCV 
to efficiently propagate in primary hepatocytes (Podevin et al., 2010, Ploss et al., 2010). Such 
systems have the advantage of being more physiologically relevant than current tissue 
culture systems, such as in the formation of polarised monolayers. Indeed, it was recently 
reported that the use of culture media where FBS was substituted for human serum, was 
sufficient to induce a hepatocyte-like morphology of Huh7 cells and a 1000-fold increase in 
the virus production of the JFH-1 isolate (Steenbergen et al., 2012). A combination of these 
systems will help give insight into some of the differences observed between current tissue 
culture and in patients, such as the coordination of receptors in polarised hepatocytes, and 
the use of different apolipoproteins in virus release. 
 
1.4.2 Animal models 
Chimpanzees are the only other natural host capable of supporting HCV infections, but the 
clinical course in chimpanzees is generally milder and with less chance of establishing a 
chronic infection (Bassett et al., 1998, Boonstra et al., 2009).  When chimpanzees were 
inoculated with the JFH-1 isolate it caused only limited viraemia and was cleared by day 3 
(Kato et al., 2008, Wakita et al., 2005). Similar observations of culture adaptive mutations 
showed that while enhancing replication in cell culture systems, they dramatically reduce the 
infectivity in chimpanzees (Bukh et al., 2002). This highlights an as yet unknown difference in 
the requirements of HCV in cell culture verse in vivo.   
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Much work has tried to establish mice as a host for the HCV lifecycle as they are not naturally 
susceptible to HCV infection. While mouse hepatocytes have been shown to support very 
limited replication, they are naturally completely refractory to entry, reviewed in (Boonstra 
et al., 2009). That was until very recently when the complete virus lifecycle was efficiently 
recapitulated over several weeks in humanised mice through the expression of CD81, 
occluding and in combination with an inhibited innate immune response (Dorner et al., 
2013). A pre-clinical model such as this, especially if it is applicable to different genotypes, 
will be invaluable in developing the second and third generation DAAs. 
 
1.5 Phosphorylation 
A large part of this investigation focuses on the phosphorylation of the viral protein NS5A. As 
such the following section will briefly introduce the key concepts in phosphorylation and 
draw parallels with other known examples of viral phosphorylation.  
 
Phosphorylation is the post-translational modification (PTM) of a protein by the enzyme-
catalysed (kinases) addition of an inorganic phosphate molecule (PO4
-3). Typically this occurs 
on the side chain hydroxyl group of serines, threonine and tyrosine, but phosphorylation of 
the basic amines of arginine, lysine, histidine as well as the carboxylic acid groups of 
aspartate and glutamate are known (Klumpp and Krieglstein, 2002, Besant et al., 2009, 
Attwood et al., 2011). Indeed due to the technical challenges in investigating the 
phosphorylation of basic amino acids their reported occurrence in the literature is most 
likely an under representation. It is estimated that 1.7 % of the human genome can be 
ascribed to the kinases family.  
 
Typically a kinase will recognise a short consensus protein motif flanking the residue to be 
phosphorylated. The phosphorylation of a residue has both steric and charge effects on the 
neighbouring protein environment; as such they are predominantly involved with regulating 
a the function of a protein through conformation changes. Phosphorylations can also be 
readily removed by the phosphatase family of enzymes, making them a reversible PTM. It is 
estimated that up to 30 % of the human proteome is phosphorylated by kinases, highlighting 
how extensively utilised this regulatory mechanism is (Manning et al., 2002).  
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1.5.1 Methods for investigating phosphorylation 
The gold standard in the identification of phosphorylation sites is mass spectrometry, 
reviewed in (Witze et al., 2007). Typically proteins are resolved by SDS-PAGE, enzymatically 
cleaved into smaller peptides and then analysed by a variety of mass spectrometry (MS) 
techniques. This technique can definitively identify which amino acids in a given peptide 
have the addition of a phosphate group. However, the amount of protein required for such 
an approach often precludes the analysis of low abundance proteins, or where the 
phosphorylated form is only a minor species. Furthermore, the requirement for a high 
abundance of naturally occurring enzyme cleavage sites to produce small enough peptide 
fragments for MS analysis is also a constraint. 
 
Further limitations come from the suppressive effect that phosphorylation can have on the 
detection of peptide fragments by MS. The detection of molecules by MS requires they have 
a net charge and typically in the analysis of peptides this is a positive charge (due to the high 
density of protonatable amine/amide groups). The addition of negatively charged phosphate 
groups can therefore suppress the detection of highly phosphorylated peptide fragments. As 
a result of these effects, not observing a phosphorylation event by MS is insufficient 
evidence to conclude that the residue is not phosphorylated.  
 
When the use of MS is not applicable, such as for low abundance proteins, then genetic 
disruption of phosphorylation sites is a common approach. Typically putative 
phosphorylation sites are predicted based upon homology to kinase recognition sequences 
or when there is conservation of serine rich regions. Mutagenesis is then used to disrupt 
phosphorylation sites and either phenotypic events or the ability of the protein to be 
labelled with radioactive inorganic phosphate, are subsequently observed. Such mutations 
are termed phosphoablatant or phosphomimetic and often involve substitution to alanine or 
aspartic/glutamic acid respectively. The lack of hydroxyl and amine groups means that 
alanine cannot be phosphorylated, while aspartic/glutamic acid mimics the steric and 
negative charge of a phosphorylated residue. It is worth bearing in mind that kinases 
inhibitors are used extensively as ways of probing the function of kinases, however due to 
the high sequence and structural homology within the kinome, these inhibitors are very 
rarely 100 % specific towards only a single kinase. 
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In this investigation a combination of these approaches are utilised; the MS analysis of 
purified protein to identify phosphorylation sites and the mutagenesis of these sites to 
investigate the functional role.  
 
1.5.2 Phosphorylation of viral proteins 
A recent review of medically relevant virus showed that phosphorylation was ubiquitous 
across all classes of viruses (RNA, DNA and retroviruses) and that many DNA viruses code for 
their own viral kinases (Keating and Striker, 2012). The Flaviviridae family is not exempt from 
this, non-structural proteins from Yellow fever virus (YFV), Dengue virus (DENV) and bovine 
virus diarrhoea virus (BVDV) have all been shown to be phosphorylated by host kinases 
(Jakubiec and Jupin, 2007). 
 
1.5.3 Examples of phosphorylation events 
A phosphorylation mechanism, termed sequential phosphorylation cascade, is of relevance 
to later findings and therefore introduced here. In such a mechanism a serine rich region 
within a protein has the sequential addition of several phosphate groups typically involving 
one or more kinases. Key to this process is the requirement by the kinase that a 
neighbouring residue is phosphorylated, typically in the -4, -3 or -1 position. This proximal 
phosphorylation completes the kinase recognition motif and thereby allows efficient kinase 
activity. Several proteins such as glycogen synthase kinase-3 (GSK3) and casein kinase I and II 
(CKI and CKII) have such recognition motifs and are involved in the sequential 
phosphorylation cascades of cellular proteins like PTEN, GRASP65 and β-catenin (Tang et al., 
2012, Cordier et al., 2012, Liu et al., 2002).  
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Figure 1.9. Sequential phosphorylation cascade of 
PTEN protein. 
Illustration of residues 361 – 370 of the 
phosphatase and tensin homolog (PTEN). After an 
initial priming phosphorylation by CKI the peptide 
is sequentially phosphorylated by GSK3 and CKII to 
produce an extensively phosphorylated region. 
Figure adapted from (Cordier et al., 2012). 
 
 
 
 
 
 
 
 
 
An example of a sequential phosphorylation cascade in the PTEN protein is illustrated in 
Figure 1.9. Here the initial phosphorylation by CKII completes the recognition motif for GSK3 
thereby priming phosphorylation in the -4 position, this phosphorylation then primes the 
next phosphorylation by GSK3 in the -4 position and so on (Cordier et al., 2012). It required 
sophisticated temporal NMR in order to decipher this complex mechanism of 
phosphorylation and also required a preliminary understanding of the kinases involved and 
the sites of phosphorylation.  
 
Another phosphorylation mechanism that later has parallels to NS5A phosphorylation is that 
of the polo like kinase-I (PlkI) protein, a key regulator of cell cycle progress. This protein has 
also been shown to be important for virus replication and is discussed in that respect later. 
PlkI is composed of a polo-box domain (PBD) at the C-terminus and a kinase domain at the N-
terminus. The PBD has been shown to bind the phosphorylated recognition motif SpS(P/T) 
and subsequently direct the activity of the kinase domain either towards the same protein or 
a third protein that it is associated with (Park et al., 2010). The result of having the PBD and 
kinase domain in different regions of the protein is that the priming phosphorylation 
recognised by the PBD can be in a spatially distant region to the residue that PlkI 
phosphorylates. 
CKII GSK3
GSK3
GSK3
CKII
CKII
CKII
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This mechanism of distant phosphorylation has been demonstrated in the P protein of the 
Parainfluenza virus-5 (PIV5), the prototype member of the Paxamxyovirus genus. Here a 
phosphorylation at serine 157 of the P protein facilitates the binding of PlkI via the PBD and 
subsequently directs the PlkI phosphorylation of serine 308 (Sun et al., 2009). A comparison 
between this long range priming phosphorylation of the P protein and recent discoveries 
about the NS5A protein is discussed later (Section 3.3). 
 
 
1.6 The Non-structural 5A protein 
1.6.1 Structure and function of NS5A 
The Non-Structural 5A protein (NS5A) is a large (56-58 kDa), multi-functioning 
phosphoprotein that has an essential role throughout the virus life cycle. It is composed of 
three major domains (I, II and III) linked by low complexity sequences, although in recent 
years domains II and III have been increasingly defined as a single, unstructured domain, 
discussed later (Figure 1.10A).  The protein is anchored to phospholipid membranes by an N-
terminal amphipathic helix (residues 1-33) in a manner essential for replication (Brass et al., 
2002, Penin et al., 2004). 
 
The crystallographic structure of domain I was solved using x-ray diffraction and gave 
numerous insights into potential mechanisms of action (Tellinghuisen et al., 2005). This 
structure (residues 36-198) had an asymmetric unit composed of two identical domain I 
monomers in a dimeric conformation that formed a large, positively charged groove, 
proposed as a putative RNA binding groove. When this structure was computationally 
modelled with the N-terminal amphipathic helix on a phospholipid membrane, it was 
predicted that NS5A would be anchored to the membrane in a way that the putative RNA 
binding groove was projected outwards in a manner that could facilitate the binding of RNA, 
illustrated in (Figure 1.10B). 
 
The Tellinghuisen et al. crystal structure of NS5A showed that domain I could be divided into 
two sub-domains, IA and IB, the former confirmed the presence of a coordinated zinc ion 
between four highly conserved cysteines (C39 C57, C59 and C80); disruption of which was 
previously shown to abrogate replication (Tellinghuisen et al., 2004). Of relevance later, a 
disulphide bond was observed between Cys142 and Cys190 in each monomer subunit 
(Tellinghuisen et al., 2005). However, the biochemical disruption of it by a C190G mutation 
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was shown to only cause a minor impairment to replication, despite computational analysis 
that suggested the absence of such a bond was structurally unfavourable (Tellinghuisen et 
al., 2004).  
 
A second domain I crystal structure was solved in 2009 and showed a near identical 
monomer structure, but in a dramatically different dimer conformation (Love et al., 2009). In 
this new dimer the monomers were stacked tightly together with residues from both sub-
domains IA and IB involved in the dimer interface, unlike the Tellinghuisen et al. structure 
where dimer interface residues were predominantly from sub-domain IA (Tellinghuisen et 
al., 2005). Interestingly the disulphide bond present in the Tellinghuisen et al. structure, 
between Cys142 and Cys190, was not present in this structure although the thiol groups 
remained in close proximity. Love et al. modelled multiple dimer units together to theorise 
the presence of a superhelical structure composed of repeating Tellinghuisen et al. NS5A 
dimers that would no longer be membrane associated. However there has yet to be in vivo 
evidence to suggest either the presence, or possible functions, or such a species. 
 
Domains II and III, unlike domain I, have been shown to be inherently unstructured (Hanoulle 
et al., 2009b, Liang et al., 2007), forming long flexible domains as illustrated in Figure 1.10B. 
Undoubtedly the unstructured nature of these domains is central to the ability of NS5A to 
interact with such a diverse range of proteins, with 130 host protein interactions being 
identified to date, including all HCV non-structural proteins (de Chassey et al., 2008, 
Macdonald and Harris, 2004, Dimitrova et al., 2003, Tripathi et al., 2013). It could be readily 
imagined that with the amphipathic helix in domain I anchoring NS5A to lipid membranes, 
the flexible nature of domains II and III leaves them free to interact with other proteins in a 
‘fly-casting’ type mechanism (Shoemaker et al., 2000). Several examples of such a 
mechanism are discussed in (Gsponer and Babu, 2009). This is supported by data showing 
that several interaction partners of NS5A, notably CypA, NS5B, VAP-B and SH3 domains, have 
all been shown to have short linear binding motifs that would be compatible with this type of 
model. 
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Figure 1.10. Structure of the NS5A protein. 
A. NS5A is composed of three domains (I, II and III) linked by two low complexity sequences 
(LCS I and LCS II). The N-terminus of NS5A contains a 33 aa amphipathic helix (AH) and 
domain I coordinates a zinc ion in a highly ordered manner. B. Illustration of the two NS5A 
domain I monomers (blue and yellow) in the dimer conformation observed by (Tellinghuisen 
et al., 2005), anchored to the membrane (grey) by the AH (Penin et al., 2004). The 
unstructured nature of domains II and III are illustrated.  
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Furthermore, it was recently discovered that domain II forms several transient α-helices that 
were unobservable with previous NMR techniques. These transient helices had low-affinity 
SH3-binding properties and were shown to interact with the host protein BinI (Feuerstein et 
al., 2012). It is therefore entirely plausible that this combination of transient secondary 
structure and linear binding epitopes is what facilitates the diverse range of protein 
interactions formed by NS5A (Liang et al., 2007). 
 
The low complexity sequence I (LCS I) is a 36 aa, serine rich region of NS5A linking domains I 
and domain II, Figure 1.10. This region has been shown to be essential for NS5A 
phosphorylation (Appel et al., 2005, Lemay et al., 2013, Tanji et al., 1995) but through what 
mechanism remains to be eluded. Based on the Tellinghuisen et al. crystal structure it is 
conceivable that an extensively phosphorylated LCS I could compete with RNA for binding 
within the NS5A dimer.  
 
The low complexity sequence II (LCS II) is a short, 13 aa proline rich region of NS5A linking 
domains II and III. Within this region are two class II polyproline motifs, PP2.1 and PP2.2, 
which have been characterised extensively for the ability to bind cellular SH3 domains 
(Macdonald et al., 2004, Tan et al., 1999, Zech et al., 2003).  The function of these motifs in 
the virus life cycle has been investigated and showed that PP2.1 but not PP2.2, is a 
requirement for replication in a genotype 1b replicon. The common genotype 2a isolate JFH-
1 does not contain the PP2.1 motif, but in comparison to the 1b replicon the PP2.2 motif was 
also not required for replication (Hughes et al., 2009a). While the PP2.2 motif may not be 
required for virus replication, roles in ion channel modulation (Mankouri et al., 2009) and 
inhibition of apoptosis (Amako et al., 2013) suggests a role in virus persistence. This is 
supported by a lack of infectivity in chimpanzees of a genotype 1b virus harbouring a 
mutation of the first PP2.1 motif (Nanda et al., 2006). 
 
The involvement of the NS5A protein in perturbing host pathways has been extensively 
documented and will be only briefly introduced here as it is not central to this study. The 
NS5A protein has been shown to inhibit apoptosis, both intrinsic and extrinsic, through 
several different pathways including the TNF-α pathway by an interaction with the TNF-α-
responsive adaptor protein (TRADD) (Ghosh et al., 2000); through direct sequestering of p53 
in the cytoplasm (Lan et al., 2002); and inhibition of the pro-apoptotic potassium ion channel 
Kv2.1 (Mankouri et al., 2009, Amako et al., 2013). As well as being anti-apoptotic, NS5A also 
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modulates the three major mitogenic signalling pathways in favour or virus persistence. Both 
the extracellular signal-regulated kinase (ERK) pathway and p38-Mitogen-Activated Protein 
Kinase (p38MAPK) pathway have been shown to be inhibited by NS5A, reviewed in 
(Macdonald and Harris, 2004); while the third pathway, the stress-activated protein 
kinase/c-Jun N-terminal kinase (SAPK/JNK) pathway, is activated by NS5A (Park et al., 2003). 
The net effect on these MAPK pathways is a perturbation of host cell cycle control; this 
would correlate with observation that there was an increase proportion of hepatocytes in 
the G1 phase in HCV infected patients when compared to patients with alcohol induced liver 
disease (Freeman et al., 2003). 
 
Many of these interactions that modify host signalling pathways are dispensable for the 
replication of the virus in an acute cell culture setting. It is thought that many of these 
pathways are involved in the chronic persistence of infection that is observed in vivo, 
supported by their conservation across evolutionary diverse genotypes (Macdonald and 
Harris, 2004). While the NS5A protein has key functions throughout the virus life cycle, the 
following sections will focus solely on those interactions that have been shown to be 
important in either the replication or production of virus.  
 
1.6.2 The role of NS5A in replication 
NS5A has long been established as a critical viral protein for replication and as such has been 
extensively studied. As a non-enzymatic protein it achieves these functions through a 
plethora of protein-protein interactions with virus and host proteins. Through deletion 
analysis of NS5A it has been shown that domain I, LCS I and resides 244-302 at the C-terminal 
end of domain II, form the minimum requirement for virus replication (Appel et al., 2008). It 
is worth noting that the majority of studies investigating which elements of NS5A are 
required for replication focus on short term, < 96 hrs, replication assays.  
 
An interaction between NS5A and NS5B has been well established with recent NMR mapping 
some element of this interaction to the C-terminus of NS5A domain II (Coelmont et al., 2010, 
Shimakami et al., 2004, Shirota et al., 2002). Interestingly it was recently shown that the 
phosphorylation state of NS5A directs whether it has an inhibitory or enhancing effect on 
NS5B activity and could point towards a potential role in regulation (Ivanov et al., 2009). 
NS5A has been shown to interact with NS3 in bacterial expression and yeast two hybrid 
systems (Dimitrova et al., 2003) and it was shown that the catalytic activity of NS3 is required 
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for the hyperphosphorylation of NS5A (Neddermann et al., 1999). However, whether there is 
a functional interaction between NS5A and NS3 has not been shown.  
 
The ability of HCV to bind RNA was first predicated from the Tellinghuisen et al. crystal 
structure in 2005. Since then it has been shown biochemically that NS5A binds uridylate and 
guanylate-rich RNA, as well as the 3’UTR (positive- and negative-sense) (Huang et al., 2005). 
More recently it was shown that all three domains of NS5A can bind RNA individually, albeit 
with a lower affinity than full length NS5A (Foster et al., 2010, Huang et al., 2005). 
Interestingly Huang et al. also demonstrated that extensive phosphorylation of NS5A was not 
a requirement for the in vitro RNA binding that they reported, hinting at a potential 
regulatory mechanism if it is later shown that extensive phosphorylation of NS5A is 
inhibitory to RNA binding. 
 
The functional importance of NS5A binding RNA is not known and hard to establish. Specific 
mutations or deletions that block NS5A from binding RNA have not yet been established and 
therefore it can only be speculated as to what function the RNA binding properties have. It 
has been proposed that NS5A binding RNA is essential in replication; this being supported by 
the tight and critical associations it forms with the replication machinery NS5B and NS3. 
Similarly it is thought that RNA binding is key in virus assembly as deletions discussed later 
that block assembly also block the NS5A:core interaction and reduce the interaction of core 
with viral RNA (Masaki et al., 2008). 
 
1.6.2.1 Host Factors 
Numerous host proteins have been shown to interact with NS5A in a manner critical for the 
replication of virus, only those relevant to this thesis are discussed below. Other interactions 
are reviewed in (de Chassey et al., 2008, Macdonald and Harris, 2004, Tan, 2006). The 
Cyclophilins (Cyp) are a family of peptidyl-prolyl isomerases (PPIase) enzymes that catalyse 
the cis/trans isomerisation of the peptide bond preceding a proline residue, typically 
resulting in major conformational shifts. Much work has investigated the importance of the 
Cyp family in the HCV lifecycle. They have been shown as critical host factors for several 
viruses including severe acute respiratory syndrome (SARS)-Coronovirus and Human 
Immunodeficiency Virus (HIV) (Watashi and Shimotohno, 2007) and most recently HCV. Two 
isoforms have been shown to be important in the HCV life cycle, CypA and CypB, through 
interactions with viral factors NS5A and NS5B respectively. Disruption of these interactions is 
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deleterious to replication (Chatterji et al., 2009, Coelmont et al., 2010, Heck et al., 2009, 
Yang et al., 2010). 
 
The majority of recent work has focused on understanding the molecular details of the 
NS5A-CypA interaction, as several CypA inhibitors are progressing through clinical trials 
(Paeshuyse et al., 2006). Structural evidence now shows that the active site of CypA interacts 
with the C-terminus of NS5A domain II, and likely catalyses an isomerisation of a prolyl bond 
within this region (Coelmont et al., 2010, Grise et al., 2012, Hanoulle et al., 2009a). 
Interestingly this binding site was recently shown to overlap with the binding site of NS5B 
(Rosnoblet et al., 2012). Further details of these interactions and requirement are discussed 
later (Section 4.1). Moreover it has been shown that CypA stimulates the RNA binding of 
NS5A domain II in an isomerase dependent manner; while NS5A domain II harbouring two 
CypA independent mutations (D316E and Y317N) did not exhibit this simulation (Foster et 
al., 2011).  
 
The vesicle associated membrane protein (VAMP)-associated proteins (VAP) are type II 
membrane proteins localised to the ER and involved in numerous host processes including 
membrane trafficking and lipid transport (Lev et al., 2008). The importance of VAP proteins 
and HCV was initially demonstrated by Tu et al. and later interactions of viral proteins with 
VAP-A (hVAP-33) and VAP-B were identified (Gao et al., 2004, Hamamoto et al., 2005, Tu et 
al., 1999). VAP-A was shown to interact with both NS5A and NS5B, and knockdown of VAP-A 
resulted in a relocalisation of NS5B and a small reduction in RNA replication (Gao et al., 
2004). VAP-B has recently been shown by NMR to bind domain III of NS5A in a region 
previously proposed by Masaki et al. as important for basal-phosphorylation of NS5A (Gupta 
et al., 2012, Masaki et al., 2008). 
 
The phosphorylation state of NS5A and subsequent interaction with VAP-A is considered 
controversial. It was putatively shown that the phosphorylation of NS5A regulated binding to 
VAP-A in an inverse manner, with hyperphosphorylation of NS5A apparently being inhibitory 
to this interaction (Evans et al., 2004). This model has not been subsequently validated, but 
nevertheless is used as one of the main arguments for a more general model where 
hyperphosphorylation of NS5A negatively regulates RNA replication. However Evans et al. 
did suggest the region of NS5A that interacts with VAP-A is in the region of the LCS I. 
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That the VAP proteins play a key role in replication is supported by the antiviral activity of 
Viperin, which was shown to act by interacting with VAP-A and displacing NS5A (Helbig et al., 
2011, Wang et al., 2012). Paul et al. recently isolated both VAP-A and VAP-B as significantly 
enriched components of HCV RNA positive DMVs isolated from infected cells (Paul et al., 
2013). Interestingly VAP-A also interacts with two other host factors important for the HCV 
lifecycle, OSBP (Wyles et al., 2002, Wyles and Ridgway, 2004) and occludin (Lapierre et al., 
1999). Whether the interaction of these proteins with VAP-A is relevant to HCV infection is 
yet to be suggested.  
 
The importance of PI4KIIIα/ β in the synthesis of the PI4P lipids, the formation of the 
membranous web and the virus life cycle have been discussed previously (Section 1.3.2). An 
interaction between NS5A and PI4KIIIα was shown to be essential for these effects and the 
binding site on NS5A was mapped to the C-terminus of domain I, residues 187-214 (JFH-1 
numbering). This was refined further to show that residues 203-209 formed the functional 
interaction site of PI4KIIIα, termed PFIS (Reiss et al., 2013). Mutation of the PFIS was 
sufficient to block the NS5A-PI4KIIIα interaction and cause the reduction in virus replication, 
PI4P synthesis and membranous web formation. The interaction of NS5A with PI4KIIIα has 
also been observed (Lim and Hwang, 2011). Interesting observation of effects on the 
phosphorylation state of NS5A and the interaction with PI4KIIIα have been made and are 
discussed shortly. 
 
The role of the lipid droplet organelle in the production of infectious virus is well established, 
discussed previously (Section 1.3.3) and reviewed (Miyanari et al., 2007). It has been well 
established that the NS5A protein interacts and localises with LDs, but whether this 
interaction plays a critical role in virus replication has not been well defined. The lipid droplet 
associated tail-interacting protein 47 (TIP47) was shown to interact with the N-terminal 
amphipathic helix of NS5A and shRNA knockdown subsequently showed a loss of virus 
replication (Vogt et al., 2013). However triple alanine mutations in domain I (99-101 and 102-
105) dramatically reduced the localisation of NS5A and other non-structural with lipid 
droplets, but with no reported effect on virus replication (Miyanari et al., 2007). Implying 
that while the LD-associated TIP47 is essential for virus replication, the recruitment of NS5A 
to LD is not.  
 
Another interesting host factor that was recently shown to interact with NS5A is the lipid 
droplet associated Rab18 (Salloum et al., 2013). Rab proteins are GTPases of the Ras 
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superfamily involved in membrane trafficking, vesicle formation and membrane fusion. 
Salloum et al. showed that the NS5A-Rab18 interaction was critical for replication, observing 
a significant drop in replication upon Rab18 silencing. Interestingly upon ectopic expression 
of Rab18 they also observed an increase in virus release but not replication. As Rab proteins 
are involved in vesicle trafficking it is plausible that ectopic expression of Rab18 might 
facilitate the increased export of maturing virus particles or increase the recruitment of 
resources to the membranous web. 
 
Protein name 
Role in virus 
life cycle 
Region of 
NS5A Mechanism Reference 
VAMP-
associated 
protein A 
VAP -A Replication unknown 
Possible 
scaffolding 
replication 
complex. 
Tu e al, 1999. 
Gao et al, 2004 
and Evans et al, 
2004 
Cyclophilin A CypA Replication 
DII Unknown 
Hanoulle et 
al,2009 
D317, Y317 
(DII) 
Unknown Yang et al, 2010 
306-333 (DII) 
Isomerisation of 
DII 
Rosnoblet et al, 
2012 
310-330 (DII) 
Cis/trans 
isomerisation 
Coelmont et al, 
2010 
Cyclophilin B CypB Replication DII 
poss. NS5B 
interaction 
Hanoulle et al, 
2009 
Phosphotidylino
sitol-4 kinase III 
alpha 
PI4KIII
α 
Replication 
DI 
Membranous 
web formation 
Reiss et al, 2011 
187-214 (DI) 
Stimulation of 
kinase activity 
Reiss et al, 2013 
Tail-interacting 
protein-47 
TIP47 Replication 
amphipathic 
helix 
Unknown, LD 
localisation? 
Yogt et al, 2013 
Protein kinase R PKR Persistence 
237-298 
(LCSI/DII) 
Inhibition of PKR Gale et al, 1998 
 
Table 1.1. Host interacting partners of NS5A that are essential to virus replication. 
 
 
The NS5A protein also makes a key interaction with the interferon-inducible protein kinase R 
(PKR). This kinase is an element of the innate immune response which in response to dsRNA 
halts cellular translation (Balachandran et al., 2000). The NS5A protein has been shown to 
bind and inhibit the kinase activity of PKR, but in a genotype dependent manner. NS5A from 
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genotype 1 but not genotype 2a/3a is able to inhibit PKR, partly explaining the improved 
outcome for genotype 2a/3a patients on interferon treatment. The interaction of NS5A with 
PKR is the mechanism behind how the previously identified interferon sensitivity 
determining region (ISDR), residues 237-272 (JFH-1 numbering), effectively predicted the 
outcome of interferon treatment (Enomoto et al., 1995, Gale et al., 1997, Pascu et al., 2004). 
However deletion of the PKR binding site, residues 237-298 (JFH-1 numbering), did not block 
HCV replication, suggesting that the interaction of NS5A with PKR is not a requirement for 
replication in a cell culture system, at least over a 72 hour infection (Appel et al., 2008). 
While the PKR binding site in NS5A is adjacent to regions of NS5A that are highly 
phosphorylated, there has been no evidence that NS5A is a substrate of the PKR kinase; 
indeed bacterially expressed NS5A has been shown to  not be phosphorylated by PKR (Chen 
et al., 2010, Gale et al., 1997). Further a serine to alanine mutation the phosphorylation site 
222 (JFH numbering) did not disrupt the binding of PKR (Katze et al., 2000). Several kinases 
have also been identified as essential in the virus lifecycle, casein kinase I (CKI) and polo-like 
kinase I (PlkI), discussed in further detail later (Section 1.6.4.3). 
 
1.6.3 The role of NS5A in assembly 
Domain III is the primary region of NS5A that is critical for the assembly of infectious virus. 
Whether domain I and regions of domain II are also required for virus assembly is challenging 
to investigate as they both contain elements essential for virus replication. However, In 
chapter 4 results are presented that argue against a role of the domain II in virus assembly. 
 
The entirety of domain III can be deleted with no observable effect on virus replication, but a 
near complete block on virus assembly (Appel et al., 2008). Further deletions identified 
residues 427 - 457 (JFH-1 numbering) as the major epitope responsible for this phenotype, 
with concurrent deletion of resides 376 - 426 increasing the impairment to virus release. This 
correlates with Tellinghuisen et al. who identified serine 457 (JFH-1 numbering) as the major 
requirement, with an alanine mutation at this point blocking virus release. This however is 
contrary to observations by Masaki et al. who showed that mutation of serine 457 alone was 
insufficient to block assembly, but required additional mutations at serine 452 or 454 to elicit 
the same phenotype (Masaki et al., 2008, Tellinghuisen et al., 2008a). Furthermore, Masaki 
et al. demonstrated that mutation of serine 452, 454 and 457 also disrupted the interaction 
with core and reduced the amount of RNA that co-immunoprecipitates with core. These 
mutations also shifted the localisation of NS5A from fractions enriched in LD proteins 
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towards fractions enriched in ER markers (Masaki et al., 2008). In line with Appel et al. these 
mutations had no effect on virus replication. 
 
Protein name 
Role in virus 
life cycle 
Region of 
NS5A Mechanism Reference 
Apolipoprotein E ApoE Assembly 
205-280 and/or 
DIII 
Unknown 
Benga et al, 
2010. Cun et 
al, 2003 
Annexin A2 ANXA2 Assembly Domain III Unknown 
Backes et al, 
2010 
Phosphotidylinositol-
4 kinase III beta 
PI4KIIIβ Secretion Unknown Unknown 
Coller et al, 
2012 
Rab18 Rab18 
Possibly 
assembly 
Unknown Unknown 
Salloum et al, 
2013 
Oxysterol binding 
protein 
OSBP Assembly Unknown Unknown 
Amako et al, 
2009 
 
Table 1.2. Host interacting partners of NS5A that are essential to virus production.  
 
 
More recently this was reiterated in the genotype 1a virus H77S, where it was shown that 
mutation of the serine cluster 452-457 (JFH-1 numbering) again had no effect on replication 
but a complete block of virus release. Interestingly an extra serine at position 458 (glutamic 
acid in JFH-1) and threonine at 462 (both JFH-1 numbering) also elicited a reduction in virus 
assembly that were not previously investigated (Kim et al., 2011). 
 
There was a concurrent change in the phosphorylation state of NS5A when mutations were 
inserted into domain III. While Masaki et al. observed a reduction in basal-phosphorylation 
with mutation of these serine clusters (Figure 1.11), Tellinghuisen et al. observed a reduction 
in hyperphosphorylation and this discrepancy has yet to be resolved.  
 
More supporting evidence of the importance of domain III in the assembly of infectious 
virion was shown by the generation of a culture adapted JFH-1 virus with enhanced virus 
production, giving a 3 log increase in released virus titres. When sequenced the adaptive 
mutations clustered in domain III of NS5A and when engineered back into WT JFH were 
shown to account for the majority of increase in virus release (Liu et al., 2012). 
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1.6.3.1 Host Factors 
The importance of interaction between core and lipid droplets for the production of 
infectious virus has already been mentioned (Section 1.3.3). The recruitment of NS5A to LDs 
is determined by residues 99-105 in domain I, but for the co-localisation of NS5A with core 
on LDs there is the additional requirement for domain III of NS5A (Appel et al., 2008, 
Miyanari et al., 2007). The region of domain III required for this co-localisation is likely to 
correspond to the serine rich region 452-457 (JFH-1 numbering) identified by Masaki et al. to 
be essential for an interaction with core (Masaki et al., 2008). Recently Ploen et al. presented 
on the lipid droplet associated protein TIP47 as being a component of the lipoviralparticle, 
and observed that overexpression of TIP47 with a mutated Rab9 binding site was sufficient 
to block virus production (Ploen et al., 2012). Whether this is involved with the 
aforementioned interaction that NS5A makes with TIP47 is as yet unknown. 
 
The NS5A protein has been shown to interact with apolipoproteins, discussed earlier for 
their importance in lipoparticles and virus assembly/maturation (Section 1.3.3). It was shown 
that siRNA knockdown of ApoE was refractory to virus production in Huh7.5 cells, and 
subsequently attributed this to an interaction with NS5A, an interaction that was reduced 
when domain III was deleted (Benga et al., 2010). Later Cun et al. confirmed an interaction 
with NS5A but mapped it to residues 205-280 (Cun et al., 2010). The ApoA1 protein, a 
component of the high-density lipoprotein (HDL), was also shown to interact with NS5A, and 
to co-localise with it on the Golgi apparatus, but no functional information was derived from 
the interaction (Shi et al., 2002). 
 
The interaction of NS5A with annexin A2 was identified by proteomics and shown to be 
dispensable for replication, but critical for the release of infectious particles (Backes et al., 
2010). Deletion studies identified domain III as the critical element required for the co-
localisation of annexin A2 to with NS5A. Exactly whether this interaction is involved with 
assembly or release of infectious virus is still uncertain, and whether or not this interaction is 
modulated by NS5A phosphorylation would be interesting to investigate. 
 
The chemical inhibition or siRNA knockdown of the host kinase CKII was also shown to 
abrogate virus production, while not affecting replication (Section 1.6.4.3) (Tellinghuisen et 
al., 2008a). Another host factor whose knock down results in a reduction in infectious virus 
production is the oxysterol binding protein (OSBP) (Amako et al., 2009). Deletion studies 
identified domain I of NS5A as the site of OSBP binding, but it is once again worth noting that 
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as domain I is critical for the localisation and trafficking of NS5A, that domains II and III don’t 
bind OSBP does not exclude an in vivo interaction. Furthermore, it is worth noting that the 
OSBP protein has both a VAP-A and PI4P binding domain (Amako et al., 2009).  
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1.6.4 Phosphorylation of NS5A 
1.6.4.1 Background of NS5A phosphorylation 
NS5A is a phospho-protein that exists in two forms with slightly different mobility on SDS-
PAGE; these have been termed a basally phosphorylated (apparent molecular weight of 56 
kDa) and a hyperphosphorylated (58 kDa) form.  These two forms are commonly referred to 
as p56 and p58; however, in JFH-1 there is a 19 aa insertion in domain III compared to 
genotype 1b, they migrate with apparent molecular weights of 63 and 65 kDa (Figure 3.1A). 
This increase in an apparent molecular weight of 2 kDa, in a manner sensitive to phosphatase 
treatment, is indicative of an extensively phosphorylated protein. This is supported by 
observations that the in vitro incorporation of 5 phosphates per molecule of NS5A was still 
insufficient to recapitulate this shift in molecular weight (Huang et al., 2004). Interestingly 
these two phosphorylation species are always observed as two discrete bands by SDS-PAGE, 
without the presence of intermediary species.  
 
As has been introduced previously, domains II and III of NS5A are inherently unstructured; 
with only small, transient elements of secondary structure being recently identified (Gupta 
et al., 2012, Feuerstein et al., 2012). As reviewed in (Gsponer and Babu, 2009, Dyson and 
Wright, 2005) extensive post-translational modifications (PTM) is a common feature of 
intrinsically unstructured proteins (IUPs). Indeed phosphorylations appear to predominantly 
occur in unstructured regions of proteins (Iakoucheva et al., 2004). Through altering the local 
charge and hydrophobicity of a protein these modifications elicit effects on the proteins 
conformation both locally and globally (Wright and Dyson, 1999). The unstructured domains 
of NS5A are thought to act in a similar fashion, with extensive phosphorylation modulating 
protein-protein interaction sites through these local effects on protein conformation. 
Through this mechanism NS5A is able to interact with a diverse network of proteins and 
enabling it to function in spatially and temporally distant events like replication, virus 
production and modulating host cell pathways.  
 
Much work has previously tried to conclusively map the location of phosphorylation sites by 
a combination of mutagenesis or biochemical analysis (MS, Edman degradation etc.). 
Previously, with the absence of highly efficient replicon and virus systems, much of this work 
was constrained to ectopic expression of NS5A, either as a single protein or as part of 
polyprotein. It is well established that phosphorylation of NS5A is dependent on, at a 
minimum, other non-structural proteins and most likely active replication complexes (Koch 
and Bartenschlager, 1999, Neddermann et al., 1999). As NS5A is a serine/threonine rich 
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protein it brings into question the functional relevance of phosphorylation sites identified by 
in vitro kinase assays, where the ratio of kinase to substrate is vastly higher than would occur 
in vivo. With this in mind it is worth considering that, with a recent exception (Lemay et al., 
2013), the identification of NS5A phosphorylation sites by mass spectrometry, on protein 
purified from cells harbouring either replicons or virus, has not been carried out. 
 
The serine rich LCS I was shown to be important for phosphorylation by Tanji et al. who 
showed that mutation of serines at residues 225, 229 and 232 in NS5A (ConI) resulted in a 
loss of hyperphosphorylation on NS5A when ectopically expressed from a NS2-5B 
polyprotein in COS-1 cells (Tanji et al., 1995). It was later shown by MS that NS5A expressed 
as a single protein in Sf9 cells was phosphorylated in the region of 222-232, and after 
additional in vitro kinase treatment identified phosphorylation at serine 222 (S2194 ConI) 
(Katze et al., 2000). Interestingly when Tanji et al. mutated serine 222 they saw no effect on 
phosphorylation despite all the serines within this LCS I being absolutely conserved across 
HCV genotypes. 
 
More recently it was demonstrated by mass spectrometry that serine 222 was a major 
phosphorylation site in a JFH-1 subgenomic replicon, and mutation of this residue to aspartic 
acid (as a phosphomimetic) had a modest inhibitory effect on RNA replication. Contrary to 
Tanji et al, a mutation of serine 222 to alanine had a modest inhibitory effect on 
hyperphosphorylation (Lemay et al., 2013). 
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Figure 1.11. Summary of regions important for NS5A phosphorylation. 
Numbering of highlighted region refers to either H77 polyprotein (2193-2414) or JFH-1 NS5A 
(217-460). a (Tanji et al., 1995); b (Lemay et al., 2013); c (Nordle Gilliver et al., 2010); d (Reed 
and Rice, 1999); e (Masaki et al., 2008); f (Appel et al., 2005); g (Tellinghuisen et al., 2008a); h 
(Kim et al., 2011); i (Katze et al., 2000) 
 
 
Another residue, serine 232, was shown to be phosphorylated in vitro after casein kinase I 
(CKI) treatment of a synthetic mimetic of the LCS I. In line with the requirement for a priming 
phosphorylated serine in the -3 position for efficient CKI phosphorylation, a synthetic 
phosphorylation at serine 229 greatly enhanced phosphorylation of the LCS I peptide. 
Interestingly the phosphomimetic, glutamic acid, did not recapitulate this increase in 
efficiency suggesting here glutamic acid does not sufficiently mimic a phosphorylated serine 
(Quintavalle et al., 2007). Two major culture adaptive mutations in a ConI replicon, S2197P 
and S2204I (serines 225 and 232, respectively), were both associated with significant 
enhancements in replication and a concurrent reduction in hyperphosphorylation (Blight et 
al., 2000, Krieger et al., 2001). However, as mentioned earlier these adaptive mutations do 
not establish a robust infection in chimpanzees (Bukh et al., 2002) 
 
To investigate the phenotype of other putative phosphorylation sites in the LCS I Appel et al. 
introduced phosphoablatant or phosphomimetic mutations across this region in a Con I 
subgenomic replicon. A broad enhancement in replication was observed when 
phosphoablatant mutations were introduced (225, 229, 232 and 235, JFH-1 numbering) and 
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I
348
I
407
I
416
I
451
I
460
2219
I
2223
I
I
247
I
251
hyper-phosa basal-phose,f virus releaseg
• phosporylated (ConI)i
• hyper-phos (JFH-I)b
• replication (JFH-I)b
n.p.c n.t.d
n.p. = no phenotype
n.t. =  not tested
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one phosphomimetic (serine 229, JFH-1 numbering) (Appel et al., 2005). These are discussed 
in further detail in (Section 3.3) due to the relevance to results generated herein. 
 
The mass spectrometry analysis of NS5A expressed as a single protein by a baculovirus 
system identified serine 247 as phosphorylated. The functional relevance of this 
phosphorylation was investigated by mutagenesis in both replicon and virus systems, 
however it was shown to have no phenotype (Nordle Gilliver et al., 2010). While the deletion 
of this entire region (residues 244-302, JFH-1 numbering) was shown to elicit no effect on 
the replication or release of the JcI chimeric virus, there was however a reduction in NS5A 
hyperphosphorylation (Appel et al., 2008). 
 
Similarly a phosphorylation site in the proline rich LCS II was identified using Edman 
degradation analysis of NS5A ectopically expressed from a polyprotein in a vaccinia-T7 
system in BHK21 cells. Such analysis identified serine 2321 (lysine 345 in JFH-1) as 
phosphorylated, but the functional relevance of this phosphorylation could not be 
investigated because, at the time, both replicon and virus systems were still in development 
(Reed and Rice, 1999). To our knowledge, the phenotype of S2321 phosphorylation has not 
been retrospectively investigated. 
 
In recent years the importance of domain III in the assembly of infectious virus has been well 
established (Section 1.6.3). As part of many of those studies it was shown that mutations 
which disrupted virus production also had effects on the phosphorylation of NS5A. In the 
J6/JFH (genotype 2a) chimeric virus the mutation to alanine of two serine clusters in domain 
III, 408-415 and 452-457 (JFH-1 numbering) dramatically reduced the basal phosphorylation 
of NS5A, Figure 1.11 (Masaki et al., 2008). As mentioned previously these mutations had no 
effect on virus replication but the second cluster abrogated virus assembly. In a ConI 
(genotype 1b) replicon mutation of the same two serine clusters also significantly reduced 
the basal phosphorylation of NS5A with no apparent effect on replication (Appel et al., 2008) 
 
A marked reduction in hyperphosphorylation of NS5A was also observed in the culture 
adapted virus JFH-AM120, previously discussed, where culture adaptive mutations 
predominantly clustered in domain III of NS5A. It was shown that this increase in virus 
production was not the result of enhanced replication, implying that extensive 
hyperphosphorylation is not a requirement for virus production (Liu et al., 2012). 
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Contrary to the observations that domain III is important for basal phosphorylation 
Tellinghuisen et al. convincingly showed that alanine mutation of serine 457 (in the second 
serine cluster of domain III) caused a reduction in hyperphosphorylation. However in line 
with other studies, virus assembly was abrogated and virus replication was not affected as a 
result. When a phosphomimetic mutation was made, to aspartic acid, a wild type phenotype 
was restored (Tellinghuisen et al., 2008a). Interestingly the phosphomimetic mutation 
neither enhanced above WT the levels of virus release nor impaired replication, arguing that 
if phosphorylation at serine 457 was the “switch” to virus release, it does not switch off virus 
replication. The phenotype of serine 457 was also later investigated in the context of NS2 
and virus assembly. It was shown that phosphoablatant mutations resulted in disruption of 
the punctate localisation of NS2 and that this was restored by phosphomimetic mutations 
(Popescu et al., 2011a). 
 
It is worth noting that to date no putative phosphorylation sites in domain III have been 
confirmed biochemically by techniques such as mass spectrometry. Nevertheless the current 
mutagenesis data is very suggestive that phosphorylation of serines within these two 
clusters in domain III is requirement for the assembly of virus, Figure 1.11. Furthermore, 
while it is disputed in the literature as to whether phosphorylated domain III is a component 
of basal- or hyperphosphorylated NS5A, the consensus is that it is involved with the former. 
 
1.6.4.2 Factors effecting NS5A phosphorylation 
While the identification of NS5A phosphorylation sites is far from complete, many different 
virus and host factors have been shown to dramatically effect NS5A phosphorylation, 
summarised in Table 1.3. The formation of hyperphosphorylated NS5A is dependent on the 
presence of the NS3-5A polyprotein in cis, with the addition in trans of each protein being 
insufficient for hyperphosphorylation (Koch and Bartenschlager, 1999, Asabe et al., 1997). 
Furthermore, the protease activity of NS3 in cis was also shown as a requirement for 
hyperphosphorylation, together arguing that the phosphorylation of NS5A is dependent on 
translation (Neddermann et al., 1999).  
 
As mentioned, several culture adaptive mutations within the LCS I result in a reduction in 
hyperphosphorylation and a corresponding enhancement of replication (Blight et al., 2000, 
Krieger et al., 2001, Neddermann et al., 2004). Specifically Blight et al. showed that the 
replication enhancing mutation S2204I (serine 232 in JFH-1) reduced hyperphosphorylation, 
while the equally replication enhancing mutation A2199T/S (alanine 227 in JFH-1) did not 
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reduce hyperphosphorylation (Evans et al., 2004). However, more recent analysis of a ConI 
polyprotein expressed by a Vaccinia/T7 system showed that the mutation A2199S had 
significantly increased levels of NS5A hyperphosphorylation (Qiu et al., 2011). Moreover, it 
was shown that NS5A with a glycine instead of an isoleucine mutation at S2204, NS5A was 
still hyperphosphorylated, but to a lesser extent than WT. Suggesting that it is not simply the 
absence of a phosphorylation site at position 2204, but the steric/conformation influence of 
the bulkier isoleucine reside that reduces hyperphosphorylation (Fridell et al., 2011). 
 
Similar effects have been observed with culture adaptive mutations in the NS4B protein, 
were the K1846T mutation showed a reduction in hyperphosphorylation and an 
enhancement to virus replication (Evans et al., 2004). Other work showed that swapping the 
C-terminal domain of NS4B with that of ConI or H77 isolates resulted in a specific reduction 
in NS5A hyperphosphorylation, no effect on replication and a reduction in virus production. 
(Han et al., 2013). These phenotypes were also partially rescued by adaptive mutations in 
NS4B and NS5A. Interestingly the culture adaptive mutations that reduce NS5A basal or 
hyperphosphorylation do not appear to confer a different sub-cellular localisation of NS5A, 
in both cases having WT localisation to lipid droplets (Han et al., 2013, Liu et al., 2012). The 
application of modern high resolution confocal microscopy would undoubtedly shed more 
light on this. 
 
Several point mutations in NS4A, between residues 1697-1710 (polyprotein numbering), 
were also shown to reduce hyperphosphorylation of NS5A in a manner that was recovered 
by culture adaptive mutations within NS3 (Lindenbach et al., 2007). Most interestingly was 
the direct linear relationship between the reduction in NS5A phosphorylation and the 
reduction in RNA replication that was observed. That this relationship is the opposite of the 
many other studies previously discussed highlights that our understanding of NS5A 
phosphorylation is insufficient to be able to rationalise these different experimental 
observations, Table 1.3. 
 
Alongside the effects of virus factors on NS5A phosphorylation many studies have identified 
several host cellular proteins and chemical inhibitors that also influence NS5A 
phosphorylation. For example, upon siRNA knockdown or chemical inhibition of the 
phosphatidylinositol 4-kinases-IIIα (PI4KIIIα) there is a consistent drop in NS5A basal-
phosphorylation and replication (Reiss et al., 2013, Bianco et al., 2012). 
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 Agonist 
Effect on 
phosphorylation Other effects Comments References 
In
h
ib
it
o
r 
AL-9, PI4K 
inhibitor 
Reduced basal-
phosp. 
Impaired 
replication 
Same effects with 
siRNA knockdown 
Reiss et al., 2013, 
Bianco et al., 2012. 
Undisclosed, CKI 
inhibitor 
Reduced hyper-
phosp. 
Impaired 
replication  
Neddermann et al., 
2004. Quintavalle et 
al., 2006 
Daclatasvir, NS5A 
inhibitor 
Reduced hyper-
phosp. 
Impaired 
replication 
Block on NS5A 
phosphorylation not 
the mechanism of 
inhibition 
Qiu et al., 2011 
BI2536, PlkI 
inhibitor 
Poss. reduced 
hyper-phosp. 
Impaired 
replication 
Same effects with 
siRNA knockdown 
Chen et al., 2010. 
M
u
ta
ti
o
n
s 
S2197P and 
S2204I (serine 
225 and 232 in 
JFH-1) 
Reduced hyper-
phosp. 
Increased 
replicon (ConI).  
Blight et al., 2000. 
Krieger et al., 2001 
Multiple LCSI 
mutations 
Reduced hyper-
phosp. 
Impairment or 
enhancement to 
replication 
Genotype dependent 
effect on replication. 
(1b enhance, 2a 
inhib.) 
Appel et al., 2005, 
Fridell et al., 2013 
S2204A (serine 
232 in JFH-1) 
Reduced hyper-
phosp. 
Increased 
replicon (ConI)  
Neddermann et al., 
2004 
S222A 
Reduced hyper-
phosp. 
Slightly reduced 
replication (JFH)  
LeMay et al., 2013 
Serine cluster 
domain III, 
(serines 408-415, 
452-457 in JFH-1) 
Reduced basal-
phosp. 
Wildtype 
replication. 
Impaired 
release 
 
Masaki et al., 2008. 
Appel et al, 2008. 
Culture adapted 
virus 
Reduced hyper-
phosp. 
Increased virus 
production 
Wt RNA replication. 
No change in LD 
association 
Liu et al., 2012 
O
th
er
 p
ro
te
in
s 
NS3 protease 
activity 
Reduced hyper-
phosp.  
Wt NS3 in trans does 
not recover phos 
Neddermann et al., 
1999 
Multiple NS4A 
point mutations 
Reduced hyper-
phosp. 
Impaired 
replication 
Linear relationship 
between replication 
and phosphorylation 
Lindenbach et al., 
2007 
NS4B culture 
adaptive 
mutations. 
K1846T 
Reduced hyper-
phosp. 
increase 
replication  
Evans et al., 2004. 
NS3/4A/4B in cis 
Reduced hyper-
phosp. 
n/a 
 
Koch et al., 1999. 
Nedderman et al 1999 
Absence of NS4A 
Reduced hyper-
phosp. 
n/a 
 
Kaneko et al., 1994. 
Asabe et al., 1997 
Regions of NS4B 
Reduced hyper-
phosp. 
Wildtype 
replication, 
reduced virus 
production 
Chimeras of C-
terminal domain 
from ConI and H77 
isolates 
Han et al., 2013 
Amphiphysin II 
Reduced hyper-
phosp. 
n/a 
 
Masumi et al., 2005 
 
Table 1.3. Factors effecting phosphorylation  
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While it is tempting/possible that PI4KIIIα is involved with NS5A phosphorylation, there has 
been no reported evidence that phosphatidylinositol 4-kinases-IIIα (PI4KIIIα) directly 
phosphorylates NS5A, more over there is only very limited evidence of this lipid kinase 
having protein kinase activity (Suer et al., 2001). Nevertheless, it is also worth noting that the 
PI4PKIIIα binding site is between residues 187-214, just N-terminal of the phosphorylated 
LCS I. Observations with a PI4KIIIα inhibitor, AL-9, also showed an alteration in the basal 
phosphorylation state of NS5A (Bianco et al., 2012, Reghellin et al., 2012). Furthermore, both 
basally and hyperphosphorylated NS5A could be co-immunoprecipitated with PI4KIIIα, 
suggesting that phosphorylation of NS5A might not regulate this interaction (Reiss et al., 
2013). 
 
The NS5A inhibitor Daclatasvir has also been shown to have dramatic effects on the 
phosphorylation of NS5A, causing a rapid and significant reduction in hyperphosphorylated 
NS5A prior to having an effect on inhibiting replication (Qiu et al., 2011, Fridell et al., 2011). 
As well as blocking phosphorylation and replication, Daclatasvir also causes a dramatic 
relocalisation of NS5A from the ER towards lipid droplets, and that the Daclatasvir resistance 
mutation Y93H is refractory to this relocalisation (Targett-Adams et al., 2011, Qiu et al., 
2011). While the mechanism of action of Daclatasvir is not fully understood, it is not believed 
to inhibit HCV replication by blocking NS5A phosphorylation.  
 
1.6.4.3 Kinases involved in NS5A phosphorylation 
The identification of kinases that phosphorylate NS5A and the precise sites that they 
phosphorylate remain to be unambiguously determined. A range of kinases have been 
reported to phosphorylate NS5A either in vitro or in vivo and these are discussed in turn, 
Table 1.4. 
 
Casein kinase I and II (CKI and CKII) have both been shown to phosphorylate NS5A in a 
variety of systems, and knockdown or inhibition of these kinases abolishes replication or 
virus assembly respectively. The recognition motifs for these two kinases are pSXXS/T and 
SXXE/D respectively. Ectopic expression of CKI-α, -δ and -ε with the NS3-5B polyprotein 
resulted in an increase in NS5A hyperphosphorylation, while the siRNA knockdown or 
chemical inhibition of endogenous CKI-α resulted in a reduction in hyperphosphorylation 
(Neddermann et al., 2004, Quintavalle et al., 2006). It was subsequently shown that CKI-α 
could phosphorylate a synthetic mimic of the LCS I at position serine 232 (Quintavalle et al., 
2007). Interestingly kinase inhibitors with activity towards CKI enhanced the replication of a 
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non-culture adapted ConI SGR to levels comparable with those containing the S2204A 
adaptive mutation. The S2204A mutation, like the S2204I culture adapted mutation, 
enhances replication and results in a reduction in NS5A hyperphosphorylation (Neddermann 
et al., 2004).  
 
Casein kinase II (CKII) has also been shown to phosphorylate NS5A, initially identified in an in 
vitro kinase screen (Kim et al., 1999) and subsequently shown to phosphorylate S457 in 
domain III in the context of Huh7 cells infected with the JcI virus (Tellinghuisen et al., 2008a). 
Disruption of CKII phosphorylation of NS5A - either by site mutation, drug inhibition or siRNA 
knockdown - was inhibitory to the release of infectious virus, but not viral RNA replication. 
Controversially, and discussed earlier, Tellinghuisen et al. implicated phosphorylated serine 
457 to exist in the hyperphosphorylated species, but this is not the consensus in the 
literature (Appel et al., 2005, Liu et al., 2012, Masaki et al., 2008). 
 
Kinase involved 
Region of 
NS5A involved 
Effect on 
phosphorylation System Reference 
Casein 
Kinase I-α 
CKIα 
Hyper-
phosphorylation 
Silencing CKIα 
inhibited 
replication 
in vitro kinase, 
overexpression in 
cell 
Quintavalle 
et al, 2006 
Casein 
Kinase I-α 
CKIα S232 (JFH-1) - 
in vitro kinase 
assay 
Quintavalle 
et al, 2007 
Casein 
Kinase II 
CKII Phosphorylated - 
in vitro kinase 
assay 
Kim et al, 
1999 
Casein 
Kinase II 
CKII 
S457 (JFH-1), 
hyper-
phosphorylation 
Inhibition reduced 
virus release 
Replicon (siRNA 
and inhib) and in 
vitro kinase assay 
Tellinghuisen 
et al, 2008 
Casein 
Kinase II 
CKII - 
Regulation of NS5B 
polymerase activity 
in vitro 
kinase/polymeras
e assay 
Ivanov et al, 
2008 
Polo-like 
Kinase I 
PLKI 
DI, LCSI-DII, 
LCSII-DIII 
Silencing PLKI 
inhibited 
replication 
Replicon (siRNA 
and inhib) and in 
vitro kinase assay 
Chen et al, 
2010 
cyclic 
adenosine 
monophosp
hate 
dependent 
protein 
kinase A-α 
PKAα phosphorylated - 
in vitro kinase 
assay 
Ide et al, 
1997 
Phosphotidy
linositol-4 
kinase IIIα  
PI4KIIIα 
Possible NS5A 
kinase? Basal 
phosphorylation 
- 
Replicon (siRNA, 
chemical 
inhibition and 
mutagenesis) 
Reiss et al,  
2013 
 
Table 1.4. Summary of known kinases involved with the phosphorylation of NS5A 
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Interesting observations in an in vitro polymerase system showed that the phosphorylation 
state of NS5A directed whether or not it inhibited the RdRp activity of NS5B (Ivanov et al., 
2009). Specifically, CKII phosphorylated NS5A blocked the polymerase activity of NS5B, 
whereas CKI phosphorylated NS5A did not, and the converse was seen when a poly-A was 
used instead of viral RNA as RdRp template. 
 
The polo-like kinase I (PlkI) is another kinase that was shown to in vitro phosphorylated NS5A 
(Chen et al., 2010). Each individual domain of bacterially expressed NS5A was capable of 
being phosphorylated by PlkI, note that domain II and III were inclusive of the LCSI and LCSII 
respectively. The shRNA knockdown or chemical inhibition of PlkI was sufficient to 
specifically block viral RNA replication, and there was indications of a concurrent reduction in 
hyperphosphorylated NS5A (Chen et al., 2010). The exact residue phosphorylated by PlkI in 
vitro was not determined, but the consensus recognition motif for PlkI does correlate to 
serines 225, 229 and 232 in the LCS I. 
 
The kinase cAMP-dependent protein kinase A-α subunit (PKAα) has also been shown to 
phosphorylate NS5A in an in vitro kinase system, but what region of NS5A was 
phosphorylated or whether there was an in vivo function was not investigated (Coito et al., 
2004, Ide et al., 1997). Similarly a yeast kinase screen identified number of kinases capable of 
in vitro phosphorylation of NS5A that have yet to be investigated further, these yeast kinases 
had high homology to the following human kinases: glycogen synthase kinase-3 (GSK3), 
protein kinase C (PKC), AKT3, serum/glucocorticoid-regulated kinase 2 (SGK2), AKT1, MEK, 
MKK, (Coito et al., 2004).  
 
 
 
 
 
 56 
 
 
 
 
 
 
 
 
 
 
 
 
2 Chapter 2: Materials and Methods 
 
 
Chapter 2: Materials and Methods 
57 
 
2.1 Mammalian cell line 
The human hepatocellular carcinoma cell line, Huh7, is permissive to the complete HCV 
lifecycle in tissue culture and was used throughout. 
 
2.2 Plasmid and virus sequences 
DNA constructs of either the full length pJFH-1 virus (Wakita et al., 2005), luciferase reporter 
sub-genomic replicon (SGR-luc JFH-1) (Targett-Adams & McLauchlan 2005) or neomycin 
reporter SGR with NS5A containing a One-Strep-tag (1ST) (pSGR-5A1ST) (Amako et al., 2009) 
were used throughout. The Litmus28i (New England Biolabs, NEB) was used as a sub-cloning 
vector; previously the NsiI/HindIII fragment from the JFH-1 was cloned into the multiple 
cloning site (MCS) of Litmus 28i. 
 
H77 - genotype 1a, accession number: AF011753 
ConI - genotype 1b, accession number: AJ238799 
JFH-1 - genotype 2a, accession number:  AB047639 
HC-J6 - genotype 2a, accession number: D00944 
 
2.3 Bacteria stains 
Escherichia coli (E. coli) DH5α genotype: F- φ80lacZΔM15 Δ(lacZYA-argF) U169 recA1 endA1 
hsdR17(rk-, mk+) phoA supE44 thi-1 gyrA96 relA1 λ- (Invitrogen) were used for cloning. 
 
2.4 Antibodies 
  Target (species) Source Comments Dilution 
P
ri
m
ar
y 
NS5A (sheep) MacDonald et al, 
2003. 
Polyclonal serum Various 
NS5A (mouse) Lindenbach et al., 
2005 
Monoclonal, 9E10 Various 
Tubulin (rat) Abcam Monoclonal Various 
GAPDH (mouse) Abcam Monoclonal, 6C5 1 : 20,000 
Core (sheep) In house Polyclonal serum Various 
Se
co
n
d
ar
y 
Donkey α-Sheep Sigma-Aldrich HRP conjugate 1 : 10,000 
Goat α-Rat Sigma-Aldrich HRP conjugate 1 : 10,000 
Goat α-Mouse Sigma-Aldrich HRP conjugate 1 : 10,000 
Donkey α-Goat/Sheep LiCor Fluorescence 800 nm 1 : 10,000 
Goat α-Mouse LiCor Fluorescence 700 nm 1 : 10,000 
Donkey α-Sheep Invitrogen Fluorescence,  various  1 : 1,000 
Goat α-Rat Invitrogen Fluorescence, various  1 : 1,000 
Goat α-Mouse Invitrogen Fluorescence, various  1 : 1,000 
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Table 2.1. Summary of antibodies and dilutions. 
 
 
2.5 Basic molecular biology techniques 
2.5.1 Preparation of plasmid DNA from bacterial cultures 
Chemical competent bacteria were prepared following the Inoue et al. method and 
transformed with plasmid DNA at a volume ratio of 50:1 by heat shock at 42 °C for 45 
seconds, followed by incubation at 30 °C for 60 minutes (Inoue et al., 1990). After incubation 
transformed bacteria were plated onto agar plates containing the appropriate antibiotic and 
incubated o/n at 30 °C. Single colonies were subsequently picked from agar plates into LB 
medium again containing the appropriate antibiotic, cultures were grown at 30 °C, 200 rpm 
agitation until saturated, typically overnight. Bacterial broths were pelleted at 4000 x g, 60 
mins at 4 °C, supernatants removed and bacteria cell pellet either stored at -20 °C or 
processed immediately. DNA was extracted by alkaline lysis and purified by anion-exchange, 
typically using the commercial kit Maxiprep (Qiagen). In brief, bacterial pellets were 
resuspended in resuspension solution (50 mM Tris.Cl pH 8.0, 10 mM EDTA, 100 μg/ml RNase 
A), before the addition of lysis buffer (200 mM NaOH, 1 % (w/v) SDS) and gently mixed 
before incubation for 5 mins, RT and the addition of neutralisation buffer (3 M potassium 
acetate pH 5.5). Bacterial debris was pelleted at 4000 x g, 60 min at 4 °C and the clarified 
supernatant containing DNA loaded onto an anion-exchange column. Long term storage of 
plasmid DNA was as glycerol preparations of bacterial cultures, prepared by resuspending a 
pelleted 1 ml bacterial culture in 30 % (v/v) glycerol : 70 % (v/v) LB medium and freezing to -
80°C. 
 
2.5.2 Polymerase chain reaction (PCR) 
The polymerase chain reaction was utilised for site-directed mutagenesis (see below), PCR 
cloning and screening bacterial colonies. For the latter, a stab culture was generated by 
picking bacterial colonies into 10 µl of dH2O and incubated for 10 mins at RT before 
progressing into the PCR. Reactions were composed of either 50 ng template or 10 µl of stab 
culture, 1 µM forward and reverse primers, 1 mM dNTP, 1 % (v/v) glycerol, 6 % (v/v) DMSO. 
PCR reactions were cycled depending on experiment, but in general, 30 sec at 95 °C followed 
by, 40 cycles of 30 sec at 95 °C, 60 sec at 55 °C, 10 min at 68 °C. 
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2.5.3 Site-directed (Quikchange) mutagenesis  
Complementary site-directed mutagenesis primers were designed using PrimerX software 
(Lapid and Gao, 2003) following the constraints 25 to 45 bp, GC content 40-100 %, melting 
temp between 60-90 °C and 15 to 21 bp flanking sequence, Appendix figure 8.15. PCR 
reactions composed of 50ng template, 1 µM forward and reverse primers, 1 mM dNTP, 1 % 
(v/v) glycerol, 6 % (v/v) DMSO. PCR reactions were cycled as follows, 30 sec at 95 °C followed 
by, 5 cycles of 30 sec at 95 °C, 60 sec at 52 °C, 25 min at 68 °C then 13 cycles of 30 sec at 95 
°C, 60 sec at 55 °C, 25 min at 68 °C. After PCR cycling the input template was degraded by the 
addition of 1 µl DpnI and incubation for 60 mins at 37 °C, before transformation into bacteria 
as described (Section 2.5.1). Mutagenesis of NS5A was performed directly on a Litmus28i 
(NEB) sub-clone containing an NsiI/HindIII fragment of the mJFH-1 cDNA, and then cloned 
into the relevant vector as described. 
 
2.5.4 Protein quantification 
Protein solutions, e.g. cell lysates, were quantified using bicinchoninic acid (BCA) assay 
(Thermo Scientific). Bovine serum albumin (BSA) was prepared to 10 mg/ml in dH20 and 
serially diluted 10-fold over 12 concentrations. To each reaction well (96-well format) either 
2 μl cell lysate or 10 μl BSA standards was added, along with either 10 μl dH20 or 2 μl of the 
buffer used for the cell lysate followed by the addition of 88 μl BCA reaction mixture as 
directed. The 96-well plate was incubated at 37 °C for 20 minutes before reading absorbance 
at 570 nm and manual calculation  protein concentrations using a linear regression.  
 
2.5.5 Gel electrophoresis, SDS-PAGE and Western blot 
Cells were washed twice with PBS, lysed by resuspension in Glasgow lysis buffer (GLB – 1 % 
(v/v) Triton X-100, 120 mM KCl, 30 mM NaCl, 5 mM MgCl2, 10 % (v/v) glycerol, 10 mM PIPES-
NaOH, pH 7.2) containing protease and phosphatase inhibitors, and incubated on ice for 15 
mins.  Insoluble material was pelleted by centrifugation at 500 x g for 5 mins at 4 °C. 
Following separation by SDS-PAGE proteins were transferred to a polyvinylidene fluoride 
(PVDF) membrane and blocked in 50 % (v/v) Odyssey blocking buffer (LiCor) in PBS. The 
membrane was incubated with primary antibody in 50 % (v/v) Odyssey blocking buffer, then 
incubated with fluorescently labelled α-Goat (800nm) or α-Mouse (700 nm) before imaging 
on a LiCor Odyssey Sa fluorescent. Primary antibodies α-NS5A (9E10) (Lindenbach et al., 
2005); α-NS5A (sheep) and α-Core (sheep), in house. 
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2.5.6 Bacterial expression of GST-SH3 domains 
GST tagged fusion proteins of SH3 domains were created previously and expressed as 
described in (Macdonald et al., 2004). In brief, bacteria were transformed with DNA (Section 
2.5.1) and a single colony used to inoculate 10 ml LB and grown o/n at 30 °C. This saturated 
starter culture was then used to inoculate 100 ml of LB which was subsequently grown at 30 
°C until it reached an OD of 0.6, and induced with 1 mM Isopropyl β-D-1-
thiogalactopyranoside (IPTG). After 4 hrs of induction bacteria were cooled to 4 °C, pelleted 
at 2,000 x g for 30 mins at 4 °C. Bacterial pellet was resuspended in lysis buffer (1 % (v/v) 
Triton X-100 in PBS), sonicated for 10 cycles of 45 sec and cell debris pelleted at 4,000 x g. 
GST fusion proteins were subsequently immobilised to glutathione resin (GE Healthcare) o/n 
at 4 °C following manufacturers guidelines. Decorated glutathione resin was then used in 
NS5A interaction experiments.   
 
2.6 Nucleic acid techniques 
2.6.1 Phenol/chloroform purification 
Nucleic acid was purified from solutions containing proteins (typically following an 
endonuclease or I.V.T. reaction) by phenol/chloroform extraction. An equal volume of 
phenol:chloroform:isoamylalcohol (25:24:1, pH 8 for DNA or pH 5.2 for RNA) (Sigma-Aldrich) 
was added to the reaction, vortexed and phases separated by centrifugation at 16,000 x g for 
5 mins at RT. Aqueous phase was removed  and added to an equal volume of chloroform, 
vortex and phases separated as described. DNA was purified from second aqueous phase by 
ethanol precipitation, see below. 
 
2.6.2 Ethanol precipitation 
Nucleic acid was desalted and concentrated, typically after phenol/chloroform purification, 
by ethanol precipitation. To nucleic acid the addition of 2 volumes 100 % (v/v) ethanol, and 
0.1 volumes 3M sodium acetate, pH 5.2, before cooling to -20 °C for 20 mins and pelleting at 
16,000 x g for 30 mins. DNA pellet was washed in 70 % (v/v) ethanol and resuspended in 
dH2O, typically 20-100 µl. 
 
2.6.3 Quantification 
Nucleic acid was quantified by absorbance at 260 nm by NanoDrop (Thermo Scientific) or 
direct comparison with markers after agarose electrophoresis, Hyperladder I (Bioline) or 
Millenium Markers (Millipore) for DNA and RNA respectively. 
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2.6.4 Endonuclease digestion 
Typically 3-10 μg of DNA was digested with 10 U of commercial endonucleases (BamHI, RsrII, 
AfeI etc.) in the relevant commercial buffers for 4 – 8 hrs. A standard temperature of 37 °C 
was used unless denoted otherwise by the manufactures. Digested DNA fragments were 
purified by agarose gel electrophoresis and extracted from the gel using the commercial 
QIAquick  gel extraction kit (Qiagen). 
 
2.6.5 Agarose gel electrophoresis 
Gels were prepared at between 0.8 - 1.0 % (w/v) agarose in 1 x TAE (40 mM Tris, 0.11 % (v/v) 
acetic acid, 1 mM EDTA with the addition of SYBR safe at 1:10,000 dilution. Samples were 
prepared in loading buffer (1 x TAE, 5 % (v/v) glycerol and containing bromophenol blue) 
before loading onto gel and electrophoresing at 100 V for between 15-60 mins. Gels were 
imaged with blue light and orange filter. 
 
2.6.6 DNA sequencing and analysis 
DNA was sequenced by commercial company using Sanger sequencing techniques with 
custom primers designed against the relevant sequence, see Appendix figure 8.16. 
 
2.6.7 In vitro transcription of RNA 
DNA constructs, e.g. mSGR-luc JFH-1 or mJFH-1, were linearised by XbaI and overhanging 
ends degraded by mung bean nuclease treatment.  DNA was phenol/chloroform extracted 
and 1 µg of linearised DNA used as template in a 20 µl RiboMAX reaction (Promega). RNA 
transcripts were purified by phenol/chloroform extraction and quantified by absorbance at 
260 nm. RNA was also analysed by agarose gel electrophoresis to confirm integrity and 
quantification. 
 
2.7 Mammalian tissue culture 
2.7.1 Mammalian tissue culture 
Huh7 cells were cultured in Dulbecco’s Modified Eagles Medium (DMEM; Sigma) 
supplemented with 10 % foetal bovine serum (FBS), 100 IU penicillin/ml, 100 µg/ml 
streptomycin and 1 % non-essential amino acids (Lonza) in a humidified incubator at 37 °C, 5 
% CO2. Cells were passaged every three days by washing in phosphate buffered saline (PBS) 
prior to incubating with trypsin-EDTA solution (Sigma-Aldrich) for 5 mins to detach cells, then 
resuspending in complete culture media before either reseeding for further passage or using 
for experiments. For virus propagation media was supplemented with 25 mM HEPES. 
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Replicons containing a neomycin resistance gene were passaged 1:5 every 3 days under 0.5 
mg/ml G418 (Sigma-Aldrich). 
 
2.7.2 Transfection of DNA 
DNA was transfected into cells using FuGene 6 (Promega) transfection reagent according to 
the manufacturer’s directions. For example, Huh7 cells were seeded at 2x105 cells / 6-well 24 
hrs prior to transfection. Transfection reaction was prepared by adding 1 µg plasmid DNA to 
98 µl Opti-MEM (Life technologies) followed by the addition of 3 µl FuGene 6, gentle mixing 
and incubation at RT for 30 mins. Transfection reaction was then added drop-wise to seed 
cells, without exchange of media. Typically at 48 hours post-transfection (hpt) cells were 
washed twice in PBS and lysed in GLB.  
 
2.7.3 Immunofluorescence 
In experiments utilising confocal microscopy based immunofluorescence (IF) cells were 
seeded onto 20 mm sterile glass coverslips housed in normal 12-well tissue culture plates. 
Cells were fixed by washing twice in PBS before the addition of 4 % (w/v) paraformaldehyde 
(4 % PFA) in PBS and incubation at RT for 20 minutes. Cells were then washed in PBS twice 
before either storing at 4 °C or permeabilising by the addition of 0.1 % (v/v) Triton-X100 in 
PBS for 7 mins followed by washing in PBS. After cells were fixed and permeabilised they 
were ready for immunostaining. Primary and secondary staining was carried out in 5 % (v/v) 
FBS in PBS, in the case of primary for 1 hr at RT or o/n at 4 °C and for secondary staining 1 hr 
at RT. Antibody dilutions denoted in Table 2.1. After staining coverslips were air dried to near 
complete dryness before mounting onto glass slides with Prolong gold (Invitrogen).  
 
2.7.4 SNAP/CLIP-tag labelling of proteins 
Labelling solution was prepared by dissolving SNAP/CLIP-substrates (e.g. SNAP-505, NEB) in 
DMSO to 1 mM, before diluting in complete DMEM culture medium to a final concentration 
of to 5 μM. Huh7 cells were subsequently incubated with labelling solution for 1 hr under 
normal tissue culture conditions before washing twice with complete media, and incubating 
for a further 30 mins with fresh complete media to allow unreacted dye to wash out. Cells 
were then either fixed in 4 % PFA as described earlier or imaged directly. 
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2.8 Sub-genomic replicon assays 
2.8.1 Transient replication assay 
Huh7 cells were washed twice in diethylpyrocarbonate (DEPC)-treated PBS before 
electroporating 4x106 cells in DEPC-PBS with 2 µg of RNA at 950 µF and 270 V. Cells were 
resuspended in complete media before being seeded into both 96-well plates (n=6) at 3x104 
cells / well, and 6-well plates (n=2) at 3x105 cells / well, both plates incubated under cell 
culture conditions.  After 4, 24, 48 and 72 hours post-electroporation (hpe) cells were 
harvested by lysis with either 30 µl or 200 µl passive lysis buffer (PLB; Promega), 96- and 6-
well respectively. Luciferase activity was determined from 96-well samples on a BMG plate 
reader by automated addition of 50 µl LarI reagent (Promega) and total light emission 
monitored over 12 seconds 
 
2.8.2 Drug efficacy assays (EC50) 
Huh7 cells were electroporated and seeded as described for luciferase based replication 
assay in 96-well plates (Section 2.8.1). The drug to be tested was serially diluted 12 times 
with 5-fold dilutions in DMSO, followed by further dilutions in complete DMEM media until 
DMSO concentration was < 0.5 % (v/v). At 4 hpe the cells were treated with the serially 
diluted drug, incubated under normal conditions and harvested at 48 hpe by washing the 
cells in PBS followed by the addition of 30 µl PLB. Luciferase activity was then determined by 
addition of 50 µl luciferase reagent (LAR I, Promega). Data was modelled using a log[agonist] 
vs. response model (Appendix Figure 8.10A) and EC50 calculated using Prism (Graphpad). 
 
2.8.3 Drug toxicity assay (CC50) 
Drug toxicity assays were carried out in the same manner (typically in parallel) as the drug 
efficacy assays. However at 48 hpe there was an addition of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT, Sigma) to cells at a final concentration of 1 µM, 
followed by incubated for 2 hrs under normal TC conditions. Following this media was 
removed from cells and the MTT precipitate dissolved by the addition of 100 µl DMSO and 
absorbance measured at 570 nm. Data was modelled and CC50 calculated as for EC50.  
 
2.9 Full length virus assay 
2.9.1 Electroporation of cells 
Huh7 cells were washed twice in DEPC-treated PBS before electroporating 2x106 cells in 
DEPC-PBS with 1 µg of RNA at 950 µF and 270 V. Cells were resuspended in complete media 
and seeded at 1x106 cells / well into 6-well plates. At 72 hpe cells were split at 1:5 before 
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incubating for a further 72 hrs. At 144 hpe cells were harvested in 400 µl TRIzol for qRT-PCR 
analysis while supernatants were removed and clarified at 2800 x g for 5 mins at RT before 
storing at -80 °C. 
 
2.9.2 Titration of virus by focus forming assay 
Virus supernatants were clarified at 2,800 x g for 5 minutes at RT before being titred on Huh7 
cells as follows. In 96-well format, clarified virus supernatants were serially diluted 5-fold in 
complete DMEM media + HEPES before the addition of 100 µl diluted virus to Huh7 cells that 
were seeded 24 hrs before into 96-well plates at 8x103 cells / well, final volume 200 µl.  Cells 
incubated under normal cell culture conditions for 72 hrs before washing in PBS and fixation 
in 4 % PFA for 20 min.  Cells were permeabilised in 0.1 % (v/v) Triton X-100, 10 % (v/v) FBS, 1 
X PBS for 7 mins followed by staining with α-NS5A (sheep) (Macdonald et al., 2003) at 1:5000 
followed by a corresponding secondary fluorescent antibody. Foci were counted manually to 
determine virus titres. 
 
2.9.3 Genome quantification by qRT-PCR 
To quantify the number of HCV genomes total cell RNA was extracted by TRIzol following 
manufacturer’s instructions (Invitrogen).  Total extracted cellular RNA, 100 ng, was analysed 
by qRT-PCR using a one-step qRT-PCR TaqMan based kit as directed (Eurogentec), primers 
and probe designed against the 5’ UTR described previously (Takeuchi et al., 1999). 
 
2.10 Expression and purification of NS5A-1ST 
2.10.1 Generating replicon stable cell line 
A stable Huh7 cell line harbouring the SGR-5A1ST subgenomic replicon (Amako et al., 2009) 
was passaged 1:5 every 3 days under 0.5 mg/ml G418 selection (Sigma) and cell passage 
number was maintained low to avoid culture adaptations. At each passage excess cells were 
washed twice in PBS, pelleting at 500 x g, 5 min at RT, before the resuspension in GLB, 2 ml 
per T175, and storing at -20 °C until NS5A-OST purification. 
 
2.10.2 Purification of NS5A-OST by affinity column 
In batch, lysates were clarified by centrifugation at 4000 x g, 5 min at 4 °C, filtered through 
0.45 µm cellulose filter before affinity purification of NS5A-OST in batch on Strep-Tactin 
Sepharose columns, 5 ml CV (IBA) following the manufacturer’s instructions.  Bound protein 
washed with 1 CV of wash buffer supplemented with low salt (0.5 M NaCl) or high salt (1 M 
NaCl, 1 % (v/v) Triton X-100) for three and four washes respectively before two standard 
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washes and competitive elution with 2.5 mM desthiobiotin, 0.5 CV. Peak elution fractions, 3 
and 4, were identified by Western blot analysis and concentrated, first by centrifugation 
filtration (10 kDa MCO) followed by methanol/chloroform precipitation. Final precipitate was 
resuspended in 20 µl of 1X SDS-LB and separated further on a 12 % Tris-Glycine SDS-PAGE.  
After staining with Coomassie R250 followed by de-staining in 50 % (v/v) water, 40 % (v/v) 
MeOH, 10 % (v/v) acetic acid the band corresponding to NS5A was excised for mass 
spectrometry analysis.   
 
2.11 Phospho-mapping by Mass spectrometry (MS) 
2.11.1 Enzymatic digestion of protein 
In-gel proteolytic digestions with endoproteinases trypsin and Glu-C were performed after 
reduction with DTE and S-carbamidomethylation with iodoacetamide. Gel pieces were 
washed two times with 50 % (v/v) aqueous acetonitrile containing 25 mM ammonium 
bicarbonate, then once with acetonitrile and dried in a vacuum concentrator for 20 min.  
Endoproteinase Glu-C from Staphylococcus aureus strain V8 (Sigma-Aldrich) and sequencing 
grade modified porcine trypsin (Promega) were reconstituted in 25 mM ammonium 
bicarbonate to give a final enzyme concentration of 0.004 μg/μl.  Gel pieces were rehydrated 
by adding 50 μl of either endoproteinase solution and allowed to digest overnight at 37 oC. 
 
2.11.2 Enrichment by Titanium dioxide affinity 
Peptide solutions were dried down in a vacuum concentrator to approximately 10 μl and 
diluted to 100 μl with a solution of 1 M glycolic acid in 80 % (v/v) aqueous acetonitrile, 5 % 
(v/v) trifluoroacetic acid.  Phosphopeptides were selectively enriched using manually packed 
titanium microcolumns as described by (Larsen et al., 2005).  Enriched Phosphopeptides 
were purified by Poros Oligo R3 reversed-phase a material and eluted directly onto a ground 
steel MALDI target plate with freshly-prepared 10 mg/ml solution of 2,5-dihydroxybenzoic 
acid (Sigma-Aldrich) in 50 % (v/v) aqueous acetonitrile, 1 % (v/v) phosphoric acid. 
 
2.11.3 Separation by HPLC 
The nanoLC system was interfaced with a maXis LC-MS/MS System (Bruker Daltonics) with a 
nano-electrospray source fitted with a steel emitter needle (180 µm O.D. x 30 µm I.D., 
Proxeon). Positive ESI- MS & MS/MS spectra were acquired using AutoMSMS mode. 
Instrument control, data acquisition and processing were performed using Compass 1.3 SP1 
software (microTOF control, Hystar and DataAnalysis, Bruker Daltonics). Instrument settings 
were: ion spray voltage: 1,500 V, dry gas: 6 L/min, dry gas temperature 160 °C, ion 
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acquisition range: m/z 50-2,200. AutoMSMS settings were: MS: 0.5 s (acquisition of survey 
spectrum), MS/MS (CID with N2 as collision gas): ion acquisition range: m/z 350-1,400, 0.1 
sec acquisition for precursor intensities above 100,000 counts, for signals of lower intensities 
down to 1,000 counts acquisition time increased linear to 1.5 sec, the collision energy and 
isolation width settings were automatically calculated using the AutoMSMS fragmentation 
table:, 3 precursor ions, absolute threshold 1,000 counts, preferred charge states: 2 – 4, 
singly charged ions excluded. 2 MS/MS spectra were acquired for each precursor and former 
target ions were excluded for 60 sec. 
 
2.11.4 ESI MS analysis 
Samples were loaded onto a nanoAcquity UPLC system (Waters) equipped with a 
nanoAcquity Symmetry C18, 5 µm trap (180 µm x 20 mm Waters) and a nanoAcquity BEH130 
1.7 µm C18 capillary column (75 m x 250 mm, Waters). The trap wash solvent was 0.1 % 
(v/v) aqueous formic acid and the trapping flow rate was 10 µl/min. The trap was washed for 
5 min before switching flow to the capillary column.  The separation used a gradient elution 
of two solvents (solvent A: 0.1 % (v/v) formic acid; solvent B: acetonitrile containing 0.1 % 
(v/v) formic acid). The flow rate for the capillary column was 300 nl/min Column 
temperature was 60 °C and the gradient profile was as follows: initial conditions 5 % (v/v) 
solvent B (2 min), followed by a linear gradient to 35 % (v/v) solvent B over 20 min, then a 
wash with 95 % (v/v) solvent B for 2.5 min. The column was returned to initial conditions and 
re-equilibrated for 25 min before subsequent injections 
 
2.11.5 MALDI MS analysis 
Positive-ion MALDI mass spectra were obtained using an ultraflex III mass spectrometer 
(Bruker, Bramen, Germany) in reflectron mode, equipped with a Nd:YAG smart beam laser.  
MS spectra were acquired over a mass range of 800-4000 m/z.  Final mass spectra were 
externally calibrated against an adjacent spot containing 6 peptides of known m/z (des-Arg1-
Bradykinin, 904.681; Angiotensin I, 1296.685; Glu1-Fibrinopeptide B, 1750.677; ACTH (1-17 
clip), 2093.086; ACTH (18-39 clip), 2465.198; ACTH (7-38 clip), 3657.929.). Peptides were 
manually selected for MS/MS fragmentation, which was performed in LIFT mode without the 
introduction of a collision gas. Fragmentation spectra were acquired manually with laser 
intensity and number of summed spectra optimised for each acquisition.  The default 
calibration was used for MS/MS spectra, which were baseline-subtracted and smoothed 
(Savitsky-Golay, width 0.15 m/z, cycles 4); monoisotopic peak detection used a SNAP 
averaging algorithm (C 4.9384, N 1.3577, O 1.4773, S 0.0417, H 7.7583) with a minimum S/N 
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of 6.  Bruker flex. Analysis software (version 3.3) was used to perform the spectral processing 
and peak list generation for both the MS and MS/MS spectra. 
 
2.11.6 Computational analysis of spectra 
Tandem mass spectral data were submitted to database searching using a locally-running 
copy of the Mascot program (Matrix Science Ltd., version 2.3), through the Bruker 
ProteinScape interface (version 2.1).  All spectral data were searched against an in-house 
database containing the expected protein sequence. Search criteria specified: Enzyme, either 
trypsin or Glu-C; Fixed modifications, Carbamidomethyl (C); Variable modifications, 
Oxidation (M) Phosphorylation (S,T); Peptide tolerance, 250 ppm for MALDI-MS/MS and 10 
ppm for LC-MS/MS; MS/MS tolerance, 0.5 Da for MALDI-MS/MS and 0.1 Da for LC-MS/MS; 
Instrument, MALDI-TOF-TOF or maXis.   
 
2.12 Statistical analysis of data 
Statistical analysis of data was carried out using a Students t-test assuming a two tailed 
distribution with a unequal variance. Error bars presented on all graphs illustrate the 
Standard Error of the Mean. 
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3.1 Introduction 
The NS5A protein is a highly phosphorylated protein that migrates as two different bands on 
a SDS PAGE gel, termed the basally phosphorylated and hyperphosphorylated species. These 
have an apparent molecular weight of 56 and 58 kDa respectively, however in genotype 2a 
the NS5A protein has a 19 aa insertion in domain III meaning it migrates as a 63 and 65 kDa 
species, Figure 3.1A.  
 
Our current understanding about regions of NS5A important for phosphorylation, and what 
the functional role of phosphorylation is, has been reviewed extensively in (Section 1.6.4). 
Much of this literature has focused on the importance of LCS I and domain III in the 
phosphorylation of NS5A. The dogma is that basal-phosphorylation is important for RNA 
replication and hyperphosphorylation is important for virus production, however this dogma 
is no longer supported by the literature. For example, the LCS I has been shown to be 
important for hyperphosphorylation (Lemay et al., 2013, Tanji et al., 1995) but mutations 
within this region have been shown to both enhance as well as impair replication in a 
genotype dependent manner (Appel et al., 2005, Fridell et al., 2013, Lemay et al., 2013). 
Similarly domain III is known to be essential for virus production, but mutations of serine 
clusters with those regions results in a reduction of NS5A basal-phosphorylation with no 
effect on hyperphosphorylation (Appel et al., 2005, Masaki et al., 2008). There is however 
evidence that phosphorylated serine 457 is a component of the hyperphosphorylated 
species (Tellinghuisen et al., 2008a). 
 
Much of the established literature on the phosphorylation on NS5A has been derived from 
either reverse genetic approach (Appel et al., 2005, Masaki et al., 2008, Tanji et al., 1995, 
Tellinghuisen et al., 2008a) or biochemical analysis of ectopically expressed NS5A (Katze et 
al., 2000, Nordle Gilliver et al., 2010, Reed and Rice, 1999). The use of reverse genetics has 
strongly implicated several serines as being sites of phosphorylation, however it is possible 
that these serines are not phosphorylated but are instead involved in kinase recognition or 
protein structure. As such biochemical observation, typically by MS, is required to confirm 
which serines are actual phospho-acceptors. 
 
The ectopic expression of NS5A has facilitated the MS identification of two serines (Katze et 
al., 2000, Nordle Gilliver et al., 2010). However, it is well established that the correct 
phosphorylation of NS5A is dependent on - at a minimum - the presence of other virus 
proteins as well as non-kinase host proteins (Koch and Bartenschlager, 1999, Reiss et al., 
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2013). Therefore whether these serines are phosphorylated in the context of a replicon or 
virus remains to be shown, especially as mutation of these sites elicited no phenotype in 
replicon (Nordle Gilliver et al., 2010). 
 
Indeed with the exception of a very recent study (Lemay et al., 2013) the mass spectrometry 
identification of phosphorylation sites on NS5A purified from infected cells has not been 
done. The technical challenges associated with this type of approach meant that Lemay et al. 
only managed to identify a single phosphorylation at position S222. When a virus harbouring 
an ablation of the S222 site (S222A) was labelled with 32P they observed only a slight 
reduction in intensity of the hyperphosphorylated species and no change in the basally 
phosphorylated species (Lemay et al., 2013). This again supporting the idea that NS5A has 
significantly more than one phosphorylation site, however these were likely not observed by 
LeMay et al. for reasons surrounding the detection of phosphopeptides by MS discussed 
previously (section 1.5.1). If more phosphorylation sites are to be identified by MS then 
significantly more purified protein is required, alongside new enzymatic digestion and 
phosphopeptide enrichment approaches. 
 
Taken together this highlights how poor our current understanding is of the complexities of 
NS5A phosphorylation and how it is involved in the virus lifecycle. The aim of this study was 
therefore to identify and characterise novel phosphorylation sites in the context of an 
actively replicating system. It was expected to shed light on exactly which residues in the 
serine rich clusters of the LCS I and domain III are actual sites of phosphorylation. This more 
detailed phosphorylation map would then be able to facilitate the production of 
phosphospecific antibodies, which could in turn be used to probe the role of each 
phosphorylation site in greater detail. 
 
To facilitate maximum expression levels of NS5A a Huh7 cell line a subgenomic replicon with 
a neomycin resistance gene was utilised, Figure 1.8. This stable replicon cell line could be 
sequentially passaged on a large scale and under selectional pressure, allowing for the 
purification of NS5A at significantly higher levels than previously and from Huh7 cells actively 
replicating HCV RNA.  
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3.2 Results 
3.2.1 Identification of NS5A phosphorylation sites by mass spectrometry. 
The human hepatocellular carcinoma cell line, Huh7, containing a HCV subgenomic replicon 
was used to express NS5A in a functionally relevant context, and on a large enough scale so 
as to facilitate the MS identification of phosphorylated residues. Advantage was taken of the 
ability of NS5A domain III to tolerate in-frame insertions with no effect on the function of the 
protein in virus RNA replication, and only limited impairment to virus production, discussed 
in (Section 5.1). The JFH-1 NS3-5B subgenomic replicon in which NS5A was tagged with the 
One-Strep affinity tag (OST) was therefore utilised. This tag had been previously shown not 
to affect RNA replication (Amako et al., 2009) and provided a highly efficient and selective 
purification strategy. This allowed the purification of NS5A with a higher efficiency and 
greater stringency than a traditional IP approach.   
 
A stable cell line harbouring the above replicon was cultured on a large scale and over 
several passages. At each passage surplus cells were pelleted at 1,200 x g for 5 mins and 
resuspended in Glasgow lysis buffer (Section 2.5.52.5.5). It is important to note that during 
the propagation of replicon harbouring cells the passage number was kept low, as a loss in 
hyperphosphorylated NS5A following long term passage of replicon harbouring cells is 
routinely observed (see Figure 3.1A).  The sequence analysis of replicons following long term 
passage did not reveal any mutations in NS5A (data not shown) but mutations elsewhere in 
the genome were not investigated.   
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Figure 3.1. Summary of NS5A and NS5A-OST purification. 
A Huh7 cells harbouring ConI or JFH-1 NS3-5B replicons were lysed at the indicated passage 
(p) in GLB and analysed by SDS-PAGE, western blot probed with α-NS5A (sheep) and 
fluorescent secondary, followed by quantification of different phosphorylation species. ** 
p<0.01. B. Purification of NS5A-OST by Strep-Tactin affinity column following (Section 
2.10.2). ns = non-specific band C. Concentrated NS5A-OST was separated further by 12 % SDS 
PAGE, Coomassie stained and the band corresponding to NS5A excised for MS phospho-
mapping.  
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The NS5A-OST was affinity purified from cell lysates using Strep-Tactin beads from 
cytoplasmic lysates as described (Section 2.10.2). Purification was conducted in batch, and 
an example western blot illustrating the different steps is shown in Figure 3.1B. In total 
NS5A-OST was purified from cell lysates corresponded to approximately 5 x 109 cells. Purified 
NS5A-OST was concentrated by centrifugation filtration (10 kDa MWCO), followed by 
methanol/chloroform precipitation prior to separation by SDS-PAGE.  After staining of the 
gel with Coomassie Brilliant Blue R250, the band corresponding to NS5A was excised (Figure 
3.1C).  The excised gel slice was subjected to trypsin cleavage, TiO2 enrichment of 
phosphorylated peptides and mass spectrometry analysis by MALDI, ESI and tandem MS-MS 
to identify the phosphorylated species (Section 2.11). In both systems ions were 
automatically selected for collision-induced dissociation (CID) to generate MS/MS spectra 
from which the phosphopeptide sequence and location of phosphorylation could be 
assigned. 
 
A total of 10 phosphopeptides were identified that corresponded to six different regions of 
NS5A and contained a total of 12 phosphorylation sites. The acquisition of MS/MS spectra on 
all 10 phosphopeptides allowed for sequence assignment. Firstly the phosphopeptide with 
m/z 1120 corresponded to NS5A domain I and showed that serine 146 was phosphorylated.  
Secondly, the two phosphopeptides with m/z 2023 and 2103 corresponded to the LCS I and 
showed a single phosphorylation at serine 222 and a double phosphorylation of serine 222 
and 225. The fourth phosphopeptide with m/z 943 corresponded to the LCS II and showed 
that threonine 348 was phosphorylated. The MS spectra for the four assigned 
phosphopeptides serine 146, 222, 222/225 and threonine 348 are shown in Figure 3.2 and 
corresponding MS/MS spectra along with b- and y-ion assignment is shown in Appendix 
figures 8.1, 8.2, 8.3 and 8.4. 
 
A further three phosphopeptides with a m/z of 2183, 2263 and 2343 also corresponded to 
the LCS I region with a m/z consistent with the addition of 3, 4 and 5 phosphates 
respectively, Figure 3.2C. While the MS/MS spectra allowed sequence assignment of the 
phosphopeptide, it was not possible to assign the exact phosphorylation sites, appendix 
figures 8.5, 8.6 and 8.7. In the case of the tri- and tetra-phosphorylated peptides the MS/MS 
data supports the presence of multiple isomers based on observation of four and five 
phosphorylated serines in the tri- and tetra-phosphorylated peptides respectively. In the 
case of the penta-phosphorylated species the ion abundance was too low for complete 
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assignment. The partial assignment of the tri- tetra- and penta-phosphorylated peptides was 
however sufficient to confirm that serines 229, 230, 232 and 235 were amongst the 
phosphorylated residues.  
 
A further two phosphopeptides with m/z 2423 and 2503 were identified by MS and had a 
m/z consistent with the addition 6 and 7 phosphorylations respectively on the same LCS I 
peptide fragment described. These putative hexa- and hepta-phosphorylated peptides co-
eluted from the HPLC with the other LCS I phosphopeptides and so are observed in the same 
MS spectrum, figure 3.C. However, ion suppression effects caused by such extensive 
phosphorylations resulted in insufficient ion abundance for MS/MS data to be collected, and 
therefore not even a partial assignment could be carried out. For similar reasons, the 
presence of an octa-phosphorylated species of this peptide fragment 221-240 cannot be 
excluded. Our data point to a complex pattern of phosphorylation in this region of NS5A, 
discussed later. 
 
Finally three other phosphopeptides with m/z 3724, 1931 and 1349 corresponded to NS5A 
residues 241-273, 375-395 and 396-409 respectively. The MS/MS allowed for complete 
sequence assignment but only partial assignment of the phosphorylation site. The region of 
partial assignment is denoted in Table 3.1. 
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Figure 3.2. Mass spectrometric analysis of NS5A phosphorylation. 
A. Schematic of NS5A structure showing amino acid residue numbers for JFH-1, amphipathic 
helix (AH), zinc binding motif (Zn2+), and low complexity sequences (LCS). B. The mass spectra 
of NS5A phosphopeptides after analysis by HPLC-MS/M, the main monoisotopic peaks were 
selected for collision induced dissociation to allow the precise assignment of 
phosphorylation sites, for MS/MS spectra see appendix figures 8.1-8.4. C. Mass spectra of 
phosphopeptide fragment corresponding to the LCS I region (sequence shown), for MS/MS 
see appendix figure 8.5-8.7.  
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Peptide fragment observed 
by mass spectrometry 
Phosphorylation 
number and location 
Calculated  
[M+H]
+
 
Observed 
[M+H]
+
 
Type of MS analysis 
MALDI ESI MS/MS 
KAPpTPPPR 1 - T348 943.4761 943.4575 Y N Y 
IPCQLPpSPE 1 - S146 1120.4743 1120.4482 Y Y Y 
GpSPPSEASSSVSQLSAPSLR 1 - S222 2023.9332 2023.9508 Y Y Y 
GpSPPpSEASSSVSQLSAPSLR 2 - SS222/225 2103.8995 2103.8706 Y Y Y 
GSPPSEASSSVSQLSAPSLR 3 - multiple isomers 2183.8659 2183.8477 Y N Y 
GSPPSEASSSVSQLSAPSLR 4 - multiple isomers 2263.8322 2263.811 Y N Y 
GSPPSEASSSVSQLSAPSLR 5 - multiple isomers 2343.7985 2343.7756 Y N Y 
GSPPSEASSSVSQLSAPSLR 6 - unassigned 2423.7648 2423.7419 Y N N 
GSPPSEASSSVSQLSAPSLR 7 - unassigned 2503.7311 2503.7082 Y N N 
ATCTTHSNTYDVDMVDANLLM
EGGVAQTEPESR 
1 - T242, T244, T245, 
S247, T249 
3724.5449 3724.5441 N Y Y 
TFGQPPSSGDAGSSTGAGAAE 1 - S387, S388 1931.7655 1931.7629 N Y Y 
SGGPTSPGEPAPSE 1 - S396, T400, S401 1349.5257 1349.5414 Y N Y 
 
Table 3.1. Summary of identified phosphopeptides of NS5A 
Summary of observed phosphorylated peptides and, where possible, assignment of 
phosphorylated residue (red) and partial assignment of phosphorylated residues 
(underlined). 
 
 
3.2.2 Role of phosphorylation sites in the HCV lifecycle. 
To investigate the role of the four identified phosphorylation sites (146, 222, 225 and 346) in 
the virus life cycle each residue was mutated to either alanine to block phosphorylation 
(phosphoablatant), or aspartic acid to introduce a negative charge, thereby acting as a 
phosphomimetic. These mutations were introduced into the luciferase based subgenomic 
replicon (mSGR-luc) and the full length JFH-1 virus construct (Figure 4.2), allowing 
investigation of the role of phosphorylation at different stages of the virus lifecycle (Hughes 
et al., 2009b). In addition to the four individual mutations, the two serines at 222 and 225 
were mutated simultaneously. Details regarding the manner in which the mutations were 
inserted into the above constructs is explained in further detail in Section 4.2.1. A NS5B 
polymerase inactive mutant, where the catalytic GDD motif had been mutated to GND, was 
included as a negative control in all assays.  
 
The effect of these mutations on replication was determined by a luciferase based 
replication assay. In vitro transcripts of phosphomutant replicons were electroporated into 
Huh7 cells and luciferase activity measured at 4 and 72 hpe. It has been previously 
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established that luciferase activity correlates with the number of intracellular HCV genomes 
and so is used as a measure of replication competency (Targett-Adams and McLauchlan, 
2005).  
 
 
 
Figure 3.4. Mutagenic analysis of phosphorylation in the context of the HCV subgenomic 
replicon.  
In vitro transcribed RNA was electroporated into Huh7 cells and luciferase activity 
determined at 4 and 72 hpe (Section 2.8.1). A. Luciferase activity at 72 hpe is shown (n=3) 
normalised to activity at 4 hours. * p<0.05 significance from wildtype. B. Western blot 
analysis of cell lysates at 72 hpe probed with NS5A (9E10) or GAPDH (mouse) antibodies.  
Use of 7.5% SDS-PAGE allowed the separation of the basally (lower band) and 
hyperphosphorylated (upper band) forms of NS5A. C. Quantification of the percentage of 
total NS5A that is hyperphosphorylated from western blot.  Western blots were imaged by 
fluorescence using a LiCor Odyssey 5a, enabling highly accurate quantification (n=3).  ** p 
<0.01 significance from wildtype. n.d. – no data due to low levels of expression.   
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The effect of phospho-mutations at residues 146, 222, 225 and 348 on the replication 
capacity of the NS3-5B replicon is shown in Figure 3.4A.  Neither the phosphoablatant nor 
phosphomimetic mutations at serines 146 and 222 (S146A/D, S222A/D) or threonine 348 
(T348A/D) had any significant effect on RNA replication; all of the resulting subgenomic 
replicons were able to replicate with equal efficiency (~100 fold increase in luciferase 
expression over 72 hpe). In contrast the S225A phosphoablatant mutation resulted in a one-
log reduction in replication, whereas S225D had no phenotype, suggesting that 
phosphorylation of this residue is important for HCV genome replication.  Consistent with 
this, the double alanine substitution (S222/225A) almost completely abolished the 
replicative ability of the subgenomic replicon, with levels of luciferase activity at 72 hpe only 
slightly above the GND negative control (an inactivating mutation in the NS5B polymerase).  
Again, a double aspartic acid substitution (S222/225D) had no phenotype.  Thus it appears 
that S222 phosphorylation does play a subtle role in genome replication but that this is only 
manifest in the context of a further phosphorylation event at S225.   
 
When analysed by western blot wildtype, NS5A appears as a doublet of what have been 
referred to as basally and hyperphosphorylated forms.  To assess the potential effects of 
these mutations on NS5A expression and the relative abundance of these two forms, lysates 
from cells electroporated with subgenomic replicon RNAs were analysed by western blotting 
(Figure 3.4B).  In most cases there was no difference in the expression profile of NS5A 
compared to wildtype.  Where possible, the percentage of hyperphosphorylated NS5A was 
determined by quantification of western blots (Figure 3.4C), although the low levels of NS5A 
expression in the poorly replicating mutants S225A and S222/225A did not allow 
quantitation.  Note that the use of a fluorescent based western blot greatly improved the 
accuracy of quantification over traditional chemiluminescence techniques. Surprisingly, 
S225D and S222/225D exhibited a reduction in hyperphosphorylation, although these 
residues (along with S229 and S232) have previously been proposed as phosphoacceptor 
sites in the hyperphosphorylated form of NS5A.  This may indicate that an aspartate residue 
may mimic the charge, but not the structural effects, of phosphorylation.  However, the 
most intriguing result was the reduction in hyperphosphorylation exhibited by the S146D 
mutation.  As S146A still exhibits wildtype levels of the hyperphosphorylated species, this 
suggests that S146 is not a phosphoacceptor within this form, but that phosphorylation of 
this residue negatively regulates hyperphosphorylation. 
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To investigate whether this series of mutations elicited an effect at later stages of the virus 
lifecycle like virus production the series of phospho-mutations were inserted into the mJFH-1 
virus. Huh7 cells were electroporated with in vitro transcribed RNA and cultured for 144 hrs, 
including a 1:5 passage at 72 hpe (Section 2.9.1). At 72 and 144 hpe supernatants were 
removed and virus titre determined by focus forming assay (Section 2.9.2) and total RNA was 
extracted and intracellular HCV genomes quantified by qRT-PCR using primers targeted to 
the 5’UTR (Section 2.9.3).  
 
A similar set of data was obtained when this series of mutations was evaluated in the context 
of the full length JFH-1 infectious clone (Figure 3.5). The majority of the mutants showed 
wildtype levels of both intracellular genome abundance measured by qRT-PCR (Figure 3.5A) 
and released virus titre measured by focus forming assay (Figure 3.5B).  Again S225A 
exhibited an approximately one-log reduction in both assays and S222/225A was almost 
completely deficient in virus replication and assembly. The western blot analysis (Figure 
3.5C) also closely mirrored that observed for the subgenomic replicons, although in this case 
a low level of hyperphosphorylation  could be seen in the context of the S146D mutant, this 
was clearly reduced compared to both wildtype and S146A. 
 
It was therefore concluded that that the phenotype of these mutants is entirely manifest at 
the level of virus genome replication and there are no additional effects on virion assembly 
or release. The reductions in virus titre that are observed correlate with a reduction in 
replication, this corresponds to observations made previously that replication is the rate 
limiting step with respect to virus production (Binder et al., 2013). 
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Figure 3.5. Mutagenic analysis of phosphorylation in the context of JFH-1 virus. 
In vitro transcribed RNA was electroporated into Huh7 cells. Cells were cultured for 144 hrs, 
including a 1:5 passage at 72 hpe. A. Total RNA was extracted from cells at 72 and 144 hpe 
and HCV genomes quantified by qRT-PCR using primers targeted to the 5’UTR (Section 2.9.3) 
(n=3).  * p<0.05 from wildtype.  HCV genomes for the non-replicating control, GND, were still 
detectable, most likely due to the stability of the 5’UTR. B. Supernatants were assayed for 
released infectious virus titre by focus forming assay at 72 and 144 hpe.  C. Lysates were 
prepared from cells at 144 hpe and probed for NS5A (9E10), Core (sheep) and GAPDH 
(mouse).   
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3.2.3 The effect of S225A on NS5A localisation 
Whilst determining the titre of the released virus of S225A it was noted that the distribution 
of NS5A-S225A in infected cells was dramatically different from that of WT. To investigate 
this in greater detail, cells harbouring the denoted replicons were grown on coverslips and at 
72 hpe were fixed and immunostained with α-NS5A (sheep) and the lipid droplet associating 
fluorophore BODIPY-C12. When imaged by confocal microscopy the re-distribution of NS5A-
S225A into large, bright puncta was clear (Figure 3.6). While the mutation of the 
phosphorylation site serine S225 did cause a 1 log drop in replication and correspondingly 
virus titre, it was still capable of undergoing the complete virus lifecycle. Indicating that while 
the subcellular distribution of NS5A is dramatically altered, the protein can still function.  
 
 
 
Figure 3.6. Differences in the subcellular localisation of S225A 
Huh 7 cells were electroporated with SGR-WT or SGR-S225A, seeded onto coverslips and at 
48 hpe fixed and immunostained for α-NS5A (sheep) in green and lipid droplets (BODIPY-
555-C12) in red. 
 
 
It was decided to pursue the different sub-cellular localisation of NS5A-S225A in the context 
of fluorescently labelled full length virus and there was the recent capability to undertake 
live-cell confocal imaging in a biosafety level 3 (BSL3) environment. 
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Two different approaches were utilised, firstly the S225A/D mutations were introduced into 
the JcI virus where the NS5A protein had been previously tagged with emerald GFP (emGFP) 
and RFP (Schaller et al., 2007). The insertion of the emGFP and RFP had been previously 
shown to have no effect on replication and only a modest reduction in virus titre. Secondly a 
novel NS5A tag system was developed for application to both live- and fixed-cell imaging and 
is the focus of Chapter 4. While the insertion of the S225A/D mutation into the JcI-
emGFP/RFP virus was successful, due to time constraints on the project, it was not possible 
to generate any data with the system. As such, only anecdotal observations were made and 
have not been included. What can be noted was that the JcI-emGFP/RFP viruses were still 
viable after the introduction of S225A/D mutations and were still able to produce infectious 
virus. Furthermore, the sub-cellular distribution phenotype of S225A was also observed in 
this system. 
 
3.2.4 Threonine 348 and the binding of SH3 domains. 
The analysis identified threonine 348 within LCS II as a phosphoacceptor, but neither a 
phosphoablatant nor a phosphomimetic mutation at this site had any phenotype in 
replication and/or virus production. However, it was intriguing that this residue was located 
in the middle of a well characterised class II polyproline motif PP2.2 (PxxPxR) that binds to a 
range of SH3 domains, discussed previously (Section 1.6.1). It was therefore thought that the 
phosphorylation of threonine 348 might be involved in regulating the binding of SH3 
domains to the PP2.2 motif (Figure 3.7A). Interestingly previous studies have shown that 
mutation of this motif to alanine (PA2.2) blocks SH3 binding but had no effect on virus 
replication and only minimal effects on virus release (Hughes et al., 2009a). It was proposed 
by Hughes et al. that the PP2.2 motif is only required for virus persistence, if this is the case 
it could explain why mutations of the phosphorylation site T348 also have no effect on virus 
replication and release.  
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Figure 3.7. The effect of T348 phosphorylation on SH3 binding. 
A. Sequence of the phosphopeptide from LCS II showing the conserved prolines (bold) and 
the phosphorylated threonine residue (red).  B. Lysates from Huh7 cells electroporated with 
the indicated subgenomic replicons were subjected to GST pull-down using either GST-
LynSH3 (lanes 1-4) or GST alone (lanes 5-8).  5% of the input lysate and the total bound 
fraction were analysed by western blot with an anti-NS5A antiserum (sheep).  Equivalent 
loading of the GST fusions was verified by Coomassie staining (lower panel).  PA2: mutation 
of the two prolines highlighted in A to alanine (Hughes 2009b).  C. As for B. but lysates were 
subjected to GST pull-down using GST-LynSH3, FynSH3 or SrcSH3.   
K A P T P P P R R R R
T348A T348D WT PA2.2 T348A T348D WT PA2.2
GST-LynSH3 GST alone
In
p
u
t
B
o
u
n
d
NS5A
Coomassie
stain
Input
LynSH3
FynSH3
SrcSH3
GST
T348A T348D WT PA2.2
Bound
NS5A
JFH-1 PP2.2 motif
B
C
A
345 - - 355
Chapter 3: The Phosphorylation of NS5A 
84 
 
To investigate whether the phosphorylation of threonine 348 was affecting SH3 binding a 
glutathione pull down of GST-SH3 domains with infected cell lysates was carried out (Section 
2.5.6). In brief, GST tagged SH3 domains were expressed and purified in bacteria as 
described and used to decorate glutathione-Sepharose resin. The decorated resin was 
incubated with lysates from cells infected with JFH-1 WT or harbouring T348A/D mutations. 
The GST-SH3 pull-down was then analysed by SDS-PAGE and western blot for α-NS5A (9E10). 
As a negative control for the interaction between the PP2.2 motif and SH3 domains the NS5A 
mutation PA2.2 was used. 
 
Both the T348A and T348D mutants bound with equal efficiency as wildtype to the GST-
LynSH3 domain fusion protein, while the PA2.2 mutant showed a dramatic impairment, 
Figure 3.7B. The Coomassie stain of the GST-LynSH3, and the western blot of NS5A input, 
showed that the same amount of bait and prey were present in each pull down (Figure 3.7B). 
Two other SH3 domains, Fyn and Src, were also investigated to see if the regulation of SH3 
binding to the PP2.2 motif by phosphorylation at T348 was substrate specific, but in case 
both T348A and T348D bound to the SH3 domains with comparable efficiency, Figure 3.7C. 
 
It is still feasible that the phosphorylation of threonine 348 is involved with regulating the 
binding of different proteins to the PP2.2 motif; it is also possible that the phosphomimetic 
aspartic acid is insufficient to recapitulate the effect of a phosphate group. Alternatively it is 
possible that this phosphorylation site regulates the activity of the putative nuclear 
localisation single (NLS) that is one residue downstream of threonine 348 (Ide et al., 1996), 
while the localisation of NS5A to the nucleus is not been convincingly demonstrated the 
recruitment of nuclear pore complex proteins into the membranous web has been (Neufeldt 
et al., 2012). It is therefore a possibility that this NLS at the start of domain III is important in 
trafficking NS5A out of the tightly enclosed membranous web, and that the negative charge 
of the phosphorylation at threonine 348 could regulate this by masking the positive charge 
of the NLS. Furthermore the four arginines (residues 353-355) at the centre of the putative 
NLS have previously been shown not to be important for replication in either ConI 
(Tellinghuisen et al., 2008b) or JFH-1 (data not show). 
 
3.2.5 Analysis of phosphorylation within LCS I 
In addition to the mono- and di-phosphorylated peptides mapping to LCS I (S222 and 
S222/225), the mass spectrometric analysis revealed evidence for the existence of multiply 
phosphorylated species containing between three and seven phosphorylation events (Table 
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3.1).  In order to investigate the potential function of these phosphorylation events a further 
set of phosphoablatant and phosphomimetic mutants were generated and their phenotypes 
were evaluated in the context of the SGR-luc-JFH-1 subgenomic replicon as described 
previously (Section 3.2.2). 
 
As illustrated in Figure 3.8A, S228A/D and S230A/D mutations appeared to have no 
phenotype; however, S229 was a key residue as both S229A and S229D mutations 
completely abrogated RNA replication. Consistent with this a triple mutation of 
S228/229/230 to either alanine or aspartic acid was also completely defective.  S232 
resembled S225 in that the S232A mutation reduced replication by approximately one-log, 
whereas S232D exhibited wildtype activity. These data points to important roles for S229 
and S232 in HCV genome replication, at this stage it is pertinent to note that these residues 
were identified as phosphoacceptors in the tri- and tetra-phosphorylated peptides, but they 
were present in combination with other phosphorylated residues in multiple isomers that 
could not be assigned.  
 
 
Figure 3.8. Mutagenic analysis of putative phosphorylation sites within LCS I. 
In vitro transcribed RNA was electroporated into Huh7 cells and luciferase activity measured 
at 4 and 72 hpe. A. Luciferase activity at 72 hpe is shown (n=3) normalised to activity at 4 
hours.  * p<0.05 from wildtype. B. Western blot analysis of cell lysates at 72 hpe probed with 
α-NS5A (9E10) or α-GAPDH (mouse) antibodies.   
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Western blot analysis of NS5A expression in cells harbouring the subgenomic replicons 
reflected the levels of replication (Figure 3.8B), however this analysis led to an intriguing 
observation regarding the mobility of the two phosphorylated forms.  Although the mobility 
of the hyperphosphorylated form did not vary, there were differences in the mobility of the 
basally phosphorylated forms between the various mutants. Specifically, although alanine 
substitutions did not change the mobility of the basally phosphorylated form compared to 
wildtype, aspartic acid substitutions resulted in a subtle retardation of its mobility. This could 
also be seen to a lesser extent for mutations at S222, S225 and the combination of S222/225, 
but interestingly not for S146 or T348 (Figure 3.4B), suggesting that this was not simply due 
to the substitution of an acidic residue into the protein.  
 
The differences in the migration of the basal-phosphorylation species as a result of 
phosphomimetic mutations in the LCS I was investigated further. For completeness the two 
remaining serines within this region, serine 235 and 238, were also mutated to aspartic acid. 
When lysates from cells harbouring these phosphomimetic mutations were analysed by SDS-
PAGE a clear trend emerged. As the position of the aspartic acid mutation progressed 
towards the C-terminus of this serine cluster there was a concomitant retardation of 
mobility, Figure 3.9. 
 
This shift in the apparent molecular weight of the basal-phosphorylation species was clearly 
not a result of the aspartic acid mutation, as the mutation of serine 146, 222 or threonine 
348 to aspartic acid does not elicit the same effect (Figure 3.4A). Due to the serine-rich and 
extensively phosphorylated nature of the LCS I, this change in molecular weight is most likely 
the result of differing degrees of phosphorylation. The presence of these phosphomimetic 
mutations could therefore be influencing different patterns of phosphorylation within this 
region. One explanation for this result is that phosphorylation of one residue completes the 
kinase recognition motif for a neighbouring residue to be phosphorylated, and so on, 
resulting in a phosphorylation cascade. This is discussed in further detail (Section 3.3.2)  
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Figure 3.9. Phosphomimetic mutations in LCS I increase the apparent molecular weight of 
the basally phosphorylated NS5A form. 
Lysates from electroporated cells were prepared at 72 hpe and analysed by western blotting 
with antibodies to α-NS5A (9E10) or α-GAPDH (mouse).  Lysates were separated by 7.5% 
SDS-PAGE at low voltage for an extended time (110V, 120 min) allowing for optimal 
resolution of basally and hyperphosphorylated forms.  The NS5A western blot is shown at 
both low and high exposures.  
 
 
 
3.2.6 Regulation of hyperphosphorylation by S146. 
As shown in Figure 3.4B, 3.5C and 3.9, the introduction of a phosphomimetic  at serine 146 
resulted in a reduction of the level of hyperphosphorylation, suggesting that phosphorylation 
of this residue in some way negatively regulated phosphorylation at other sites (presumably 
within the serine rich LCS I).  It was reasoned that if the sequential phosphorylation with LCS 
I contributed to hyperphosphorylation, then the introduction of mutation S146D, which 
reduces hyperphosphorylation, might influence this process. To investigate this effect the 
mutation S146D was introduced into the panel of LCS I phosphomimetic  mutations 
discussed previously, Figure 3.9. This generated a panel of mSGR-luc constructs where 
phosphomimetic  mutations of residues 222-238 were present either with or without the 
S146D mutation.  
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Figure 3.10. Analysis of LCS I phosphomimetic mutations in the context of S146D.  
In vitro transcribed RNA was electroporated into Huh7 cells and luciferase activity measured 
at 4 and 72 hpe.  A polymerase inactive mutant, GND, was included as a negative control. 
Luciferase activity at 72 hpe is shown (n=3) normalised to activity at 4 hours.  For each 
mutant the results obtained in either a wildtype (grey bars) or S146D mutant (black bars) 
background are shown side by side.  * p<0.05 from wildtype.  
 
 
This panel of phosphomutants was first investigated for the effect on replication by 
electroporating in vitro transcripts into Huh7 cells and determining luciferase activity at 72 
hpe. Figure 3.10 demonstrates that for S225D, S228D, S230D, S232D and S238D the addition 
of the S146D mutation had no effect on replication, as all of these subgenomic replicons 
were indistinguishable from wildtype.  As previously shown (Figure 3.8), S229D was 
completely replication defective and was not rescued by the S146D mutation.  Interestingly 
two mutations, S222D and S235D, showed an altered phenotype, whereby in the wildtype 
background these mutations had no effect on replication, but in the context of S146D they 
both exhibited impaired or ablation of replicative capacity, S222D and S235D respectively. 
 
Western blot analysis of cell lysates showed two distinct features. Firstly, the introduction of 
S146D alongside LCS I mutations (S228D, S230D, S232D and S238D) did not block their ability 
to increase the M.Wt of basally phosphorylated NS5A (Figure 3.11A). Secondly, the presence 
of any S->D mutation in LCS I (222-238) did not block the ability of S146D to reduce 
hyperphosphorylation of NS5A (Figure 3.11B). These data shows that phenotype of both 
S146 and LCS I phosphomimetic mutations cannot elicit a dominant effect over the other. 
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Figure 3.11. Effect of S146D on LCS I phosphorylation. 
A. Lysates from electroporated cells were prepared at 72 hpe and analysed by western 
blotting with antibodies to α-NS5A (9E10) or α-GAPDH (mouse). The presence or absence of 
the S146D mutation is indicated by +/- signs. B. Quantification of the percentage of total 
NS5A that is hyperphosphorylated from western blot.  Western blots were imaged by 
fluorescence using a LiCor Odyssey 5a, enabling highly accurate quantification (n=3). ** p 
<0.01 . n.d. – no data due to low levels of expression. 
 
 
It has been discussed previously that the NS5A inhibitor Daclatasvir is able to reduce the 
hyperphosphorylation of NS5A within 4 hrs of treatment, while the block on replication does 
not occur for 24 hrs (Section 1.6.4.2). This effect on NS5A phosphorylation is not thought to 
be the mechanism of action of Daclatasvir. However, it has been shown that in patients 
S
2
2
2
D
S
2
2
5
D
S
2
2
8
D
S
2
2
9
D
S
2
3
0
D
S
2
3
2
D
S
2
3
5
D
S
2
3
8
D
W
T
G
N
D
0
2 0
4 0
6 0
P
e
rc
e
n
t 
o
f 
N
S
5
A
 h
y
p
e
rp
h
o
s
p
h
o
ry
la
te
d
n .d n .dn .d
* * * * * * * * * * * * * *
w ith o u t S 1 4 6 D  m u ta tio n w ith  S 1 4 6 D  m u ta tio n
A
B
+- +- +- +-
NS5A
GAPDH
S235D
+- +- +-
NS5A
GAPDH
S232D S238D
S225DS222D S228D S230D
Chapter 3: The Phosphorylation of NS5A 
90 
 
treated with Daclatasvir there is a rapid drop in the number of circulating virus particles (6 - 9 
hrs), long before inhibition of replication (Guedj et al., 2013). With the phosphorylation of 
NS5A known to be important in virus production, could the effect of Daclatasvir on NS5A 
phosphorylation be the mechanism behind this rapid drop in virus production seen in vivo?  
 
To investigate this further the effective concentration, 50% (EC50) of Daclatasvir on 
replication was determined for replicon constructs containing the phosphomutations in the 
LCS I, with and without the S146D mutation. Huh7 cells were electroporated with mSGR-luc 
in vitro transcripts and at 4 hpe cells were treated with Daclatasvir at a range of 
concentrations (1 fM to 10 μM), for details see (Section 2.8.2). At 48 hpe luciferase activity 
was determined and used to calculate EC50s. As a positive control the Daclatasvir resistance 
mutation Y93H was used to demonstrate a shift in EC50. If phosphorylation of these serines 
was involved in the mechanism of action of Daclatasvir then a change in EC50 would be 
expected. However, as can be seen in Table 3.2, no combination of any phosphorylation 
mutation elicited a significant effect on the inhibitory concentration of Daclatasvir. 
 
 
 
Table 3.2. The effect of LCSI 
phosphomutants in combination with 
S146D on the inhibitory concentration of 
Daclatasvir. 
In vitro transcripts were electroporated 
into Huh7 cells and at 4 hpe were treated 
with Daclatasvir (1 fM to 10 μM). 
Luciferase was determined at 48 hpe and 
EC50 concentrations by analysis in Prism 
(Graphpad). 
 
 
 
 
 
  
LCSI 
mutation 
With or without 
mutation S146D 
(+/-) EC50, pM 
S222D 
- 27.6 
+ n/a 
S225D 
- 32.2 
+ 9.8 
S228D 
- 28.1 
- 10.9 
S230D 
+ 16.8 
- 7.4 
S232D 
+ 31.3 
- 11.5 
S235D 
- 21.7 
+ 17.0 
S238D 
- 33.7 
+ 12.7 
WT 31.9 
S146D 18.5 
Y93H 47 030.0 
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3.2.7 S222 phosphorylation is a hallmark of the hyperphosphorylated NS5A species.  
It has been previously reported that S222 is a critical phosphoacceptor in the formation of 
hyperphosphorylated NS5A, although the evidence for this is indirect and it was possible that 
pS222 was present in both phosphorylated species.  In order to address this question a 
sheep polyclonal phosphospecific antiserum was raised against phosphorylate S222 using an 
appropriate phosphopeptide.  Figure 3.12A presents a validation of this reagent and shows 
that the α-pS222 antiserum did indeed only react with the hyperphosphorylated NS5A form.  
A very faint band could be seen corresponding to basally phosphorylated NS5A, however this 
is likely due to recognition of the surrounding peptide sequence.  Reassuringly the serum 
showed only very limited cross-reactivity with the S222A or S222D mutants, again the faint 
bands are likely due to recognition of the surrounding sequence.   
 
Furthermore, western blot analysis using this reagent revealed that, as expected, pS222 
reactivity was much reduced in the S146D mutant (Figure 3.12B) and that the pS222 
antibody was more reactive towards the basal phosphorylated band in mutations S225D, 
S228D and S232D (Figure 11C). This is the first biochemical evidence that S222 
phosphorylation is enriched in the hyperphosphorylated NS5A form and that the S146 is 
involved with regulating this phosphorylation. It cannot however be rule out that pS222 is 
also present at very low levels in the basally phosphorylated form. 
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Figure 3.12. Phosphorylated S222 is predominately in the hyperphosphorylated form. A 
phosphospecific antibody was raised in sheep against pS222 using an appropriate 13mer 
peptide and purified by IgG enrichment.  A. Specificity of the pS222 antibody. Lysates from 
Huh7 cells electroporated with the indicated subgenomic replicons were analysed by SDS-
PAGE/western blot and probed with either α-pS222 or α-NS5A (sheep). B. and C. lysates 
processed as in A. 
 
 
3.3 Discussion 
This investigation has attempted to make significant progress towards a comprehensive 
analysis of the phosphorylation of NS5A by analysing protein purified from a physiologically 
relevant context, i.e. from Huh7.5 cells harbouring a JFH-1 derived subgenomic replicon. 
With the exception of the recent publication (Lemay et al., 2013), this study therefore 
represents the only biochemical analysis of NS5A phosphorylation expressed in human cells 
in the context of the other non-structural proteins and an active RNA replication complex.  
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Both studies identified S222 within LCS I as a major site of phosphorylation (Lemay et al., 
2013). However, whereas LeMay et al. only identified S222 as a phosphoacceptor, this study 
identified a large number of other sites of phosphorylation, not only in LCS I but also in 
domains I, III and LCS II (Table 3.1).  More phosphorylation sites were identified than 
previous due simply to the amount of starting material – LeMay et al. used 7.5 x 107 cells, 
this study used approximately 100-fold more. This allowed for the detection of 
phosphopeptides that are detected with a lower efficiency by MS (peptides that are large 
and/or highly phosphorylated) as well as those that are physiologically less abundant. 
 
NS5A contains no trypsin cleavage sites within the C-terminal 121 residues that form domain 
III. This has hampered previous phospho-mapping attempts because large peptide fragments 
are poorly detected by MS analysis. To overcome the absence of trypsin cleavage sites in 
domain III the purified protein was also digested with Glu-C endoproteinase. This protease 
cleaves C-terminal to glutamic residues and results in a further 11 cleavage sites throughout 
domain III, resulting in peptide fragments that are significantly more amenable to MS 
analysis. Despite this approach the putative phosphorylation sites in the C-terminal serine 
cluster identified by Masaki et al. and Tellinghuisen et al. were not observed (Figure1.11). 
This could be a reflection of poor protease activity in the locality of phosphorylation sites. 
For example, the putative phosphorylation site serine 457 is adjacent to a Glu-C cleavage site 
(-SEED-), if phosphorylation of this serine were to block Glu-C digestion then the peptide 
fragment containing pS457 would remain 41 aa in length and would not be detectable by 
MS. Similarly if these phosphorylated peptides were in low abundance and extensively 
phosphorylated, this too would limit their detection by MS. Therefore the data generated 
here does not preclude the presence of phosphorylation sites within this region. Neither this 
study nor LeMay et al. were able to discriminate between phosphoacceptors present on the 
basal and/or hyperphosphorylated NS5A forms, due to the loss of resolution when 
separating large amounts of protein by SDS-PAGE. 
 
3.3.1 LCS I is the predominant location for hyperphosphorylation of NS5A 
The majority of phosphoacceptor residues identified in this study were in LCS I, between 
serines 222 and 238. Remarkably, this serine rich cluster is absolutely conserved across all 
genotypes of HCV highlighting the importance of this region in the virus lifecycle.  A 19 aa 
phosphopeptide corresponding to this region was shown to be extensively phosphorylated, 
containing combination of between 1 and 7 phosphorylated residues, Figure 3.2C and Table 
3.1. While the assignment of phosphorylation at serine 222 and the double serine 222/225 
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was possible, the presence of different isomers precluded the definitive assignment of the 
tri, tetra-, penta-, hexa- and hepta-phosphorylated species. It was however possible to 
partially assign serines 229, 230, 232 and 235 as amongst the phosphorylated resides in 
these species, Appendix figure 8.5-8.7. Note that the phosphorylation of serines 228 and 238 
is not excluded on the bases they were not observed in this analysis.  
 
By generating an antiserum specific to phospho-S222 it was possible to provide the first 
definitive evidence that phosphorylation of S222 is indeed a hallmark of 
hyperphosphorylated NS5A. The antiserum showed very little reactivity towards the basally 
phosphorylated NS5A species, or towards NS5A containing the S222A or S222D mutants 
(Figure 3.12A).  However, despite the fact that S222 phosphorylation was only detected in 
the hyperphosphorylated species, in this study mutation at this residue did not affect the 
ratio of hyper- to basally phosphorylated NS5A (Figure 3.4).  This suggests that 
phosphorylation of S222 alone is neither the sole component of, nor sufficient to produce 
the hyperphosphorylated form. This is consistent with previous studies that have implicated 
several serines in the LCS I as required for hyperphosphorylation (Tanji et al., 1995). LeMay 
et al. have also provided evidence for phosphorylation of S222 being present in the 
hyperphosphorylated NS5A form, shown by a 36% reduction in hyperphosphorylation in the 
context of the S222A mutant.   
 
To complement the biochemical analysis of phosphorylation an extensive mutagenesis of the 
identified phosphoacceptor residues within the LCS I was conducted.  Many of these mutants 
had no phenotype but this analysis pointed to a critical role for S229 – both phosphoablatant 
and phosphomimetic mutations at this site abrogated replication of the subgenomic 
replicon, in agreement with the recent data of (Fridell et al., 2013).  
 
Interesting the in vitro phosphorylation by CKI of a short synthetic peptide equivalent of the 
LCS I required the presence of a priming phosphorylation event at position S229. However, 
neither aspartic acid nor glutamic acid when introduced at this position could recapitulate 
this effect (Quintavalle et al., 2007). This suggests that in this context, aspartic acid does not 
successfully act as a phosphomimetic, potentially explaining why both alanine and aspartic 
acid mutation at position S229 are lethal for replication. In contrast the mutation of 
phosphorylation sites at serine 225 and 222/225, which resulted in only a partial or complete 
defect in replication respectively, was successfully restored by the corresponding 
phosphomimetic mutations, consistent with a role for phosphorylation at these residues 
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(Figure 3.4).  A drop in virus production was observed, but this correlated to the impairment 
to replication, in line with recent reports of replication being the rate limiting step in virus 
production (Binder et al., 2013). 
 
Interestingly no mutations within the LCS I stimulated RNA replication, this was in contrast to 
previous reports in the genotype 1b isolate ConI (Appel et al., 2005). When a comparison is 
drawn between data generated here, the ConI data and the recently published data by 
Fridell et al. an interesting observation is made, Table 3.3 (Fridell et al., 2013). Where the 
introduction of phosphomimetic or phosphoablatant mutations results in a change in RNA 
replication, there is an inverse effect in the JFH-1 than in the ConI isolate. These differences 
are hard to interpret, but presumably are indicative of fundamental genotype-specific 
differences in the interactions between NS5A and other viral (or cellular) proteins during the 
process of virus genome replication. It is worth noting that the ConI isolate used by Appel et 
al. contained two culture adaptive mutations in the NS3 protein (E1202G and T1280I). 
 
NS5A residue 
number Mutation 
Gt 1b (Appel et 
al) 
Gt 2a (this 
study) 
Gt 2a (Fridell et 
al) 
S222 (2194) 
Ablatant Wildtype Wildtype Wildtype 
Mimic Wildtype Wildtype Not tested 
S225 (2197) 
Ablatant Up 6 fold Down 6 fold Down 3 fold 
Mimic Wildtype Wildtype Wildtype 
S228 (2200) 
Ablatant Wildtype Wildtype Wildtype 
Mimic Wildtype Wildtype Not tested 
S229 (2201) 
Ablatant Up > 10 fold Down > 1000 fold Lethal 
Mimic Up 50 fold Down > 1000 fold Lethal 
S230 (2202) 
Ablatant Up 5 fold Wildtype Wildtype 
Mimic Wildtype Wildtype Not tested 
S232 (2204) 
Ablatant Up > 10 fold Down 10 fold Down 10 fold 
Mimic Wildtype Wildtype Wildtype 
S235 (2207) 
Ablatant Up > 10 fold Not tested Lethal 
Mimic Wildtype Wildtype Wildtype 
S238 (2210) 
Ablatant Wildtype Not tested Wildtype 
Mimic Wildtype Wildtype Not tested 
 
Table 3.3. Comparison of the mutations in LCS I between genotypes. 
genotype 1b data from the ConI NS3-5B replicon (Appel et al., 2005), genotype 2a data from 
the JFH-1 isolate, this study or (Fridell et al., 2013). NS5A numbering (S222-238) and H77 
reference polyprotein numbering (2194-2210).   
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3.3.2 Evidence for sequential phosphorylation across LCS I. 
During this analysis it was observed that the phosphomimetic mutations within the LCS I 
affected the mobility of the basally phosphorylated species, but not that of the 
hyperphosphorylated species. Moreover, other phosphomimetic mutations in different 
regions of NS5A did not elicit the same effect (S146D and T348D), suggesting this is specific 
to the basally phosphorylated species, and specific to the serine rich LCS I. A clear trend 
emerged whereby, as the position of the phosphomimetic mutation was shifted towards the 
C-terminus of LCS I there was a concomitant decrease in the mobility of the basally 
phosphorylated species, indicative of additional phosphorylations (Figure 3.9).  
 
One interpretation of this data is that the serines with the LCS I region are part of a regulated 
sequential phosphorylation cascade that generates the hyperphosphorylated species. The 
introduction of phosphomimetic mutations into the LCS I triggered this cascade to occur 
unregulated on the basal-phosphorylation species, giving rise to an increase in apparent 
molecular weight. The extent of extra phosphorylation on the basal-phosphorylation species 
could then indicate at what point within the sequential phosphorylation cascade it was 
triggered, i.e. near the start or end. A rapid sequential phosphorylation cascade over the LCS 
I forming the hyperphosphorylated species would explain why intermediary phosphorylation 
states of NS5A are not observed by SDS-PAGE. Indeed Quintavalle et al. have already 
demonstrated that on a synthetic peptide mimetic of the LCS I a priming phosphorylation at 
S229 is required for the CKI directed phosphorylation of S232 (Quintavalle et al., 2007). 
 
This model would be supported by observations that the ConI culture adaptive mutation 
S2204I (S232 in JFH-1) resulted in a complete loss of the hyperphosphorylated species and 
not a slight decrease in molecular weight. Hence why in the JFH-I isolate a phosphomimetic 
mutation at this position results in a significant increase in the apparent molecular weight of 
the basal-phosphorylation species. 
 
However in the case of the phosphomimetic S238D, the basally phosphorylated species 
(where the largest increase in apparent molecular weight was observed) could still be 
distinguished from the hyperphosphorylated species (Figure 3.9). This suggests that the 
mechanism for generating hyperphosphorylation cannot be fully recapitulated solely by the 
introduction of single phosphomimetic mutations in the LCS I. 
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There are many several host proteins that have been shown to undergo these sequential 
phosphorylation cascades and they were discussed in detail previously (Section 1.5.3). 
Typically more than one kinase is involved in orchestrating these sequential phosphorylation 
cascades, as is seen with β-catenin where a phosphorylation by CKI primers the three 
subsequent phosphorylations by glycogen synthase kinase 3 (GSK-3). Also, these sequential 
phosphorylation cascades do not have to proceed in a straight linear fashion, as is the case in 
the PTEN protein where phosphorylation proceeds from S385 → S380 → T383 → T382 
(Cordier et al., 2012). To investigate the details of this kind of sequential phosphorylation 
cascade would first require the identification of the phosphorylating kinases, this would then 
allow sophisticated temporal NMR analysis as to what order phosphorylation was occurring, 
such as in (Cordier et al., 2012).  
 
3.3.3 S146 regulates hyperphosphorylation. 
S146 is located within domain I and has not previously been identified as a phosphoacceptor.  
Mutation of this site had no effect on either genome replication or virus assembly, however, 
it was noteworthy that S146D exhibited a significant decrease in the abundance of 
hyperphosphorylated NS5A – decreasing from 42% (+/- 0.6 SEM) of total NS5A in wildtype, 
to 17% (+/- 1.0 SEM) in S146D.  S146D also exhibited a loss in reactivity to the phospho-S222 
antiserum, consistent with the fact that S222 phosphorylation is a hallmark of the 
hyperphosphorylated species (Figure 3.12B).  Given that phosphomimetic mutations in LCS I 
appeared to at least partially drive the conversion of the basally phosphorylated species into 
the hyperphosphorylated form, it was investigated whether these mutations could override 
the inhibitory effect of S146D on hyperphosphorylation. However, this was not the case with 
the same shift in molecular weight observed for LCS I phosphomimetic mutations both in the 
presence and absence of S146D. Conversely no phosphomutation in the LCS I prevent the 
mutation S146D from reducing the amount of NS5A that was hyperphosphorylated. Taken 
together these data might be misinterpreted as suggesting that phosphorylation at serine 
146 and the LCS I are mutually exclusive events. However, the mutation S146D in 
combination with either S222D or S235D resulted in an impairment or ablation to replication 
that was not observed when the mutations were individually introduced.  
 
It is far from certain what complex interplay is occurring between serine 146 and the LCS I in 
the formation of hyperphosphorylation, but the data generated here suggest the following 
model. Firstly the sequential phosphorylation of the LCS I region drives the formation of the 
hyperphosphorylated species, and that elements of this are essential for virus replication. 
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Secondly that hyperphosphorylation is negatively regulated by phosphorylation at S146 
(Figure 3.13). Further, based on the observation that concurrent mutation of S146D and 
S238D results in NS5A that still exhibits two species of distinct mobility, additional (as yet 
undefined) phosphorylation events are required to produce the hyperphosphorylated 
species of NS5A.  
 
 
 
Figure 3.13. Summary NS5A phosphorylation identified.  
Schematic of NS5A showing the location and relationship of phosphorylation events 
identified.  Domain I denoted by the structure of the Con1 monomer (Tellinghuisen et al., 
2005), sequences of LCS I and LCS II are shown, and domain II and III denoted by grey boxes.  
Highlighted in red are those residues identified as phosphorylation sites. Black dots over 
residues within the LCS I identify serines that were observed by MS as phosphorylated. 
 
 
There is evidence of a similar mechanism occurring on the P protein of the Parainfluenza 
virus 5 (PIV5), discussed previously (Section 1.5.3). Here a phosphorylation of the P protein 
at serine 157 allows the binding of Polo-like kinase I via the C-terminal polo-box domain 
(PBD) and a subsequent phosphorylation by the N-terminal kinase domain at position serine 
308 (Sun et al., 2009). Taken together with recent findings that PlkI can phosphorylate NS5A 
in vitro this hints at a potential mechanism by which phosphorylation of NS5A at serine 146 
might regulate hyperphosphorylation in a distal region (Chen et al., 2010). 
 
Interestingly, a serine at residue 146 is only present in genotype 1a and 2a isolates of HCV, in 
the majority of other isolates across all genotypes and subtypes (including 1b and 2b) this 
residue is an alanine, although the surrounding sequence is highly conserved.  It is possible 
therefore that the presence of a phosphorylatable residue at this position might contribute 
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to the enhanced replicative capacity of JFH-1 by allowing for an additional level of control of 
hyperphosphorylation.  
 
Further, albeit circumstantial, evidence supporting this hypothesis comes from an 
examination of the two published structures of domain I. As shown in Figure 3.14 there are 
two differing dimeric conformations of NS5A domain I, the “closed” conformation (1ZH1) 
(Love et al., 2009) and the “open” conformation (3QFM) (Tellinghuisen et al., 2005). Both 
structures utilised the genotype 1b Con1 sequence in which an alanine is present at position 
146.  In the closed conformation A146 is located close to the dimer interface, whereas in the 
open conformation it is on the opposite face of each monomer.  In the closed conformation, 
a proximal residue E148 (conserved in both JFH-1 and Con1) formed an intramolecular 
contact via a hydrogen bond with R112 on the other monomer.  It is therefore possible that 
phosphorylation at residue 146 would either disrupt or stabilise the dimer interaction 
thereby regulating a switch between the closed and open conformations.  
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Figure 3.14. Possible mechanism by which S146 phosphorylation might function. The two 
differing dimeric conformations of NS5A domain I are shown, the “closed” (1ZH1) (Love et 
al., 2009) and the “open” (3QFM) (Tellinghuisen et al., 2005), green/purple and 
purple/yellow respectively. The structural studies utilised a Con1 sequence where an alanine 
is present at position 146.  Residue E148b (conserved in JFH-1 and Con1) forms an 
intramolecular bond with R112a on the opposite monomer, blue and orange respectively 
(Love et al., 2009). It is likely that phosphorylation at 146 would exert an effect on this key 
dimer interaction of the “closed” conformation.  A schematic illustrating the relative 
orientations of “open” and “closed” conformations is shown below.  
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To further support this as a potential mechanism the structural consequences of a glutamic 
acid substitution at position A146 was modelled using the Robetta full-chain protein 
structure prediction server (http://robetta.bakerlab.org) (Kim et al., 2004). The generated de 
novo structure of ConI-A146E was then aligned with the Tellinghuisen et al. crystal structure 
using PyMol, Figure 3.15. This computational modelling suggests the introduction of a 
negative charge at position 146 can be tolerated with respect to monomer structure. This 
suggests that the mechanism by which phosphorylation of serine 146 negative regulates 
phosphorylation is not through conformational changes in the domain I monomer. 
 
 
Figure 3.15. Computational 
modelling of a glutamic acid 
substitution at position 146. 
A glutamic acid was substituted 
into the position 146 in the ConI 
sequence to mimic 
phosphorylation. De novo tertiary 
structure of domain I with the 
phosphomimetic was predicted 
using the Robetta full-chain 
protein structure prediction 
server (green) and aligned to the 
NS5A domain I crystal structure 
(purple) (Tellinghuisen et al., 
2005) using PyMol (Schrodinger, 
2010) 
 
 
 
 
 
3.4 Summary 
This analysis revealed multiple phosphorylation sites and complemented data with extensive 
mutagenesis and phenotype profiling in both sub-genomic replicon and virus systems. These 
data reveals a complex pattern of phosphorylation within LCS I and provide evidence for a 
sequential cascade of phosphorylation across this sequence and regulation by a distal 
phosphorylation event within domain I. These data provides novel insights into the 
complexity and regulation of NS5A phosphorylation and provides a framework for future 
studies, including identification of the kinases involved. Furthermore, NS5A phosphorylation 
C-terminus
N-terminus
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is likely to be a dynamic process, therefore also requiring the action of protein phosphatases, 
such as PP2A, which has been shown to be up regulated by HCV infection (Bernsmeier et al., 
2008), and to interact with NS5A (Georgopoulou et al., 2006). 
 
In summary these data does not support the previously proposed hypothesis that 
hyperphosphorylation is required for virus release and inhibits genome replication. To the 
contrary, the disruption of certain phosphorylation sites in LCS I, the proposed site of 
hyperphosphorylation, was inhibitory to replication (S222, S225 and S229) and that 
phosphomimetic at certain positions restored replication (S222 and S225). Mutations were 
also identified that significantly reduce hyperphosphorylation yet have no effect on either 
genome replication or virus production (S146D and S225D). 
 
While it is still likely that phosphorylation of NS5A regulates the different roles it plays in the 
virus lifecycle, the data here shows clearly that these roles cannot be partitioned between 
one or either phosphorylation state. Indeed upon review of the literature the consensus is 
already emerging that elements of both phosphorylated species are important for both 
replication and virus release. Key to a unifying model on the phosphorylation of NS5A is 
further attempts to completely map and characterise the regions of phosphorylation. Only 
then can the complexities of how function follows phosphorylation be fully eluded. 
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4.1 Introduction 
The domain II of NS5A spans resides 250-338 (JFH-1 numbering) of the protein and has been 
shown to be intrinsically unstructured.  Early work identified a correlation between the 
sequence of the N-terminus of domain II (residues 237-272) and how well a patient 
responded to interferon treatment,  and it was termed the interferon sensitivity determining 
region (ISDR) (Gale et al., 1997). The ISDR was later shown to act by binding the interferon 
stimulated gene PKR and inhibiting its kinase activity in a genotype dependent manner (Gale 
et al., 1998). Interestingly the deletion of this entire region (residues 244-302) was shown to 
have no effect on virus replication or virus production (Appel et al., 2008).  
 
However, the C-terminus of domain II has previously been shown to be an absolute 
requirement for virus replication (Appel et al., 2008). It was shown that in the genotype 2a 
J6/JFH-1 chimeric virus (JcI) a deletion of the C-terminal 36 aa of domain II (residues 303-
338) resulted in a complete abrogation of virus replication. Conversely the entire preceding 
N-terminus of domain II (residues 244-302) could be deleted with no detrimental effect on 
replication or virus production (Appel et al., 2008, Tellinghuisen et al., 2008b) (Figure 4.1A). 
At the same time utilising the genotype 1b SGR Tellinghuisen et al. found that small deletions 
within the C-terminal 56 aa of domain II completely abrogated replication. Further analysis 
by site-directed mutagenesis identified 16 individual residues within this region that were 
important for replication (Tellinghuisen et al., 2008b). 
 
Neither of these studies investigated whether the C-terminus of domain II contained 
residues which were important for the production of virus. Tellinghuisen et al. were 
constrained by using a genotype 1b replicon system that was not able to undergo virus 
production while Appel et al. did not introduce small enough deletions so as to generate 
non-lethal mutations, again precluding the investigating of potential effects on virus 
production.  
 
It was therefore of interest to investigated whether the highly conserved C-terminus of 
domain II contained residues important for the production of virus, as well as virus 
replication. From such data it would also be possible to draw comparisons between two 
different genotypes as to the requirement of this domain in HCV replication. 
 
Furthermore, observations by Tellinghuisen et al. found that in genotype 1b the presence of 
different culture adaptive mutations influenced whether or not an alanine point mutation in 
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domain II affected replication.  For example, an alanine substitution at proline 324 (P320 in 
JFH-1) was lethal to replication in the presence of the culture adaptive mutations E1202G, 
T1289I and K1846T. However, in presence of only the culture adaptive mutation S2204I, the 
same alanine substitution resulted in only a slight impairment to replication (Tellinghuisen et 
al., 2008b). As culture adaptive mutations are a requirement for detectable levels of ConI 
replication, it is therefore unknown as to what residues in wildtype ConI would be important 
for genome replication.  
 
Whilst this investigation was in progress work by other groups began to shed light on the 
role of domain II in virus replication. This work highlighted the host factor cyclophilin A 
(CypA) and its corresponding peptidyl-prolyl isomerase (PPIase) activity as essential for virus 
replication. Interestingly CypA has also been identified as a critical host factor in a diverse 
group of other viruses including HIV, influenza and recently here, HCV (Fischer et al., 2010).  
Disruption of the PPIase activity of CypA through a variety of mechanisms, including chemical 
inhibition, active site mutations and siRNA knockdown have all been shown to abrogate to 
HCV replication (Chatterji et al., 2009, Yang et al., 2010). 
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Figure 4.1. NS5A domain schematic and conservation across C-terminus of domain II.  
A. Three major domains linked by LCSI and II. Previously a 35 aa deletion at the C-terminus of 
NS5A was shown to be lethal to viral replication (red), while deletion of the remaining N-
terminus of domain II was tolerable to deletion (green) (Appel et al., 2008). Conservation of 
amino acids over this region in major isolates (Simmonds et al., 2005) were aligned by 
ClustalW2 and graphic generated by Jalview. Colour in sequence alignment denotes 
conservation of residue properties (hydrophobic=blue, hydrophilic=green, positive=red, 
negative=purple and proline=yellow). Numbering refers to JFH-1 NS5A aa position. B. The 
highly conserved C-terminal 30 aa of domain II were targeted for alanine scanning 
mutagenesis.  
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When cells harbouring HCV are treated with CypA inhibitors, like cyclosporine A (CsA) and 
Alisporivir, several drug resistance mutations readily arise that cluster in domain II of NS5A. 
When these resistance mutations are engineered back into the HCV virus they confer a 
consistent, and additive, increase in the concentration of inhibitors required to block 
replication (Coelmont et al., 2010, Yang et al., 2010). Recent NMR studies have also 
generated convincing evidence that CypA interacts with several residues within the C-
terminus of domain II (Coelmont et al., 2010, Hanoulle et al., 2009a). This interaction motif 
was shown to overlap with the NS5B motif and while CypA inhibitors blocked the domain 
II:CypA interaction, they did not disrupt the domain II:NS5B interaction,  thereby hinting at a 
potential mechanism for this interaction (Rosnoblet et al., 2012). While cyclosporine A is 
known to elicit its immunosuppressive effect via the calcineurin pathway, the development 
of a CsA structural analogue without this activity demonstrated that it is specifically the 
inhibition of CypA that is detrimental to HCV replication (Hopkins et al., 2010). 
 
It was therefore not only the aim of this project to investigate whether the C-terminus of 
domain II has a role in virus replication and release, but also to see whether mutation of 
residues shown to interact with CypA altered the requirement of CypA for HCV replication. 
This was achieved by utilising the fully infectious genotype 2a isolate JFH-1 that is able to 
undergo the complete virus lifecycle in tissue culture. Furthermore, this isolate does not 
require culture adaptive mutations in order to replicate in such systems, thereby avoiding 
some of the conflicting findings of Tellinghuisen et al. discussed previously. 
 
4.2 Results  
4.2.1 Generating a panel of alanine mutations in the C-terminus of domain II 
To examine the role of the C-terminus of domain II in the virus lifecycle a reverse genetics 
approach was adopted. The original deletion that Appel et al. demonstrated was lethal to 
virus replication spanned residues 303-338; however through smaller deletions it was shown 
by Tellinghuisen et al. that residues 304-308 could also be deleted with no effect on 
replication (Appel et al., 2008, Tellinghuisen et al., 2008b). The sequence alignment of 
residues 309-338 showed a high degree of conservation across all genotypes (Figure 4.1A).  It 
was therefore decided to target the entire 30 aa at the C-terminus of domain II (309-338) for 
alanine scanning mutagenesis and subsequent profiling in the JFH-1 replicon and virus 
system. Where alanine occurred in the wild type sequence a mutation to glycine was 
introduced. 
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Figure 4.2. Introduction of point mutations into HCV genomes.  
A Litmus28i sub-vector containing the NsiI/HindIII fragment from mJFH-1 was previously 
generated (Hughes et al., 2009b). Point mutations were inserted by site directed 
mutagenesis then cloned into replicon (mSGR-Luc JFH), full length virus (mJFH-1) or 
mammalian cell expression vector (pCMV10-NS3-5B) (Jones et al., 2007b) via BamHI, RsrII 
and AfeI restriction sites as indicated. All constructs were confirmed by DNA sequencing. 
 
 
Previously unique BamHI/AfeI restriction sites that flank NS5A were introduced into both 
replicon and virus constructs to increase cloning efficiency. These synonymous mutations 
were shown to have no effect on virus replication, assembly or release, and these constructs 
are prefixed with “m”, luc-mSGR, mJFH (Hughes et al., 2009b). The domain II mutations were 
first introduced by site directed mutagenesis into the Litmus28i vector containing the 
NsiI/HindIII fragment from the mJFH-1 genome (Section 2.5.3). The NS5A gene was 
subsequently cloned into the mSGR-luc and the JFH-1 infectious clone construct (mJFH-1) via 
BamHI/AfeI sites. The mutant NS5A genes were also cloned into the pCMV10-NS3-5B 
expression vector via unique BamHI/RsrII restriction sites. This vector was created by cloning 
the NsiI/RsrII fragment from mJFH-1 into the pCMV10-NS3-5B[NS5A(GFP)] to allow for the 
JFH-1
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luc NS3 NS5A NS5BNS4B4A
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ectopic expression of NS5A in the cases where mutations blocked replication (Jones et al., 
2007b). All newly synthesised constructs were confirmed by DNA sequence analysis. A 
summary of the cloning routes used is shown in Figure 4.2. 
 
4.2.2 The role of domain II in replication of the SGR 
To investigate the effect of disrupting residues in the C-terminus of domain II the panel of 
alanine mutations in the mSGR-luc JFH-1 was electroporated into Huh7 cells as described 
(Section 2.8.1) and luciferase activity measured at 4, 48 and 72 hpe. The luciferase activity at 
4 hpe correlates with translation of input transcripts, prior to onset of replication or 
degradation, as such all subsequent time points are normalised to the signal at 4 hpe to 
account for electroporation efficiency (Figure 4.3A). Raw luciferase data for each time point 
is shown in appendix (Appendix figure 8.8). As a negative control the NS5B polymerase 
inactive mutation, GDD->GND, was used throughout (SGR-luc GND) (Targett-Adams and 
McLauchlan, 2005).  
 
Of the thirty mutations, twelve (L309A, P310A, W312A, A313G, N318A, W325A, R326A, 
Y330A, V335A, A336G, G337A and C338A) were shown to completely disrupt the ability of 
the mSGR-luc-JFH-1 to replicate in Huh7 cells. A further eight mutations (A311G, R314A, 
P315A, P319A, P320A, D329A, P332A and T334A) showed a significant reduction (p>0.05) 
from WT replication. The remaining ten mutations (D316A, Y317A, L321A, V322A, E323A, 
S324A, R327A, P328A, Q331A and P333A) showed no statistically significant difference 
(p<0.05) from WT mSGR-luc-JFH-1 replication (Figure 4.3). All mutant transcripts showed a 
broadly comparable luciferase activity at 4 hpe, demonstrating that the absence of 
replication is not a result of poor electroporation efficiency (Appendix figure 8.8) 
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Figure 4.3. The NS5A domain II in replication. 
In vitro transcripts of mSGR-luc containing alanine mutations were electroporated into Huh7 
cells and followed over 72 hours. A. Luciferase activity at 72 hpe normalised to 4 hpe. B. Cell 
lysates at 72 hpe were analysed by SDS-PAGE/Western blot and probed for α-NS5A (Sheep) 
and α-Tubulin (rat). Short and long exposures of the same NS5A blot are shown. Levels of 
NS5A broadly correlate with luciferase replication levels, with the exception of A311G where 
NS5A levels are dramatically reduced compared to similarly replicating mutants. * p>0.05 
from WT, n > 3.   
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To further support the luciferase data, total protein at 72 hpe was analysed by SDS-
PAGE/Western blotting and probed for both NS5A and tubulin (Figure 4.3B). In the case of 15 
of the 18 replicating mutants, both phosphorylated forms of NS5A could be detected at 
levels broadly correlating with the observed level of replication measured by luciferase 
assay. However for mutants A311G, P315A and D329A, the NS5A protein could not be 
detected, even at higher exposures of the western blot.  For P315A and D329A the absence 
of NS5A was expected due to the very low levels of replication observed, but A311G 
replicated to levels comparable to R314A and T334A, both of which had detectable levels of 
NS5A in cell lysates. Therefore it was possible that the A311G mutation might result in the 
destabilization of NS5A, or disrupt a major antibody epitope, however when expressed from 
a NS3-5B expression vector (discussed below) NS5A was detectable in a manner 
indistinguishable from wild type, both with respect to molecular weight and intensity. 
 
4.2.3 Lethal mutations do not disrupt polyprotein processing. 
In the case of non-replicating mutations it was important to establish that loss of replication 
had resulted from a loss or disruption of a specific function of NS5A, rather than disruption 
of polyprotein translation or proteolytic processing as a whole. To investigate this, an ectopic 
expression vector containing the NS3-NS5B coding region under the control of a CMV 
promoter, pCMV10-NS3-5B, was used (Jones et al., 2007b). This would allow for replication-
independent expression and proteolytic processing of the polyprotein. The 12 non-
replicating mutants, together with the three mutants for which NS5A expression could not 
be observed (A311G, P315A and D329A) and R314A as a representative mutant with an 
intermediate phenotype, were cloned into pCMV10-NS3-5B as described previously.  
 
These plasmids were transfected into Huh7 cells as detailed in the methods (Section 2.7.2), 
and cell lysates were analysed for protein expression by Western blot at 72 hours post 
transfection (hpt). All 16 mutants expressed levels of NS5A comparable to WT and 
detectable levels of both basally and hyperphosphorylated NS5A (Figure 4.4). This confirmed 
that the lethal replication phenotype observed for these alanine mutations results from a 
direct loss of NS5A function, and was not due to global effects on NS5A translation, cleavage 
from the polyprotein or phosphorylation. Intriguingly A311G, which was undetectable in the 
context of a replicating SGR, could be detected at wildtype levels in this assay. This suggests 
that additional factors may influence the stability of NS5A when incorporated into active 
RNA replication complexes.  
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Figure 4.4. Expression of NS5A from pCMV-NS3-5B expression vector in Huh7 cells. 
Huh7 cells were transfected with the pCMV10-NS3-5B expression vector containing the 
denoted mutation. At 72 hpt cell lysates were harvested in GLB and analysed by SDS-
PAGE/Western blot and probed with α-NS5A (sheep). The non-specific band has previously 
been show to correlate well with total protein and so is included as a loading control. Both 
hyper and basally phosphorylated NS5A can be detected all mutations. 
 
 
4.2.4 The role of domain II in virus release. 
Having established what elements of domain II are required for replication it was important 
to next establish whether there were residues within this region that were critical to the 
release of infectious virus. Previous work in this lab and others, (Tellinghuisen et al., 2008b), 
have identified residues in LCS II and domain III of NS5A that have no phenotype in genome 
replication but play roles in later stages of the virus lifecycle.  For example P342A mutation 
has no effect on genome replication but reduced infectious virus titres by 1 log (Hughes et 
al., 2009a). 
 
To investigate whether domain II mutations were disrupting virus production the full length 
infectious clone JFH-1 (mJFH-1) was use. The panel of domain II alanine point mutation were 
cloned into the mJFH-1 virus as described earlier (Section 4.2.1). In vitro transcripts were 
electroporated into Huh7 cells as described and incubated for 144 hrs, with a 1:5 passage at 
72 hpe. At 144 hpe the supernatant was removed, clarified and virus titre determined using 
a focus forming assay (Section 2.9.2). In order to be able to correlate virus release with 
replication in a virus system, which may differ from the mSGR-luc system, total RNA was also 
extracted from cells and HCV genomes quantified using qRT-PCR (Section 2.9.3). This 
combination of data meant that a direct comparison between virus replication and virus 
release could be made from the same sample.  
 
A 144 hrs incubation with 1:5 passage at 72 hpe was required in order to allow for the 
degradation of input RNA in non-replicating mutants, despite this the negative control JFH-1 
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GND maintained levels of HCV genomes (or fragments thereof) at significant levels at 144 
hpe. The background level of HCV RNA at 144 hpe suggested that the 5’ UTR (the target of 
the qRT-PCR primers) was highly resistant to degradation by cellular RNases; possibly the 
result of the highly structured nature of the 5’UTR and the stabilising effect of miR-122 
(Shimakami et al., 2012).  There was however a sufficient window between WT and the GND 
negative control to identify a genome replication phenotype for the panel of mutations.  
 
11 mutations (L309A, P310A, W312A, A313G, N318A, W325A, R326A, D329A, Y330A, V335A, 
A336G, G337A and C338A) had level of intracellular genomes at or below that of the 
negative control GND, indicating that they are not capable of RNA replication. These 
mutations also released no detectable virus particles, with the exception of D329A which had 
detectable virus particles at the very limit of quantification. 9 other mutations (A311G, 
R314A, P315A, P319A, P320A, L321A, R327A, P328A and T334A) had levels of intracellular 
genomes and released infectious virus that was statistically reduced from that of WT. The 
remaining 8 mutations (D316A, Y317A, V322A, E323A, S324A, Q331A, P332A and P333A) had 
levels of intracellular genomes and released virus that was not statistically different from 
that of WT (p > 0.05). The replication of these domain II mutations and the extent to which 
certain mutations impair or block replication correlates entirely with the observations made 
in the subgenomic replicon system. 
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Figure 4.5. The effect of domain II alanine mutations of virus replication and release. 
Huh7 cells were electroporated with in vitro transcripts of mJFH-1 containing the denoted 
alanine mutations. At 72 hpe cells were passaged 1:5 before culturing for a further 72 hrs. At 
144 hpe supernatants were removed for virus titre determination by focus forming assay 
(blue), and cells harvested in TRIzol and for analysis of intracellular genomes by qRT-PCR 
(white). A. Residues 309-323 of domain II. B. Residues 324-338 of domain II. * p>0.05 from 
WT, n > 3. Lower level of quantification (LLQ) for released virus denoted by dotted line. 
 
  
m
JF
H
-1
c c
G
N
D
S3
2 4
A
W
3 2
5 A
R
3 2
6 A
R
3 2
7 A
P
3 2
8 A
D
3 2
9 A
Y 3
3 0
A
Q
3 3
1 A
P
3 3
2 A
P
3 3
3 A
T 3
3 4
A
V
3 3
5 A
A
3 3
6 G
G
3 3
7 A
C 3
3 8
A
3
4
5
6
1 0 0
1 0 1
1 0 2
1 0 3
1 0 4 R
e
le
a
s
e
d
 v
iru
s
, ffu
/
m
l
**
*
*
N S 5 A  d o m a in  I I  m u ta t io n
L
o
g
1
0
 H
C
V
 g
e
n
o
m
e
s
/
 1
0
0
n
g
 t
o
ta
l 
R
N
A
A
m
JF
H
-1
c c
G
N
D
L3
0 9
A
P
3 1
0 A
A
3 1
1 G
W
3 1
2 A
A
3 1
3 G
R
3 1
4 A
P
3 1
5 A
D
3 1
6 A
Y 3
1 7
A
N
3 1
8 A
P
3 1
9 A
P
3 2
0 A
L3
2 1
A
V
3 2
2 A
E 3
2 3
A
3
4
5
6
1 0 0
1 0 1
1 0 2
1 0 3
1 0 4 R
e
le
a
s
e
d
 v
iru
s
, ffu
/
m
l
*
*
*
*
L
o
g
1
0
 H
C
V
 g
e
n
o
m
e
s
/
 1
0
0
n
g
 t
o
ta
l 
R
N
A
B
Virus replication
Released virus
Virus replication
Released virus
Chapter 4: The role of domain II in virus replication and release 
115 
 
 
 
 
Figure 4.6. Relationship between replication and the release of infectious virus. 
Virus replication and release data (Figure 4.5) were averaged the relationship modelled by 
linear regression (Prism, Graphpad). Mutations which completely blocked virus replication 
and release were excluded (L309A, P310A, W312A, A313G, N318A, W325A, R326A, D329A, 
Y330A, V335A, A336G, G337A, C338A). 
 
A relationship was observed between the extent to which a mutation would impair 
replication and the corresponding reduction in virus release. When analysed by linear 
regression there was a direct linear relationship, R2 = 0.844, between virus replication and 
release was present (Figure 4.6). As replication precedes virus release these data are 
suggestive that genome replication – specifically the number of intracellular genomes – is a 
rate limiting step to virus release. This is in agreement with Binder et al, who through kinetic 
analysis of HCV infection also established that replication was the rate limiting factor on virus 
production (Binder et al., 2013). 
 
Therefore, the conclusion of these data is that the reduction in virus titre observed for 
domain II mutations stemmed from impairment to replication and not as a result of an 
additional impairment to the virus assembly/release pathways. These data provide further 
support for the conclusion that the C-terminus of domain II plays a pivotal role in HCV 
genome replication but does not contain residues that are essential for the process of 
infectious virus assembly and release. 
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4.2.5 The role of domain II in the assembly of infectious virus 
It has now been established that there are no residues in the C-terminal 30 aa of domain II 
that caused a drop in released virus without a corresponding drop in replication. However, to 
fully discount a role of domain II in virus production it was important to establish if any 
residues in this region were able to modulate the assembly but not necessarily the release of 
infectious virus. For example, if mutations were to enhance virus assembly, it might not be 
observed by assaying only released virus if the release pathway had then become a rate 
limiting step. While there are not many examples of such a mechanism, to discount domain II 
playing such a role the effect of alanine mutations on the assembly of infectious virus was 
investigated. 
 
 
 
 
Figure 4.7. A comparison of intracellular and extracellular infectious virus for a selection of 
domain II alanine mutations. 
In vitro transcripts were electroporated into Huh7 cells, at 72 hpe supernatants were 
removed for virus titre and cells were harvested for intracellular virus. Both extracellular and 
intracellular virus was determined by focus forming assay, n > 3. 
 
 
A representative panel of alanine mutations were selected and possible effects on virus 
assembly investigated by assaying intracellular virus titres. The panel of mutations (A311G, 
P315A, D316A, Y317A, P319A, P320A, L321A, V322A, R327A, P328A, D239A and Q331A) 
were selected on the basis they are highly conserved and result in a range of replication 
phenotypes, from WT to severely impaired. Huh7 cells were electroporated with in vitro 
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transcripts as described previously and at 72 hpe intracellular virus harvested by freeze/thaw 
lysis (Section 2.9). Released virus was collected in parallel and both intracellular and released 
virus titre was determined by focus forming assay (Section 2.9.2). Without exception, in the 
panel of domain II mutants investigated, there was no significant difference between 
intracellular virus and extracellular virus (Figure 4.7). It is formally possible that there is 
duality in function amongst certain amino acids shown to be essential for replication, but 
such a scenario is unlikely and holds many technical difficulties to investigate 
 
From these data it can therefore be concluded that the C-terminal 30 aa of NS5A do not play 
a significant role in the assembly or release of infectious virus, and instead only plays a 
critical role at the level of genome replication (Table 4.1). 
 
4.2.6 Effect of domain II mutations Cyclophilin A inhibition 
During the course of this research much work was published establishing that an interaction 
between the host protein CypA and the NS5A protein is critical for virus replication, 
discussed previously (Sections 1.6.2 and 4.1).  It was shown that the chemical inhibition or 
siRNA knockdown of CypA would readily select for resistance mutations that clustered in the 
C-terminus of domain II, and that these mutations conferred CypA independence to the 
virus. In the JFH-1 isolate the double mutant D316E and Y317N exhibited 20-fold resistance 
to CsA and unlike WT JFH-1 was able to replicate efficiently in CypA silenced cells (Yang et al., 
2010). Similarly in the ConI isolate the double mutation R318W and D320E (corresponding to 
R314W and D320E in JFH) inferred a 10-fold resistance to CsA (Coelmont et al., 2010).  
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NS5A residue 
Effect on virus lifecycle 
Virus replication Virus assembly Virus release 
L309 Lethal n/a Lethal 
P310 Lethal n/a Lethal 
A311 Impaired Impaired Impaired 
W312 Lethal n/a Lethal 
A313 Lethal n/a Lethal 
P314 Impaired n/a Impaired 
R315 Impaired Impaired Impaired 
D316 WT WT WT 
Y317 WT WT WT 
N318 Lethal n/a Lethal 
P319 Impaired Impaired Impaired 
P320 Impaired Impaired Impaired 
L321 WT WT WT 
V322 WT WT WT 
E323 WT n/a WT 
S324 Lethal n/a Lethal 
W325 Lethal n/a Lethal 
R326 Lethal n/a Lethal 
R327 WT WT WT 
P328 WT WT WT 
D329 Impaired n/a Impaired 
Y330 Lethal n/a Lethal 
Q331 WT WT WT 
P332 Impaired n/a Impaired 
P333 WT n/a WT 
T334 Impaired n/a Impaired 
V335 Lethal n/a Lethal 
A336 Lethal n/a Lethal 
G337 Lethal n/a Lethal 
C338 Lethal n/a Lethal 
 
Table 4.1. Phenotype of C-terminal domain II mutations  
Summary of alanine mutagenesis (or glycine in the case of WT alanine) on the replication, 
assembly and release of JFH-I virus.   
 
 
These resistant residues are located within a motif (RPDY) that is present twice within this 
region of domain II (R314-Y317 and R327-Y330, Figure 4.1).  As residues in both of these 
motifs showed a reduction in genome replication (R314, P315 and D329, Y330) it was 
Chapter 4: The role of domain II in virus replication and release 
119 
 
considered that this might be explained through an alteration in the dependency of NS5A on 
CypA. It was therefore investigated whether alanine mutations in either of these RDPY motifs 
were able to modulate the dependency of NS5A on CypA for HCV replication. This was 
achieved by determining at what concentration the CypA inhibitor cyclosporine A (CsA) was 
able to block HCV replication. The rationale was that, if a mutation were to reduce the 
dependence of NS5A on CypA for replication, then a concomitant increase in the 
concentration of CsA that is inhibitory to HCV replication would be observed. Conversely, if 
mutations increased the dependence on CypA then a decrease in the concentration of CsA 
required to block HCV replication would be observed. 
 
The concentration of CsA that is inhibitory to HCV replication was determined by treating 
Huh7 cells harbouring the mSGR-luc with a range of CsA concentrations and determining the 
50 % effective concentration (EC50). Note that an EC50 is the functionally equivalent of a 50 
% inhibitory concentration (IC50). The term EC50 is used in place of IC50 where it is feasible 
that the drug induced response could occur through a pathway other than inhibition of the 
target molecule.  
 
Huh7 cells were electroporated with in vitro transcripts of mutant and WT mSGR-luc-JFH-1. 
At 4 hpe cells were treated with CsA at concentrations ranging from 0.01 to 100 μM, then 
followed for a further 44 hrs before determining luciferase activity at 48 hpe (Section 2.8.2). 
Data were normalised to the 0 % inhibition plateau before modelling by a standard 
concentration of agonist vs. response model (Appendix figure 8.10A) to determine the EC50 
for each mutant replicon. As positive control for a modulation in CypA dependence the 
major resistance mutation D316E was introduced into the mSGR-luc and determined its EC50 
in parallel. Conversely, as negative control the EC50 of BMS-790052 against both WT and 
D316E replicons was determined. 
 
The EC50 curves are shown for mutants 314-317, 327-329 and WT, Figure 4.8. In the case of 
Y330 the mutation to alanine completely abrogated replicon, so prohibiting EC50 
calculations. With the exception of Y317A, all alanine mutations in both -RPDY- motifs (314-
317, 327-329) resulted in modest increases in the sensitivity of the mSGR-luc to CsA 
treatment. Conversely Y317A showed an equally modest decrease in sensitivity to CsA 
treatment. As expected D316E resulted in a 1-log increase in resistance to CsA, while 
remaining comparable to WT in its sensitivity to BMS-790052 inhibition, summary in Table 
4.2 and raw data in Appendix figures 8.10B, C and 8.11B, C.  
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Figure 4.8. Sensitivity of -RPDY- motif mutations to CsA treatment. 
Huh7 cells electroporated with the denoted mSGR-luc were treated at 4 hpe with serial 
dilutions of CsA (0.2% DMSO final) and followed over 48 hrs. After which luciferase activity 
was determined and EC50 curves calculated using Prism 6 (Graphpad). The CsA EC50 for 
Y330A could not be determined with confidence due to its low level of replication. 
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In order to correlate the loss of luciferase signal to a specific loss of the HCV replicon, and 
not a result of drug induced cell toxicity, the concentration at which CsA was toxic to cells 
was determined by a MTT assay (Section 2.8.3). In brief, at 48 hpe drug treated cells were 
incubated with 1mM MTT for 2 hrs before washing, dissolving the MTT metabolite in DMSO 
and determining absorbance at 570 nm. The cytotoxicity concentration, 50% activity (CC50) 
was calculated for WT and D316E by the same process as EC50. Both WT and D316E 
replicons showed comparable sensitivity to CsA induced toxicity (Table 4.2 and Appendix 
figure 8.10B, C). This confirmed that the calculated CsA EC50 correlated to inhibition of the 
mSGR-luc and not a cell toxicity effect.  
 
These data show that within this region of domain II there are several mutations capable of 
modulating the dependence of NS5A on the activity of cyclophilin A, but that this modulation 
is not as significant as for the major CsA resistance mutation D316E. 
 
 
Drug 
treatment 
Domain II 
mutation EC50 +/- SEM CC50 
Cyclosporin A, 
nM 
R314A 124 +/- 20.1 16,452 
P315A 108 n/a n.d 
D316A 262 +/- 20.3 n.d 
Y317A 802 +/- 22.1 n.d 
R327A 264 +/- 411.5 n.d 
P328A 228 +/- 17.8 n.d 
D329A 153 n/a n.d 
D316E 3,199 +/- 22.1 17,303 
mSGR 378 +/- 43.2 17,586 
BMS-790052, 
pM 
D316E 24 +/- 2.1 n.d 
mSGR 17 +/- 5.0 n.d 
 
Table 4.2. Summary of CsA sensitivity of DII mutant replicons. 
CsA EC50 for domain II alanine mutations in RPDY motif. As positive control the major 
resistance mutation, D316E, showed a 1-log increase in CsA resistance. Conversely the D316E 
mutation showed no change in BMS-790052 sensitivity compared to WT. n > 2.  
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4.3 Discussion 
4.3.1 Involvement of domain II in virus replication and release 
This study has utilised the HCV genotype 2a isolate JFH-1 to investigate the role of the C-
terminal 30 residues of NS5A domain II within the virus life cycle.  A total of 12 residues 
within this region were identified as essential for viral genome replication. The substitutions 
of these amino acids to alanine (or to glycine in the case of alanine residues within NS5A) 
abrogated genome replication in both full length virus and subgenomic replicons.  A further 8 
mutations resulted in a significant inhibition of replication implying that, although these 
residues are not essential, they do contribute to genome replication.  There was however, no 
residue within this region that when mutated resulted in a reduction in released virus titre 
without a corresponding reduction in viral replication, implying that this region is exclusively 
involved in genome replication.  
 
 
 
Figure 4.9. Summary of the effect of alanine mutations in the C-terminal of domain II.  
Mutations either had no statistically significant effect (green), impaired (orange) or 
completely abrogated (red) virus function when compared to WT and non-replicating (GND). 
Impairment was defined as being statistically different (p<0.05) from WT, but still with 
detectable levels of replication and/or virus release.  
 
 
These data reinforces the conclusion that the primary role of domain II is in genome 
replication, and that those residues not required for replication played no role in the release 
of infectious virions.  However, the possibility that residues essential for replication are also 
required for virus assembly and/or release cannot be ruled out. Although such a duality in 
function is unlikely and technically challenging to address experimentally. Two previous 
studies have assessed the requirements for genome replication of the corresponding region 
in the genotype 1b subgenomic replicon (Shimakami et al., 2004, Tellinghuisen et al., 2008b); 
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but as the genotype 1b isolates were not able to undergo infection in cell culture 
investigation of the later stages of the virus life cycle was precluded.  The data generated in 
that study are presented here allow a comparison of residues required for genome 
replication between the two genotypes.  
 
4.3.2 Genotype specific requirements within domain II for RNA replication. 
As illustrated in Figure 4.1 this region exhibits a high level of sequence conservation across 
the genotypes in this region of domain II.  Ten of the 30 residues are absolutely conserved, 
and a further 10 show a very high level of sequence conservation (at least 90 %). One 
prediction would be that those residues that are absolutely conserved would also play 
critical roles, however this is not entirely the case.  Although P310, W325, G337 and C338 are 
essential for genome replication in both genotype 1b and 2a, the data for other conserved 
residues is less clear cut.  For example, in this study the mutation of residues W312, A313, 
Y330 and V336 are lethal, however, in genotype 1b the corresponding mutations have either 
a WT or partial phenotype.   
 
 
 
 
Figure 4.10. Comparing the requirements of domain II for replication from different 
genotypes. 
Replication data generated previously (Tellinghuisen et al) in the genotype 1b Con I replicon 
is compared with data from this investigation using the genotype 2a JFH-1 isolate. Mutation 
to alanine (or glycine) either had no statistical effect on replication when compared to WT 
(green) or completely abrogated replication (red). Where mutation resulted in an 
intermediary impairment is denoted by orange. 
 
 
Focussing on the differences between Con1 and JFH-1, 22 residues are conserved between 
the two genotypes, yet in only a minority of these residues do the requirements match 
(Figure 4.10).  In fact only five residues appeared to be dispensable for both genotypes.  
Overall within this region, 77 % of residues in the JFH-1 isolate are required for genome 
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replication compared to only 50 % in the Con1 isolate, indicating that this region appears to 
have greater importance for genome replication in the JFH-1 isolate. 
 
These results argue strongly that it is difficult to extrapolate between data sets derived from 
genotype 1b and 2a, suggesting that there may well be significant functional differences 
between the NS5A proteins of these two genotypes. An additional confounding factor is the 
observation that the phenotype of selected mutants in the genotype 1b replicon are 
influenced by the combination of culture adaptive mutations there were present within the 
remainder of the replicon.  For example P324A (corresponding to JFH-1 P320A) is lethal in 
the context of the GIT replicon (mutations E1202G and T1280I in NS3, and K1846T in NS4A) 
but only displays a slight impairment in the NS5A mutant S2201I replicon (Tellinghuisen et 
al., 2008b). 
 
4.3.3 Involvement of domain II in cyclophilin A dependence 
How can single point mutations, in some cases as subtly as alanine to glycine, elicit such 
deleterious effects on a region of protein that has only limited elements of secondary 
structure?  One possibility might be in the context of protein-protein interactions as this 
region of NS5A has been reported to interact with the NS5B polymerase (Shimakami et al., 
2004), and the cellular factor, CypA (Hanoulle et al., 2009a, Yang et al., 2010).  
 
The involvement of this region with CypA was focused on because, as discussed, the 
inhibition of CypA activity by various methods results in the major resistance mutations 
R314W, D316E, Y317N (Coelmont et al., 2010, Yang et al., 2010). More recently NMR 
evidence has implicated A311 - N318, T334, G337 and C338 as sites of CypA interaction and 
preliminary evidence that the P315-D316 bond as the prolyl bond that is cis-trans isomerised 
by CypA (Coelmont et al., 2010, Hanoulle et al., 2009a, Yang et al., 2010). These residues are 
located within a motif, RPDY, that repeats twice in the C-terminus of NS5A, Figure 4.11.  
 
During the course of this investigation it was realised that residues within this repeating 
motif, -RDPY-, did not have corresponding phenotypes. In the first occurrence of the motif 
the mutation of the RP (314, 315) impaired replication, while the mutation of DY (316, 317) 
showed no difference from WT. In the second occurrence of this motif the reverse was 
observed, with RP (327, 328) showing no difference from WT, and DY (329, 330) impairing 
replication - indeed Y330A completely abrogated replication.  
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Figure 4.11 Summary of CypA involvement with residues 309-338 of NS5A. 
Sequence of JFH-1 NS5A with replication phenotype denoted by colour. WT (green), 
impaired (orange) or abrogated (red) replication. Major resistance mutations identified in 
(Coelmont et al., 2010, Yang et al., 2010) and major CypA interaction residues identified in 
(Hanoulle et al., 2009a, Rosnoblet et al., 2012). 
 
 
The effect of alanine mutation within this repeating RDPY motif on the susceptibility of HCV 
to CypA inhibition was investigated. Some modulation of the inhibitory concentration of CsA 
was observed for several of these mutations, but not as dramatic as the 1-log shift observed 
for the resistance mutations D316E. In contrast to the NMR discussed above, both Foster et 
al. and Chatterji et al. have shown that D316 and Y317 are not required for CypA binding in 
vitro (Foster et al., 2010, Foster et al., 2011, Chatterji et al., 2010). The data presented here 
are consistent with the latter observation, as although D316A and Y317A had no apparent 
phenotype, mutation of the surrounding residues to alanine (or to glycine in the case of A311 
and A313) was sufficient to either strongly impair or completely abolish virus replication. 
 
Taken together, these data are therefore consistent with the previously proposed hypothesis 
that binding of CypA to the motif PAWARP between residues 310-315 is important for HCV 
genome replication (Hanoulle et al., 2009a). Intriguingly the RPDY motif discussed overlaps 
with a longer sequence that is present twice within the region of interest WxRPDYxPP (x=any 
amino acid) (Figure 4.11, III) and that has a high level of conservation across all major 
genotype isolates (Figure 4.1).   
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It would be interesting to analyse the phenotype of combinatorial mutations to determine if 
there is any redundancy resulting from the duplication.  A further twist to this story is the 
observation that in Con1 (Tellinghuisen et al., 2008b), the phenotypes of mutations of the 
two DY motifs are opposite to the JFH-1 phenotype.  D320 and Y321 (corresponding to JFH-1 
D316 and Y317) are required for genome replication whereas D333 and Y334 (JFH-1 D329 
and Y330) are not required.  
 
4.4 Summary 
In conclusion, the C-terminal 30 residues of NS5A domain II has no role in either the 
assembly or release of infectious virus in the genotype 2a isolate JFH-1, and that the function 
of this region is restricted to that of the replication of viral genomic RNA. Although this role 
in genomic replication is consistent with data obtained for genotype 1b, this data highlights 
phenotypic variations between genotypes irrespective of the high sequence conservation 
and caution against extrapolation of datasets between genotypes, Figure 4.10 and Appendix 
figure 8.9.  A key challenge for the future will be to determine the mechanisms underpinning 
how single amino acid changes can completely ablate the function of a protein which holds 
no intrinsic enzymatic function.  In particular it will be intriguing to determine if any of these 
changes influence the ability of domain II to interact with either cellular or viral proteins, or 
indeed viral RNA. 
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5.1 Introduction 
The subcellular distribution of wildtype NS5A in either replicon or infect cells is that of 
discrete puncta, present throughout the cytoplasm but enriched in the perinuclear region 
where the membranous web forms. NS5A is known to co-localise with other viral proteins 
like NS3 and NS5B as well as with cellular compartments like lipid droplets and ER-derived 
membranes. Work in recent years has shown that NS5A is actively transported around the 
cell in a dynein dependent manner and two different sub-populations of NS5A have been 
observed (Wolk et al., 2008). The NS5A protein is localised in large, predominantly static 
structures that co-localise with membranous web as well as much small puncta that are 
highly mobile and are trafficked rapidly around the cell. Initially it was thought that only the 
static structures represented sites of replication, but recent findings presented by Eyre et al. 
illustrated that both static and mobile structures co-localised with HCV RNA, VAP-A and 
Rab5A (Eyre et al., 2012). While all these proteins are enriched in replication complexes, 
whether or not the small mobile structures are actively replicating remains to be shown. 
 
As has been discussed at length the NS5A protein is essential in roles that are spatially and 
temporally separate events within the cell; replication, assembly and influencing signalling 
pathways. While the consensus is that phosphorylation of NS5A is regulating these different 
roles, there is real need for functional data to support this hypothesis.  
 
The presence of functionally separate populations of NS5A has already been illustrated 
(Fridell et al., 2011, Fridell et al., 2013) and it is possibly that these functional differences 
correspond to spatially different populations of NS5A as well. All of which could be driven by 
phosphorylation. Indeed previous data herein has already illustrated that mutation of the 
phosphorylation site serine 225 is sufficient to dramatically alter the localisation of NS5A in 
replicon cells while only slightly impairing replication or virus release (Section 3.2.3). 
 
It was therefore of interest to further investigate how phosphorylation events might be 
affecting the localisation and trafficking of NS5A within a cell through the application of 
confocal-microscopy on both fixed- and live-cells. In order to distinguish between the 
different phosphorylated forms of NS5A in confocal microscopy there is the requirement to 
be able to differentially label them. Typically in fixed-cell IF this is achieved by either 
generating phosphospecific antibodies or introducing different epitope tags (FLAG, HA etc.) 
into phosphomutants and WT. Similarly in live-cell confocal imaging this is achieved by 
introducing different wavelength fluorescent protein into phosphomutants and into WT. 
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These approaches require time in cloning and in validating the insertion of epitope tags and 
fluorescent proteins. A bottle neck forms when experiments require that either WT or a 
phosphomutant be tagged with another tag, as this process of cloning and validation must 
be repeated. As such, a novel tag system was sought that allowed for much greater 
interchangeability of variables like fluorophore wavelengths, as well as opening up new 
experimental possibilities.  
 
The primary aim of this project was the direct comparison of the subcellular localisation of a 
NS5A harbouring phosphomutants and with that of wildtype. While this could be achieved 
by screening for differences in co-localisation with other proteins, such as NS3, subtle 
differences in localisation could easily be missed. However, by differentially labelling the 
phosphomutant and wildtype NS5A within the same co-electroporated cell, small differences 
in localisation would become very apparent. This could for example highlight whether or not 
the phosphomutant S146D, which lacks hyperphosphorylation, localises in the same manner 
as the culture adaptive mutation S2204I (serine 232 in JFH-1 numbering), which also lacks 
hyperphosphorylation. 
 
The secondary aim was to investigate temporal differences in the distribution of NS5A in a 
pseudo pulse-chase experiment. NS5A could be initially labelled with a fluorophore and then, 
following a defined period of time or drug treatment, could be labelled again with a different 
wavelength fluorophore. Such a system applied to live confocal imaging it could answer 
whether newly synthesis NS5A is responsible for the highly mobile puncta while ‘older’ NS5A 
is more confined to replication complexes, or vice versa. 
 
There is a diverse family of fluorescent proteins with different properties, such as those that 
are photoactivatable, pH sensitive or shift wavelength as a function of time. However, the 
modern tag systems that are emerging offer greater flexibility and access to new 
experimental space that cannot be achieved with even these sophisticated fluorescent 
proteins. These new tag systems typically involve a genetically modified protein domain that 
is able to conjugate or chelate to specific substrates. These substrates are themselves linked 
to a diverse variety of functional groups including chemical fluorophores, quantum dots, 
biotin or immobilised resins. As these fluorophores are synthetic they generally have a better 
quantum yield and are less susceptible to photobleaching than their fluorescent protein 
counter parts. 
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Figure 5.1. Illustration of the SNAP/CLIP technology. 
The SNAP or CLIP domain is traditionally fused to the N or C terminus of the protein of 
interest, when expressed it is able to covalently conjugate to a specific substrate, BG or BC 
respectively. This system was developed by NEB specifically for the confocal microscope 
imaging of cells containing labelled proteins. As such there is a wide spectrum of different 
colour fluorophores already conjugated to both benzylguanine/cytosine that are commercial 
available and are both non-toxic and cell-permeable. Figure reproduced from (NEB, 2010). 
 
 
The modern tag system adopted was based on the SNAP-tag technology developed by NEB, a 
highly versatile protein tag composed of a 20 kDa domain originally derived from the O6-
alkylguanine-DNA alkyltransferase (AGT) (Provost and Sun, 2010). This domain has been 
modified to react specifically and rapidly with benzylguanine (BG) derivatives, resulting in 
covalent linkage of the functional group to the protein of interest (Figure 5.1). To develop 
the possibility for co-labelling the SNAP domain was engineered further to alter its substrate 
specificity such that it reacted with O6-benzylcytosine (BC) derivatives. This domain, termed 
CLIP, would allow for co-labelling within a cell of two differentially tagged proteins. 
 
There is a wide variety of different commercial available substrates for both SNAP- and CLIP-
tag domains. These include cell permeable fluorescent substrates that are applicable to both 
live- and fixed- cell imaging, cell impermeable fluorescent substrates for specific labelling of 
surface markers as well as a range of affinity capture substrates. The SNAP-technology has 
also been applied to more complex experiments probing in-cell protein:protein interactions, 
these are reviewed in (Barth, 2013, Haruki et al., 2012). Most interesting is the use of a SNAP 
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and CLIP substrate joined by a long chemical linker, such a probe can be used to identify, in a 
quantitative manner, whether a SNAP-tag and CLIP-tag are in very close proximity.  
 
This project aimed to investigate NS5A in the context of active replication/infection not from 
ectopically expressed vectors. As such the first technical challenge was linking the SNAP/CLIP 
domain with the NS5A protein in a manner that did not disrupt the virus lifecycle. In the 
context of both replicon and virus the NS5A protein is translated as part of the viral 
polyprotein from which it is subsequently cleaved by the NS3/4A polymerase. The insertion 
of the SNAP/CLIP domain in either an N- or C-terminal position could possibly disrupt this 
cleavage event and was therefore excluded as a tag location. It has previously been shown 
by several groups that regions within domain III are tolerable to large insertions with no 
effect on replication and only marginal effects on virus release, Figure 5.2. As such it was 
decided to introduce the SNAP/CLIP domain as an internal insertion in domain III at one of 
these previously validated sites. 
 
The SNAP/CLIP technology has previously only been deployed as either an N- or C-terminal 
tag, with expression typically driven from a ectopic vector. It was therefore unknown 
whether the insertion of the SNAP/CLIP tag at an internal position would disrupt the folding 
of the tag, and subsequently block the ability to conjugate to the specific substrate. It was 
necessary to validate not only whether the replicon was still viable with a SNAP/CLIP-tag, but 
also whether the SNAP/CLIP-tag had retained catalytic activity and specificity towards the BG 
and BC substrate. 
 
5.2 Results 
5.2.1 Insertion of SNAP/CLIP domain into NS5A domain III 
As discussed domain III of NS5A has been shown to tolerate the insertion of small and large 
tags between residues 380-432 aa (JFH-1 NS5A numbering) (Figure 5.2). The insertion site V, 
between residues 430 and 431, was chosen for the insertion of the SNAP- and CLIP-tag as it 
had been previously validated in the JFH-1 isolate and shown to have no significant effect on 
replication or virus production (Igloi and Harris, in preparation). The location of insertion site 
V is within a 19 aa naturally occurring insertion that is present in several genotype 2a 
isolates, including JFH-1. This 19 aa insertion is not present in other genotypes, implying that 
it cannot be a key requirement for virus replication or production. 
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Site 
Isolate, 
system Insertion 
Effect on 
replication 
Effect of 
release 
NS5A 
phosphorylation Reference 
I ConI, SGR GFP-FLAG 
Significantly 
impaired 
not tested not tested 
Moradpour et 
al 2004 
II JcI, virus 
emGFP, 
RFP 
WT replication 
over 72 hrs 
Present, but 
impaired 
not tested 
Schaller et al 
2007 
III ConI, SGR GFP-FLAG Impaired not tested not tested 
Moradpour et 
al 2004 
III JFH-I, virus GFP 
WT replication 
over 72 hrs 
Present, but 
impaired 
not tested 
Masaki et al 
2008 
III JFH-1, SGR 
GFP and 
PAGFP 
WT replication 
over 72 hrs 
not tested 
Two bands, equal 
intensity 
Jones et al 
2006 
III JFH-1, SGR 
One-Strep-
tag 
WT replication 
over 72 hrs 
not tested not tested 
Amako et al 
2009 
IV ConI, SGR GFP Impaired not tested 
Two bands, equal 
intensity 
McCormick et 
al 2006 
IV ConI, SGR PSTCD 
WT replication 
over 72 hrs 
not tested 
Two bands, equal 
intensity 
McCormick et 
al 2006 
V JFHI, virus PSTCD 
WT replication 
over 72 hrs 
WT virus 
titres 
Two bands, equal 
intensity 
Igoli et al in 
preparation 
 
Figure 5.2.  Insertion sites in NS5A domain III and cloning design of SNAP/CLIP insertion. 
A. Regions of NS5A where either fluorescent proteins or affinity tags have previously been 
inserted. Sequence of inserted SNAP/CLIP domain into site V. B. Summary of the different 
virus and phenotypes of previous domain III insertions. 
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To increase the steric freedom and allow for the correct folding of the SNAP/CLIP-tags, 
essential in order to retain catalytic activity, the domain was flanked with serine rich flexible 
linkers, similar to those utilised previously (Igloi and Harris, in preparation). The insertion is 
shown in Figure 5.3B with an abridged protein sequence of the SNAP/CLIP-tag, a complete 
protein and DNA sequence is shown in Appendix figure 8.12. 
 
A simple cloning strategy was utilised for the insertion of the SNAP/CLIP domain based 
around the BclI restriction site (Figure 5.3A), a site that is unique in the previously generated 
pLitmus28i sub-clone containing the JFH-1 NsiI-HindIII fragment (Figure 4.2). The DNA coding 
sequence for the SNAP/CLIP-tag was amplified by PCR using either pSNAPf or pCLIPf vector 
as template. Custom PCR primers were designed that contained regions complementary to 
the SNAP/CLIP coding sequence as well as the containing the flexible linker sequence and 
BclI restriction sites. The PCR amplification thereby created a gene block containing the 
SNAP/CLIP with flexible linkers with flanking BclI restriction sites at either ends, Figure 5.3B. 
The mSGR-luc-JFH vector and gene block were digested with BclI and the gene block ligated 
into the parent vector. This cloning strategy obviously result in both forward and reverse 
insertions of the gene block so colonies were initially screened for the correct orientation by 
directional colony PCR and positive colonies confirmed by DNA sequencing. 
 
 
Figure 5.3. Cloning strategy for insertion of SNAP/CLIP domain. 
A. Region of NS5A domain III where the SNAP/CLIP domains were inserted, aa 428-435. B. 
Sequence of NS5A domain III showing the insertion of the SNAP/CLIP domain (blue) and 
flexible linkers (green). The unique BclI site used to insert the SNAP/CLIP gene block is 
highlighted in red. Complete sequence of SNAP- and CLIP-tag is shown in Appendix figure  
ctggagtctgat caggtagagctt
L  E  S  D   Q  V  E  L 
BclI site
ctggagtctgatcatggaagtagcgggtcatcg
L  E  S  D  H  G  S  S G  S  S
atggacaaagac ctgggtcctgca
M  D  K  D L  G  P  A
ggatcttcaggttcttcatctgatcaggtagag
G  S  S G  S  S S D  Q  V  E 
-SNAP/CLIP--
domain
B
A
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5.2.2 The effect of inserted SNAP/CLIP domains on HCV replication 
While there is now much precedence for the insertion of small to medium sized protein tags 
into domain III as being well tolerated, there have been occasions whereby insertions have 
impaired or abrogated replication, Figure 5.2B. As such it was important to first establish 
whether the insertion of the SNAP and CLIP domains into NS5A had an effect of the 
replication. To do this a luciferase based replication assay was utilised as described 
previously (Section 3.2.2 and 4.2.2). 
 
In brief, Huh7 cells were electroporated with in vitro transcripts of either a WT mSGR-luc-
JFH-1 or derivatives containing the NS5A-SNAP or NS5A-CLIP and replication followed over a 
72 hr period by measuring luciferase activity. As shown in Figure 5.4, the replication kinetics 
of the SNAP and CLIP containing replicons are indistinguishable from that of WT, confirming 
that the insertion of SNAP and CLIP domains do not disrupt the role the NS5A plays in 
replication. 
 
 
Figure 5.4. Replication competence of the mSGR-luc JFH-1 containing the NS5A-SNAP/CLIP. 
Indicated replicon genomes were electroporated into Huh7 cells and luciferase activity 
followed over 72 hrs. Luciferase activity is expressed as the fold increase over the signal at 4 
hrs. 
 
 
5.2.3 Specific in-cell labelling of SNAP/CLIP-NS5A 
It was next critical to establish whether the inserted SNAP/CLIP domain was able to fold 
correctly and conjugate specifically to the appropriate substrate. As mentioned the SNAP 
and CLIP domains have only been previously utilised as either an N- or C-terminal tag. To 
investigate whether the SNAP and CLIP domains were still able to conjugate to their 
substrates they were labelled with substrates in which the benzylguanine/cytosine groups 
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were conjugated to the fluorophore TMR-Star, termed SNAP-TMR and CLIP-TMR 
respectively. The TMR-Star fluorophore is a derivative of 6-carboxytetramethylrhodamine 
and has an excitation/emission maxima at 554/580nm. 
 
Huh7 cells were electroporated with mSGR-luc genomes containing either NS5A-SNAP or 
NS5A-CLIP, seeded into an 8-chambered microscope slide, 1cm2 tissue culture area (Ibidi) 
and incubated for 48 hrs under normal TC conditions. These 8-chambered slides allow for 
small volumes of cell labelling media to be used, as well as being suitable for mounting 
directly onto an inverted confocal microscope in subsequent live-cell imaging. The SNAP/CLIP 
cell labelling media was prepared by dissolving the SNAP-TMR and CLIP-TMR dye in DMSO to 
1 mM before diluting to 5 μM in complete media without phenol red. At 48 hpe media was 
removed from cells which were washed twice in PBS before the addition of either the SNAP-
TMR or CLIP-TMR labelling media. Cells were incubated in the presence of labelling media for 
1 hr at 37 °C, 5 % CO2 before a dye washout step where the labelling media was removed, 
cells washed with PBS and incubated for a further 30 mins in fresh complete media without 
phenol red. The dye washout step is required to allow any unconjugated dye to diffuse out of 
the cells and so increasing the signal to background. At this stage cells were able to be 
imaged directly on a confocal microscope, but to allow for co-labelling by 
immunofluorescence (IF) cells were fixed in 4 % (w/v) PFA and immunostained, described 
previously. In brief, cells were permeabilised with 0.1 % (v/v) Triton X-100, PBS for 7 mins at 
RT before washing and then incubating with α-NS5A (sheep) at 1:1000 for 1 hr at RT. Cells 
then washed and incubated with a Donkey α-Sheep (594 nm) fluorescent antibody followed 
by staining of the nucleus with DAPI via the addition of ProLong gold mounting media (Life 
Technologies). 
 
Prepared slides of both the mSGR-luc NS5A-SNAP and NS5A-CLIP replicons were imaged on 
an LSM 700 using the same laser, optic and acquisition settings, allowing for broad 
comparison between images to be made. To examine whether the SNAP-TMR or CLIP-TMR 
were non-specifically labelling cellular material Huh7 cells harbouring the WT SGR-luc were 
labelled with both SNAP- and CLIP-TMR and were imaged as described. As can be seen in 
both Figure 5.5 and 5.6 the replicons harbouring the tagged NS5A-SNAP and NS5A-CLIP were 
both able to successfully be labelled by the appropriate dye. This confirms that the mSGR-luc 
replicon is still viable with presence of these tags, as shown by luciferase assay, and that the 
SNAP and CLIP domains are still able to conjugate with the relevant substrates. 
Chapter 5: Novel Protein Tag system for NS5A live-imaging 
137 
 
 
 
Figure 5.5. Immuno-
fluorescence analysis 
of mSGR-luc NS5A-
SNAP replicon.  
Huh7 cells were 
electroporated with 
mSGR-luc NS5A-SNAP 
RNA and at 48 hpe 
labelled with the SNAP-
TMR (red) before fixing 
in PFA and 
immunostaining for 
NS5A (green), nucleus 
labelled with DAPI 
(blue). 
 
 
 
 
 
Figure 5.6. Immuno-
fluorescence analysis 
of mSGR-luc NS5A-CLIP 
replicon. 
Huh7 cells were 
electroporated with 
mSGR-luc NS5A-CLIP 
RNA and at 48 hpe 
labelled with the CLIP-
TMR (red) before fixing 
and immunostaining 
for NS5A (green), 
nucleus labelled with 
DAPI (blue). 
 
  
MergeSNAP-TMR
DAPI NS5A
mSGR-luc JFH-I NS5A-SNAP
MergeSNAP-TMR
DAPI NS5A
mSGR-luc JFH-I NS5A-CLIP
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It was important to confirm that the SNAP/CLIP fluorophores were not non-specifically 
labelling Huh7 cells, for example through accumulating in lipid rich compartments. As such 
Huh7 cells were electroporated with WT mSGR-luc replicons and subsequently labelled with 
both SNAP-TMR and CLIP-TMR dyes simultaneously and imaged as described previously. 
From Figure 5.7 it is clear that Huh7 cells, neither with or without the replicon (indicated by 
NS5A staining), were non-specifically labelled by either the SNAP-TMR or CLIP-TMR to a 
detectable degree.  
 
 
Figure 5.7. WT 
mSGR-luc replicon 
labelled with both 
SNAP-TMR and CLIP-
TMR. 
Huh7 cells were 
electroporated with 
WT mSGR-luc 
genomes and at 48 
hpe labelled with 
both SNAP-TMR and 
CLIP-TMR (red) 
before fixing in PFA 
and immune-staining 
for NS5A (green), 
nucleus labelled with 
DAPI (blue) 
 
 
While the insertion of the SNAP/CLIP domain was not detrimental to the function of NS5A it 
was important to establish whether the presence of the tag altered the sub-cellular 
distribution of NS5A. Comparison of the NS5A distribution in the tagged replicons (Figures 
5.5 and 5.6) with that of the WT replicon (Figure 5.7) showed a broadly comparable 
localisation. However, to demonstrate this in a more comparably manner, Huh7 cells were 
electroporated with either the WT or the NS5A-SNAP containing replicon separately, then 
post-electroporation cells were co-seeded 1:1 into 8-chamered slides. Cells were then 
incubated for 48 hrs, labelled with SNAP-TMR, fixed and immunostained with α-NS5A 
(sheep) followed by a donkey α-sheep (594nm) secondary as described previously (Section 
2.7.3). Cells were then stained with DAPI by the addition of ProLong Gold and imaged on a 
Zeiss LSM 700. 
MergeCLIP-TMR
DAPI NS5A
mSGR-luc JFH-I WT
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Figure 5.8. Comparison of sub-cellular localisation of NS5A-SNAP vs WT NS5A. 
Huh7 cells were electroporated with either mSGR-luc NS5A-SNAP or WT mSGR-luc RNA 
separately, then co-seeded and incubated for 48 hrs. Cells were labelled with SNAP-TMR 
(red) before fixing and immunostaining for α-NS5A (green), nucleus labelled with DAPI 
(blue). Field of view shows cells harbouring with the NS5A-SNAP containing (a) or WT (b) 
replicons. 
 
 
Figure 5.8 shows Huh7 cells harbouring either the NS5A-SNAP containing or WT replicons, 
cell (a) and (b) respectively. The identification was based on the reactivity towards both α-
NS5A and the SNAP-TMR dye, or reactivity towards only the α-NS5A staining. In the cell 
harbouring the NS5A-SNAP containing replicon mSGR-luc NS5A-SNAP there is a high degree 
of co-localisation between the SNAP-TMR dye and the α-NS5A IF staining, cell (a) in Figure 
5.8. This shows that there was a high efficiency of SNAP-TMR labelling, and that NS5A-SNAP 
is not localised to compartments and/or protein complexes that preclude the SNAP-tag from 
being labelling with the SNAP-TMR substrate. Comparison between the sub-cellular 
distribution of NS5A in the NS5A-SNAP or WT replicon, cells (a) and (b), shows a very 
comparable sub-cellular localisation. This suggests the presence of the SNAP/CLIP domain is 
not dramatically altering the distribution of NS5A. However, it is acknowledged that further 
co-labelling with virus proteins like NS3, NS5B and host compartments like lipid droplets and 
ER markers would be required to confirm that WT NS5A and NS5A-SNAP/CLIP have the same 
sub-cellular localisation.  
 
20μm 20μm 20μm
mSGR-luc JFH-I
WT and NS5A-SNAP pooled post-electroporation 
MergeSNAP-TMR NS5A
a
b
a
b
a
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5.2.4 Inserting SNAP/CLIP tags into replicons containing phosphorylation site mutations. 
The next step in the project was the introduction of the SNAP/CLIP tag into replicons where 
the major phosphorylation sites, residues 146, 222, 225 and 348, had previously been 
mutated. This would allow further investigation as described in the introduction. The SNAP-
tag domain III was introduced into the phosphoablatant replicons, while the CLIP-tagged 
domain III was introduced into the phosphomimetic replicons. In combination with the WT 
replicon tagged with both SNAP and CLIP-tags, this gave the flexibility to differentially label 
WT from phosphoablatant or phosphomimetic, as well as being able to differentially label 
between phosphoablatant from phosphomimetic. 
 
The SNAP/CLIP-tag containing domain III was cloned into mSGR-luc JFH-1 constructs 
containing the above phospho-mutants by the flanking restriction sites RsrII and AfeI. The 
RsrII restriction site is located at position 398 (JFH-1 numbering), as such it is located 
inbetween the phosphorylation sites (146-348) and the site of the SNAP/CLIP insertion 
(residue 430), therefore allowing for this simple cloning route. Correct insertion of the 
SNAP/CLIP tag in each construct was confirmed by DNA sequencing. In the case of the 
SS222/225AA mutation a SNAP-tag was not inserted as the double serine mutation had been 
previously shown to be lethal to replication. 
 
Once these constructs were created a replication assay was utilised to confirm that the 
phenotype of the various phosphorylation mutants now containing SNAP/CLIP-tags were the 
same as had been previously observed (Section 3.2.2). Huh7 cells were electroporated with 
the denoted tagged mutant constructs and luciferase activity determined at 72 hpe. 
Phenotypes of the S->A SNAP-tag and S->D CLIP-tag replicons were broadly comparable to 
those observed previously (Figure 5.9). Due to time constraints on this project the 
experiment was only conducted to an n=1. 
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Figure 5.9. Replication analysis of major phosphomutants containing the NS5A-SNAP/CLIP 
domain. 
Huh7 cells were electroporated with the denoted genomes before determining luciferase 
activity at 4, 24, 48 and 72 hpe, as described previously  
 
 
5.3 Discussion 
This project aimed to develop a novel way of visualising the NS5A protein by confocal 
microscopy that would open up new experimental space. This system also aimed to allow 
greater flexibility in the live-imaging of NS5A by allowing for interchangeable fluorophores 
without the need for lengthy cloning. This was achieved by adopting the SNAP-tag 
technology (NEB), a small (20 kDa) protein domain that can covalently conjugate a 
fluorescent substrate under physiological conditions. Such a system allows for a tagged 
protein to be labelled at a variety of different wavelengths by simply incubating live cells 
with fluorescent substrates of different wavelengths. This system also facilitates pseudo 
pulse-chase imaging approaches discussed shortly. 
 
Previously the SNAP-tag technology has only been deployed as an N- or C-terminal protein 
tag.  However, due to the nature of NS5A discussed earlier this was not possible, meaning 
the SNAP-tag had to be inserted internally to the protein. While the NS5A protein has 
previously been shown to tolerate large insertions, Figure 5.2, the SNAP-tag has not 
previously been tested in this kind of application. It was hoped that the unstructured nature 
of NS5A domain III and the introduction of flexible linker sequences either side, would allow 
for correct folding of the SNAP-tag and subsequent of catalytic activity. The SNAP and CLIP-
tag were inserted into domain III of NS5A at residue 430 (JFH-1 numbering), described as site 
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V in figure 5.2, which is within the naturally occurring 19 aa insertion found in many 
genotype 2 isolates. This site was chosen as it has previously been shown to tolerate the 
insertion of a biotinylated motif with no observable effect on the replication or production of 
the JFH-1 virus (Igloi and Harris, in preparation). 
 
The insertion of SNAP/CLIP-tag was well tolerated with respect to replication, with both 
NS5A-SNAP and NS5A-CLIP being indistinguishable from WT (Figure 5.4).  It was also 
demonstrated that the SNAP and CLIP domains are still catalytically active when inserted 
internally to a protein, as they were able to conjugate to the relevant substrate with a high 
efficiency (Figure 5.5 and 5.6).  
 
This validation has also shown that in the NS5A-SNAP/CLIP replicons there was near 
complete co-localisation between the SNAP-TMR and α-NS5A staining, showing that the 
entire NS5A population within a cell is accessible to the SNAP-TMR dye. This was expected as 
the SNAP and CLIP series of dyes utilised were designed for live-cell imaging and as such are 
small, lipophilic and cell permeable. When a cell containing the NS5A-SNAP replicon was 
compared to an adjacent cell containing the WT replicon the sub-cellular localisation of NS5A 
was highly similar, Figure 5.8. However further co-localisation with viral and host proteins 
would be required to say definitively that the presence of the SNAP/CLIP-tag does not 
disrupts the localisation of NS5A.  
 
Taken together these data supports the use of SNAP/CLIP tagged NS5A as a novel model for 
WT NS5A in the replicon system. This system was applied to investigate the role of 
phosphorylation in the sub-cellular localisation of NS5A. The SNAP/CLIP-tagged NS5A was 
inserted into replicons harbouring major phosphorylation mutations, and it was confirmed 
that those replicons had the same phenotype as in the absence of the tag, Figure 5.9. 
However due to times constraints on this project it was not progressed further.  
 
Therefore this project currently stands as proof of principle for the application of the SNAP-
tag technology to NS5A and has created the reagents for future projects. Two key 
experiments that it is felt should be prioritised are the following. Firstly, the co-
electroporation of phospho-ablatant/mimetic replicons containing the SNAP-tag with WT 
replicon containing the CLIP-tag. The subsequent co-labelling with different wavelength 
SNAP and CLIP substrates would allow for subtle differences in both localisation and live cell 
trafficking of NS5A to be determined. Such an approach could highlight whether a particular 
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phosphorylation site is associated with the static or highly mobile populations of NS5A 
discussed earlier. Secondly, a pseudo pulse-chase experiment, whereby electroporation of a 
NS5A-SNAP containing replicon, either with or without other mutations, could be labelled 
with different wavelength SNAP substrates at different time points. This could help identify 
different temporal populations of NS5A as well as being combined with drug treatments that 
are known to affect the NS5A, such as the PI4KIIIα inhibitor like AL-9 or the NS5A inhibitor 
Daclatasvir (BMS-790025) (Bianco et al., 2012, Targett-Adams et al., 2011).  
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The NS5A protein has been well established as a pleiotropic protein with functions 
throughout the virus lifecycle, but despite 20 years of research the mechanism behind these 
functions remains enigmatic. In achieving these spatially and temporally distant functions in 
the virus lifecycle NS5A has been documented to interact with some 130 proteins, viral and 
cellular. It is therefore a clear requirement that such a promiscuous protein be tightly 
regulated and, in common with other virus and cellular proteins, this regulation is in the 
form of extensive and complex phosphorylation events.  
 
Previous efforts to investigate this have been hampered by a lack of understanding about the 
location of phosphorylation sites. Although much work has implicated several clusters of 
serines as important for phosphorylation, the exact location of NS5A phosphorylation sites 
had yet to be defined. This study set out to obtain biochemical evidence in the form of mass 
spectrometry as to the location of these phosphorylation sites. As each phosphorylation site 
in itself probably represents only a small percentage of the total NS5A population, similar 
attempts to achieve this previously have been met with only limited success. Therefore in 
this study significant quantities of NS5A were purified from replicon harbouring cell lines and 
analysed by several orthogonal MS approaches. As a result a total of 12 functional relevant 
phosphorylation sites were identified spanning almost every domain of the protein. The 
subsequent functional analysis through reverse genetics highlighted several phosphorylation 
events as critical for virus replication and shed light on a complex mechanism of 
phosphorylation regulation. 
 
The data presented here shows good evidence for a rapid phosphorylation cascade occurring 
in the LCS I of NS5A. This was observed as a step-wise increase in the apparent molecular 
weight of the basal phosphorylated species whereby the further C-terminal the 
phosphomimetic the greater the increase in apparent molecular weight. It is thought to be a 
rapidly occurring cascade as no intermediary species are observed and while the data 
suggested a linear cascade, a more complex mechanism like that observed in PTEN is at this 
stage equally feasible (Cordier et al., 2012). Exactly what mechanism in the virus life cycle an 
extensively phosphorylated LCS I is important for remains unclear, and that the requirement 
for phosphorylation is genotype dependent inevitable adds further complexities. It is 
plausible that a highly phosphorylated LCS I, with the resulting clustering of negative charge, 
could compete with viral RNA for binding to the NS5A, or other, protein. Indeed the 
proximity of the LCS I to the proposed RNA binding groove is a prime candidate for such a 
mechanism (Tellinghuisen et al., 2005). 
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The observation that the phosphorylation of serine 146 in domain I significantly reduces 
NS5A hyperphosphorylation points towards a new and exciting mechanism of regulation. 
While it is almost certain that there are phosphorylation sites outside of the LCS I that are 
important for hyperphosphorylation, the LCS I is at a minimum the major component. 
Through the use of a phosphospecific antibody it has been clearly demonstrate here that the 
phosphomimetic S146D specifically inhibits the phosphorylation of serine 222, and that 
phosphorylation of S222 is a hallmark of LCS I hyperphosphorylation. A combination of 
phosphomimetic mutations in the LCS I with the S146D mutation further support a 
relationship between these distant phosphorylation sites as serines in the LCS I not 
important for replication where, when in combination with S146D, significantly impairing 
replication. While circumstantial, the close proximity of a phosphorylation at residue 146 to 
the NS5A dimer interface does hint towards a possible involvement in switching between the 
two documented dimer conformations. 
 
In pursuit of a greater insight into how phosphorylation might regulate the function of NS5A 
this study also took the SNAP-tag technology and applied it to NS5A. The insertion of the 
SNAP- and CLIP- tag into domain III of NS5A was shown to be tolerable with respect to both 
HCV replication and importantly the activity of the SNAP/CLIP-tag activity. This now serves as 
a versatile platform for both the live-cell imaging of cells with differentially labelled replicon 
proteins, as well as allowing interesting pulse-chase experiments. The demonstration by 
Fridell et al. that NS5A can be segregated into two different functional populations within a 
cell encourages a model whereby NS5A might also be spatially localised into different 
populations as well  (Fridell et al., 2011, Fridell et al., 2013). 
 
In parallel to investigating the phosphorylation of NS5A this study also set out to fully 
establish whether domain II of NS5A had a hitherto unknown function in the production of 
infectious virus, however no such effects were observed. In combination with existing data it 
is now clear that there is no residue with NS5A domain II that is essential for the production 
of infectious virus, and that any reduction in released virus correlates to an impairment of 
replication. Furthermore, the alanine mutations in the C-terminus of domain II impaired 
replication to varying degree, when this range of replication phenotypes was correlated with 
impairment to virus release there was a strong linear relationship. This supports recent 
modelling which identified replication as the rate limiting step in the production of infectious 
virus (Binder et al., 2013) 
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When the requirement of residues for replication in genotype 2a was compared with 
genotype 1b there was, despite high sequence conservation, very little correlation between 
phenotypes from the different genotypes. In fact one of the very few conserved features was 
the absolute requirement in both genotypes of the conserved GC337/338 for replication. 
These residues overlap with a previously identified VAP-B binding site (residues 337-340) and 
this could point towards how mutation of these residues disrupts replication (Hamamoto et 
al., 2005). A logical progression for this project would be to screen lethal domain II mutations 
for the loss of interaction with proteins already known to interact with this region. The 
precedence in the literature would suggest CypA, NS5B, VAP-B and HCV RNA as prime 
candidates, but through modern mammalian 2-hybrid system a much larger panel of 
proteins could be rapidly screened.  
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Appendix figure 8.1. MS/MS spectrum of phosphorylated serine 146. 
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Appendix figure 8.2. MS/MS spectrum of phosphorylated serine 222. 
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Appendix figure 8.3. MS/MS spectrum of the double phosphorylated serine 222 and 225. 
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Appendix figure 8.4. MS/MS spectrum of phosphorylated threonine 348. 
 
 
 
 
  
A
b
s 
In
t
 x
1
03
m
/z
1
0
0
2
0
0
3
0
0
4
0
0
5
0
0
6
0
0
7
0
0
8
0
0
9
0
0
1
0
0
0
b
 1
y 
1
b
 2
b
 3
y 
3b
-P
i 4
y 
6
y-
P
i 6
y 
8
y-
P
i 8
   
  0
.0
   
  0
.2
   
  0
.4
   
  0
.6
   
  0
.8
   
 1
.0
   
 1
.2
   
 1
.4
   
 1
.6
   
 1
.8
y 
4
K
A
P
T
P
P
P
R
p
b
1
b
2
b
3
b
4
b
5
b
6
b
7
b
8
y 8
y 7
y 6
y 5
y 4
y 3
y
2
y 1
S
e
q
.
K
1
12
9.
10
22
8
-
A
2
20
0.
13
94
7
71
7.
40
42
P
3
29
7.
19
21
6
64
6.
36
71
T
4
38
0.
22
92
5
54
9.
31
44
P
5
47
7.
28
20
4
46
6.
27
72
P
6
57
4.
33
48
3
36
9.
22
45
P
7
67
1.
38
75
2
27
2.
17
17
R
8
-
1
17
5.
11
90
b
-i
o
n
s
y
-i
o
n
s
 172 
 
 
 
 
 
Appendix figure 8.5. MS/MS spectrum of tri-phosphorylated LCS I. 
  
*
*
 
*
 
 
*
G
S
P
P
S
E
A
S
S
S
V
S
Q
L
S
A
P
S
L
R
Tr
i-
p
h
o
sp
h
o
ry
la
te
d
 L
C
SI
 173 
 
 
 
 
 
Appendix figure 8.6. MS/MS spectrum of tetra-phosphorylated LCS I. 
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Appendix figure 8.7. MS/MS spectrum of penta-phosphorylated LCS I.  
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Appendix figure 8.8. Absolute luciferase data for domain II alanine mutations in mSGR-luc. 
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GT 1b, ConI 
Residue 
number 
GT 2a, JFH-1 
  
Replication 
  
Virus 
replication 
Virus 
assembly Virus release 
Lethal M 309 L Lethal n/a Lethal 
Lethal P 310 P Lethal n/a Lethal 
WT I 311 A Impaired Impaired Impaired 
Impaired W 312 W Lethal n/a Lethal 
Impaired A 313 A Lethal n/a Lethal 
WT R 314 P Impaired n/a Impaired 
WT P 315 R Impaired Impaired Impaired 
Impaired D 316 D WT WT WT 
Lethal Y 317 Y WT WT WT 
Impaired N 318 N Lethal n/a Lethal 
WT P 319 P Impaired Impaired Impaired 
Lethal P 320 P Impaired Impaired Impaired 
WT L 321 L WT WT WT 
WT L 322 V WT WT WT 
WT E 323 E WT n/a WT 
WT S 324 S Lethal n/a Lethal 
Lethal W 325 W Lethal n/a Lethal 
WT K 326 R Lethal n/a Lethal 
WT D 327 R WT WT WT 
WT 
P 328 P WT WT WT 
D 329 D Impaired n/a Impaired 
Y 330 Y Lethal n/a Lethal 
Impaired 
V 331 Q WT WT WT 
P 332 P Impaired n/a Impaired 
P 333 P WT n/a WT 
Lethal V 334 T Impaired n/a Impaired 
Impaired V 335 V Lethal n/a Lethal 
WT H 336 A Lethal n/a Lethal 
Lethal G 337 G Lethal n/a Lethal 
Lethal C 338 C Lethal n/a Lethal 
 
 
 
Appendix figure 8.9. Comparison of domain II replication data from genotype 1b and 
genotype 2a. 
The genotype 2a data generated from the mSGR JFH-1 replicon herein, the genotype 1b data 
generated from the SGR-neo ConI (Tellinghuisen et al., 2008b). 
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Appendix figure 8.10. Cyclosporin A EC50 and CC50 curves for WT and D316E mutant. 
A. EC50 and CC50 mathematical model. B. EC50 and CC50 curves for WT mSGR treated with 
CsA. C. EC50 and CC50 curves for D316E mSGR treated with CsA. 
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Appendix figure 8.11. BMS-790052 (Daclatasvir) EC50 curves for WT and D316E mutant. 
A. EC50 curve for WT mSGR treated with BMS-790052. C. EC50 curves for D316E mSGR 
treated with BMS-790052. 
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Appendix figure 8.12. SNAP/CLIP-tag nucleotide and protein sequence 
A. Sequence of SNAP-tag from the pSNAPf vector (NEB, #N9183S). B. Sequence of the CLIP-
tag from the pCLIPf vector (NEB, #N9215S). 
 
 
 
  
>SNAP-tag from vector pSNAPf 5,849bp (NEB, #N9183S)
atggacaaagactgcgaaatgaagcgcaccaccctggatagccctctgggcaagctggaa
M  D  K  D  C  E  M  K  R  T  T L  D  S  P  L  G  K  L  E 
ctgtctgggtgcgaacagggcctgcaccgtatcatcttcctgggcaaaggaacatctgcc
L  S  G  C  E  Q  G  L  H  R  I  I F  L  G  K  G  T  S  A 
gccgacgccgtggaagtgcctgccccagccgccgtgctgggcggaccagagccactgatg
A  D  A  V  E  V  P  A  P  A  A V  L  G  G P  E  P  L  M 
caggccaccgcctggctcaacgcctactttcaccagcctgaggccatcgaggagttccct
Q  A  T  A  W  L  N  A  Y  F  H  Q  P  E  A  I  E  E F  P 
gtgccagccctgcaccacccagtgttccagcaggagagctttacccgccaggtgctgtgg
V  P  A  L  H  H P  V  F  Q  Q E  S  F  T  R  Q  V  L  W 
aaactgctgaaagtggtgaagttcggagaggtcatcagctacagccacctggccgccctg
K  L  L K  V  V K  F  G  E  V  I  S  Y  S  H  L  A  A L 
gccggcaatcccgccgccaccgccgccgtgaaaaccgccctgagcggaaatcccgtgccc
A  G  N  P  A  A T  A  A V  K  T  A  L  S  G  N  P  V  P 
attctgatcccctgccaccgggtggtgcagggcgacctggacgtggggggctacgagggc
I  L  I  P  C  H  R  V  V Q  G  D  L  D  V  G  G Y  E  G 
gggctcgccgtgaaagagtggctgctggcccacgagggccacagactgggcaagcctggg
G  L  A  V  K  E  W  L  L A  H  E  G  H  R  L  G  K  P  G 
ctgggtcctgca L  G  P  A 
>CLIP-tag from vector pCLIPf 5,862bp NEB, (#N9215S)
atggacaaagactgcgaaatgaagcgcaccaccctggatagccctctgggcaagctggaa
M  D  K  D  C  E  M  K  R  T  T L  D  S  P  L  G  K  L  E 
ctgtctgggtgcgaacagggcctgcaccgtatcatcttcctgggcaaaggaacatctgcc
L  S  G  C  E  Q  G  L  H  R  I  I F  L  G  K  G  T  S  A 
gccgacgccgtggaagtgcctgccccagccgccgtgctgggcggaccagagccactgatc
A  D  A  V  E  V  P  A  P  A  A V  L  G  G P  E  P  L  I
caggccaccgcctggctcaacgcctactttcaccagcctgaggccatcgaggagttccct
Q  A  T  A  W  L  N  A  Y  F  H  Q  P  E  A  I  E  E F  P 
gtgccagccctgcaccacccagtgttccagcaggagagctttacccgccaggtgctgtgg
V  P  A  L  H  H P  V  F  Q  Q E  S  F  T  R  Q  V  L  W 
aaactgctgaaagtggtgaagttcggagaggtcatcagcgagagccacctggccgccctg
K  L  L K  V  V K  F  G  E  V  I  S  E  S  H  L  A  A L 
gtgggcaatcccgccgccaccgccgccgtgaacaccgccctggacggaaatcccgtgccc
V  G  N  P  A  A T  A  A V  N  T  A  L  D  G  N  P  V  P 
attctgatcccctgccaccgggtggtgcagggcgacagcgacgtggggccctacctgggc
I  L  I  P  C  H  R  V  V Q  G  D  S  D  V  G  P  Y  L  G 
gggctcgccgtgaaagagtggctgctggcccacgagggccacagactgggcaagcctggg
G  L  A  V  K  E  W  L  L A  H  E  G  H  R  L  G  K  P  G 
ctgggtcctgca
L  G  P  A
A
B
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Appendix figure 8.13. Alignment of SNAP-tag and CLIP-tag nucleotide sequence. 
Highlighting the 15 nucleotide changes responsible for the alteration in substrate specificity 
of the SNAP- and CLIP-tags. 
 
  
SNAP-tag           1 ATGGACAAAGACTGCGAAATGAAGCGCACCACCCTGGATAGCCCTCTGGG     50
||||||||||||||||||||||||||||||||||||||||||||||||||
CLIP-tag           1 ATGGACAAAGACTGCGAAATGAAGCGCACCACCCTGGATAGCCCTCTGGG     50
SNAP-tag          51 CAAGCTGGAACTGTCTGGGTGCGAACAGGGCCTGCACCGTATCATCTTCC    100
||||||||||||||||||||||||||||||||||||||||||||||||||
CLIP-tag          51 CAAGCTGGAACTGTCTGGGTGCGAACAGGGCCTGCACCGTATCATCTTCC    100
SNAP-tag         101 TGGGCAAAGGAACATCTGCCGCCGACGCCGTGGAAGTGCCTGCCCCAGCC    150
||||||||||||||||||||||||||||||||||||||||||||||||||
CLIP-tag         101 TGGGCAAAGGAACATCTGCCGCCGACGCCGTGGAAGTGCCTGCCCCAGCC    150
SNAP-tag         151 GCCGTGCTGGGCGGACCAGAGCCACTGATGCAGGCCACCGCCTGGCTCAA    200
|||||||||||||||||||||||||||||.||||||||||||||||||||
CLIP-tag         151 GCCGTGCTGGGCGGACCAGAGCCACTGATCCAGGCCACCGCCTGGCTCAA    200
SNAP-tag         201 CGCCTACTTTCACCAGCCTGAGGCCATCGAGGAGTTCCCTGTGCCAGCCC    250
||||||||||||||||||||||||||||||||||||||||||||||||||
CLIP-tag         201 CGCCTACTTTCACCAGCCTGAGGCCATCGAGGAGTTCCCTGTGCCAGCCC    250
SNAP-tag         251 TGCACCACCCAGTGTTCCAGCAGGAGAGCTTTACCCGCCAGGTGCTGTGG    300
||||||||||||||||||||||||||||||||||||||||||||||||||
CLIP-tag         251 TGCACCACCCAGTGTTCCAGCAGGAGAGCTTTACCCGCCAGGTGCTGTGG    300
SNAP-tag         301 AAACTGCTGAAAGTGGTGAAGTTCGGAGAGGTCATCAGCTACAGCCACCT    350
|||||||||||||||||||||||||||||||||||||||.|.||||||||
CLIP-tag         301 AAACTGCTGAAAGTGGTGAAGTTCGGAGAGGTCATCAGCGAGAGCCACCT    350
SNAP-tag         351 GGCCGCCCTGGCCGGCAATCCCGCCGCCACCGCCGCCGTGAAAACCGCCC    400
|||||||||||..|||||||||||||||||||||||||||||.|||||||
CLIP-tag         351 GGCCGCCCTGGTGGGCAATCCCGCCGCCACCGCCGCCGTGAACACCGCCC    400
SNAP-tag         401 TGAGCGGAAATCCCGTGCCCATTCTGATCCCCTGCCACCGGGTGGTGCAG    450
||..||||||||||||||||||||||||||||||||||||||||||||||
CLIP-tag         401 TGGACGGAAATCCCGTGCCCATTCTGATCCCCTGCCACCGGGTGGTGCAG    450
SNAP-tag         451 GGCGACCTGGACGTGGGGGGCTACGAGGGCGGGCTCGCCGTGAAAGAGTG    500
||||||...|||||||||..||||..||||||||||||||||||||||||
CLIP-tag         451 GGCGACAGCGACGTGGGGCCCTACCTGGGCGGGCTCGCCGTGAAAGAGTG    500
SNAP-tag         501 GCTGCTGGCCCACGAGGGCCACAGACTGGGCAAGCCTGGGCTGGGTCCTG    550
||||||||||||||||||||||||||||||||||||||||||||||||||
CLIP-tag         501 GCTGCTGGCCCACGAGGGCCACAGACTGGGCAAGCCTGGGCTGGGTCCTG    550
SNAP-tag         551 CA    552
||
CLIP-tag         551 CA    552
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NS5A 
mutation Backbone 
 
NS5A 
mutation Backbone 
S146A mSGR-luc and mJFH 
 
L309A mSGR-luc, mJFH and pCMV10-NS3-5B 
S146D mSGR-luc and mJFH 
 
P310A mSGR-luc, mJFH and pCMV10-NS3-5B 
S222A mSGR-luc and mJFH 
 
A311G mSGR-luc, mJFH and pCMV10-NS3-5B 
S222D mSGR-luc and mJFH 
 
W312A mSGR-luc, mJFH and pCMV10-NS3-5B 
S225A mSGR-luc and mJFH 
 
A313G mSGR-luc, mJFH and pCMV10-NS3-5B 
S225D mSGR-luc and mJFH 
 
R314A mSGR-luc, mJFH and pCMV10-NS3-5B 
SS222/225AA mSGR-luc and mJFH 
 
P315A mSGR-luc, mJFH and pCMV10-NS3-5B 
SS222/225DD mSGR-luc and mJFH 
 
D316A mSGR-luc and mJFH 
T348A mSGR-luc and mJFH 
 
Y317A mSGR-luc and mJFH 
T348D mSGR-luc 
 
N318A mSGR-luc, mJFH and pCMV10-NS3-5B 
S228A mSGR-luc 
 
P319A mSGR-luc and mJFH 
S228D mSGR-luc 
 
P320A mSGR-luc and mJFH 
S229A mSGR-luc 
 
L321A mSGR-luc and mJFH 
S229D mSGR-luc 
 
V322A mSGR-luc and mJFH 
S230A mSGR-luc 
 
E323A mSGR-luc and mJFH 
S230D mSGR-luc 
 
S324A mSGR-luc and mJFH 
SSS228/229/230AAA mSGR-luc 
 
W325A mSGR-luc, mJFH and pCMV10-NS3-5B 
SSS228/229/230DDD mSGR-luc 
 
R326A mSGR-luc, mJFH and pCMV10-NS3-5B 
S232A mSGR-luc 
 
R327A mSGR-luc and mJFH 
S232D mSGR-luc 
 
P328A mSGR-luc and mJFH 
S235D mSGR-luc 
 
D329A mSGR-luc, mJFH and pCMV10-NS3-5B 
S238D mSGR-luc 
 
Y330A mSGR-luc, mJFH and pCMV10-NS3-5B 
NS5A-SNAP/CLIP mSGR-luc and mJFH 
 
Q331A mSGR-luc and mJFH 
S146A-SNAP mSGR-luc 
 
P332A mSGR-luc and mJFH 
S146D-CLIP mSGR-luc 
 
P333A mSGR-luc and mJFH 
S222A-SNAP mSGR-luc 
 
T334A mSGR-luc and mJFH 
S222D-CLIP mSGR-luc 
 
V335A mSGR-luc, mJFH and pCMV10-NS3-5B 
S225A-SNAP mSGR-luc 
 
A336G mSGR-luc, mJFH and pCMV10-NS3-5B 
S225D-CLIP mSGR-luc 
 
G337A mSGR-luc, mJFH and pCMV10-NS3-5B 
SS222/225AA-SNAP mSGR-luc 
 
C338A mSGR-luc, mJFH and pCMV10-NS3-5B 
SS222/225DD-CLIP mSGR-luc 
 
D316E mSGR-luc 
T348A-SNAP mSGR-luc 
   T348D-CLIP mSGR-luc 
    
Appendix figure 8.14. List of mutations created in the course of this study.  
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NS5A 
mutation Quikchange primer, Forward Quikchange primer, Reverse 
S146A CTTGCCAACTACCTGCTCCAGAGTTTTTC  GAAAAACTCTGGAGCAGGTAGTTGGCAAG  
S146D CCTTGCCAACTACCTGATCCAGAGTTTTTCTC  GAGAAAAACTCTGGATCAGGTAGTTGGCAAGG  
S222A CGCTTGGCACGGGGAGCACCTCCATCTGAGG  CCTCAGATGGAGGTGCTCCCCGTGCCAAGCG  
S222D CGCTTGGCACGGGGAGATCCTCCATCTGAGGCG  CGCCTCAGATGGAGGATCTCCCCGTGCCAAGCG  
S225A CGGGGATCACCTCCAGCTGAGGCGAGCTCCTC  GAGGAGCTCGCCTCAGCTGGAGGTGATCCCCG  
S225D CGGGGATCACCTCCAGATGAGGCGAGCTCCTC  GAGGAGCTCGCCTCATCTGGAGGTGATCCCCG  
SS222/225AA CGCTTGGCACGGGGAGCACCTCCAGCTGAGGCGAGCTCCTC  GAGGAGCTCGCCTCAGCTGGAGGTGCTCCCCGTGCCAAGCG  
SS222/225DD CGCTTGGCACGGGGAGATCCTCCAGATGAGGCGAGCTCCTC  GAGGAGCTCGCCTCATCTGGAGGATCTCCCCGTGCCAAGCG  
T348A CCCAAGAAGGCCCCGGCGCCTCCCCCAAGGAG  CTCCTTGGGGGAGGCGCCGGGGCCTTCTTGGG  
T348D CCCAAGAAGGCCCCGGATCCTCCCCCAAGGAGAC  CCCAAGAAGGCCCCGGATCCTCCCCCAAGGAGAC  
S228A CCTCCATCTGAGGCGGCATCCTCAGTGAGCC GGCTCACTGAGGATGCCGCCTCAGATGGAGG 
S228D CCTCCATCTGAGGCGGACTCCTCAGTGAGCC GGCTCACTGAGGAGTCCGCCTCAGATGGAGG 
S229A CCATCTGAGGCGAGCGCTTCAGTGAGCCAGC GCTGGCTCACTGAAGCGCTCGCCTCAGATGG 
S229D CCATCTGAGGCGAGCGACTCAGTGAGCCAGC GCTGGCTCACTGAGTCGCTCGCCTCAGATGG 
S230A CTGAGGCGAGCTCCGCAGTGAGCCAGCTATC GATAGCTGGCTCACTGCGGAGCTCGCCTCAG 
S230D CTGAGGCGAGCTCCGATGTGAGCCAGCTATC GATAGCTGGCTCACATCGGAGCTCGCCTCAG 
S228/229/230A CCTCCATCTGAGGCGGCAGCTGCAGTGAGCCAGCTATCAG CTGATAGCTGGCTCACTGCAGCTGCCGCCTCAGATGGAGG 
S228/229/230D CCTCCATCTGAGGCGGACGACGATGTGAGCCAGCTATCAG CTGATAGCTGGCTCACATCGTCGTCCGCCTCAGATGGAGG 
S232A GCGAGCTCCTCAGTGGCACAGCTATCAGCACC GGTGCTGATAGCTGTGCCACTGAGGAGCTCGC 
S232D GCGAGCTCCTCAGTGGACCAGCTATCAGCACC GGTGCTGATAGCTGGTCCACTGAGGAGCTCGC 
S235D CAGTGAGCCAGCTATCAGCACCGTCGCTGCG CGCAGCGACGGTGCTGATAGCTGGCTCACTG 
S238D GCTATCAGCACCGTCGCTGCGGGCCACCTGC GCAGGTGGCCCGCAGCGACGGTGCTGATAGC 
NS5A-SNAP/ 
CLIP 
GAGTCTGATCATGGAAGTAGCGGGTCATCGATGGACAAAGA
CTGCGAAATGAAGCGC 
CTACCTGATCAGATGAAGAACCTGAAGATCCTGCAGGACCC
AGCCCAGGCTTGCCCA 
L309A GGGTTTCCACGGGCCGCACCGGCTTGGGCACG  CGTGCCCAAGCCGGTGCGGCCCGTGGAAACCC  
P310A n/a n/a 
A311G CACGGGCCTTACCGGGTTGGGCACGGCCTGAC  GTCAGGCCGTGCCCAACCCGGTAAGGCCCGTG  
W312A n/a n/a 
A313G CCTTACCGGCTTGGGGACGGCCTGACTACAAC  GTTGTAGTCAGGCCGTCCCCAAGCCGGTAAGG  
R314A CTTACCGGCTTGGGCAGCGCCTGACTACAACCC  GGGTTGTAGTCAGGCGCTGCCCAAGCCGGTAAG  
P315A CCGGCTTGGGCACGGGCTGACTACAACCCGC  GCGGGTTGTAGTCAGCCCGTGCCCAAGCCGG  
D316A n/a n/a 
Y317A n/a n/a 
N318A n/a n/a 
P319A n/a n/a 
P320A n/a n/a 
L321A GACTACAACCCGCCGGCCGTGGAATCGTGGAG  CTCCACGATTCCACGGCCGGCGGGTTGTAGTC  
V322A CTACAACCCGCCGCTCGCGGAATCGTGGAGGAGG  CCTCCTCCACGATTCCGCGAGCGGCGGGTTGTAG  
E323A CAACCCGCCGCTCGTGGCATCGTGGAGGAGGCCAG  CTGGCCTCCTCCACGATGCCACGAGCGGCGGGTTG  
S324A CCGCCGCTCGTGGAAGCGTGGAGGAGGCCAG  CTGGCCTCCTCCACGCTTCCACGAGCGGCGG  
W325A n/a n/a 
R326A GCTCGTGGAATCGTGGGCGAGGCCAGATTACCAAC  GTTGGTAATCTGGCCTCGCCCACGATTCCACGAGC  
R327A GTGGAATCGTGGAGGGCGCCAGATTACCAACC  GGTTGGTAATCTGGCGCCCTCCACGATTCCAC  
P328A GAATCGTGGAGGAGGGCAGATTACCAACCGC  GCGGTTGGTAATCTGCCCTCCTCCACGATTC  
D329A CGTGGAGGAGGCCAGCTTACCAACCGCCCAC  GTGGGCGGTTGGTAAGCTGGCCTCCTCCACG  
Y330A GTGGAGGAGGCCAGATGCCCAACCGCCCACCGTTG  CAACGGTGGGCGGTTGGGCATCTGGCCTCCTCCAC  
Q331A GAGGAGGCCAGATTACGCACCGCCCACCGTTGC  GCAACGGTGGGCGGTGCGTAATCTGGCCTCCTC  
P332A n/a n/a 
P333A n/a n/a 
T334A GATTACCAACCGCCCGCCGTTGCTGGTTGTG  CACAACCAGCAACGGCGGGCGGTTGGTAATC  
V335A GATTACCAACCGCCCACCGCTGCTGGTTGTGCTCTCCC  GGGAGAGCACAACCAGCAGCGGTGGGCGGTTGGTAATC  
A336G CAACCGCCCACCGTTGGTGGTTGTGCTCTCCC  GGGAGAGCACAACCACCAACGGTGGGCGGTTG  
G337A CGCCCACCGTTGCTGCTTGTGCTCTCCCCCC  GGGGGGAGAGCACAAGCAGCAACGGTGGGCG  
C338A CCCACCGTTGCTGGTGCTGCTCTCCCCCCCCC  GGGGGGGGGAGAGCAGCACCAGCAACGGTGGG  
D316E CTTGGGCACGGCCTGAGTACAACCCGCCGCTC  GAGCGGCGGGTTGTACTCAGGCCGTGCCCAAG  
Appendix figure 8.15. List of oligonucleotide primers used to generate mutations.  
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Primer 
name Primer sequence Region sequenced 
SeqPrimer1 ACATGGACTTCCCGTGTCC Start of NS3 
SeqPrimer2 ACTGGCAGTGGAAAGAGCA Mid NS3 
SeqPrimer3 CTGGACCCCACCTTCACTA End of NS3 
SeqPrimer4 TAAGGAGGTCCTGTATGAG NS4 
SeqPrimer5 GGATGCGTCGCAGCGTGTGA Start of NS5A 
SeqPrimer6 CACGGCGGAGACTGCGGCG Mid NS5A 
SeqPrimer7 GGGTAGCTCCCGGTTCGGG End NS5A 
SeqPrimer8 AACGGGTGGAGTATCTCTT Mid NS5B 
SeqPrimer9 TGGGTTCGCATGGTCCTAA End NS5B 
 
Appendix figure 8.16. List of sequencing primers 
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And they all lived happily ever after…… 
 
….the end 
 
 
